#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Disturbances across whole brain networks during reward anticipation in an abstinent addiction population
#Text=Graphical abstract
#Text=Network based statistics (NBS) analyses detected a graph sub-network comprising 153 edges between 59 nodes of the connectome where the ADD group demonstrated significantly less connectivity compared with the CON group.
1-1	0-12	Disturbances	_	
1-2	13-19	across	_	
1-3	20-25	whole	_	
1-4	26-31	brain	_	
1-5	32-40	networks	_	
1-6	41-47	during	_	
1-7	48-54	reward	_	
1-8	55-67	anticipation	_	
1-9	68-70	in	_	
1-10	71-73	an	_	
1-11	74-83	abstinent	_	
1-12	84-93	addiction	_	
1-13	94-104	population	_	
1-14	105-114	Graphical	_	
1-15	115-123	abstract	_	
1-16	124-131	Network	_	
1-17	132-137	based	_	
1-18	138-148	statistics	_	
1-19	149-150	(	_	
1-20	150-153	NBS	_	
1-21	153-154	)	_	
1-22	155-163	analyses	_	
1-23	164-172	detected	_	
1-24	173-174	a	_	
1-25	175-180	graph	_	
1-26	181-192	sub-network	_	
1-27	193-203	comprising	_	
1-28	204-207	153	_	
1-29	208-213	edges	_	
1-30	214-221	between	_	
1-31	222-224	59	_	
1-32	225-230	nodes	_	
1-33	231-233	of	_	
1-34	234-237	the	_	
1-35	238-248	connectome	_	
1-36	249-254	where	_	
1-37	255-258	the	_	
1-38	259-262	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[1]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[2]	
1-39	263-268	group	_	
1-40	269-281	demonstrated	_	
1-41	282-295	significantly	_	
1-42	296-300	less	_	
1-43	301-313	connectivity	_	
1-44	314-322	compared	_	
1-45	323-327	with	_	
1-46	328-331	the	_	
1-47	332-335	CON	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
1-48	336-341	group	_	
1-49	341-342	.	_	

#Text=These differences in connectivity were mostly intra-hemispheric (55%), the majority (38%) being in the right hemisphere.
2-1	343-348	These	_	
2-2	349-360	differences	_	
2-3	361-363	in	_	
2-4	364-376	connectivity	_	
2-5	377-381	were	_	
2-6	382-388	mostly	_	
2-7	389-406	intra-hemispheric	_	
2-8	407-408	(	_	
2-9	408-411	55%	_	
2-10	411-412	)	_	
2-11	412-413	,	_	
2-12	414-417	the	_	
2-13	418-426	majority	_	
2-14	427-428	(	_	
2-15	428-431	38%	_	
2-16	431-432	)	_	
2-17	433-438	being	_	
2-18	439-441	in	_	
2-19	442-445	the	_	
2-20	446-451	right	_	
2-21	452-462	hemisphere	_	
2-22	462-463	.	_	

#Text=The anatomical distribution of these connectivity differences between the two groups involved frontal (insula, inferior frontal gyrus, orbitofrontal cortex), limbic-associated (anterior cingulate gyrus, thalamus), and striatal (accumbens, caudate, pallidum) regions.
3-1	464-467	The	_	
3-2	468-478	anatomical	_	
3-3	479-491	distribution	_	
3-4	492-494	of	_	
3-5	495-500	these	_	
3-6	501-513	connectivity	_	
3-7	514-525	differences	_	
3-8	526-533	between	_	
3-9	534-537	the	_	
3-10	538-541	two	_	
3-11	542-548	groups	_	
3-12	549-557	involved	_	
3-13	558-565	frontal	_	
3-14	566-567	(	_	
3-15	567-573	insula	_	
3-16	573-574	,	_	
3-17	575-583	inferior	_	
3-18	584-591	frontal	_	
3-19	592-597	gyrus	_	
3-20	597-598	,	_	
3-21	599-612	orbitofrontal	_	
3-22	613-619	cortex	_	
3-23	619-620	)	_	
3-24	620-621	,	_	
3-25	622-639	limbic-associated	_	
3-26	640-641	(	_	
3-27	641-649	anterior	_	
3-28	650-659	cingulate	_	
3-29	660-665	gyrus	_	
3-30	665-666	,	_	
3-31	667-675	thalamus	_	
3-32	675-676	)	_	
3-33	676-677	,	_	
3-34	678-681	and	_	
3-35	682-690	striatal	_	
3-36	691-692	(	_	
3-37	692-701	accumbens	_	
3-38	701-702	,	_	
3-39	703-710	caudate	_	
3-40	710-711	,	_	
3-41	712-720	pallidum	_	
3-42	720-721	)	_	
3-43	722-729	regions	_	
3-44	729-730	.	_	

#Text=The connectivity differences reported in this ADD sample indicate alterations between cognitive, striatal and limbic-associated regions during reward anticipation that persist into extended abstinence.
4-1	731-734	The	_	
4-2	735-747	connectivity	_	
4-3	748-759	differences	_	
4-4	760-768	reported	_	
4-5	769-771	in	_	
4-6	772-776	this	_	
4-7	777-780	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[3]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[4]	
4-8	781-787	sample	_	
4-9	788-796	indicate	_	
4-10	797-808	alterations	_	
4-11	809-816	between	_	
4-12	817-826	cognitive	_	
4-13	826-827	,	_	
4-14	828-836	striatal	_	
4-15	837-840	and	_	
4-16	841-858	limbic-associated	_	
4-17	859-866	regions	_	
4-18	867-873	during	_	
4-19	874-880	reward	_	
4-20	881-893	anticipation	_	
4-21	894-898	that	_	
4-22	899-906	persist	_	
4-23	907-911	into	_	
4-24	912-920	extended	_	
4-25	921-931	abstinence	_	
4-26	931-932	.	_	

#Text=Highlights
#Text=Analytical methods can capture key features of whole brain networks in addiction.
5-1	933-943	Highlights	_	
5-2	944-954	Analytical	_	
5-3	955-962	methods	_	
5-4	963-966	can	_	
5-5	967-974	capture	_	
5-6	975-978	key	_	
5-7	979-987	features	_	
5-8	988-990	of	_	
5-9	991-996	whole	_	
5-10	997-1002	brain	_	
5-11	1003-1011	networks	_	
5-12	1012-1014	in	_	
5-13	1015-1024	addiction	_	
5-14	1024-1025	.	_	

#Text=We compared reward network connectivity in addiction (ADD) and control (CON) groups.
6-1	1026-1028	We	_	
6-2	1029-1037	compared	_	
6-3	1038-1044	reward	_	
6-4	1045-1052	network	_	
6-5	1053-1065	connectivity	_	
6-6	1066-1068	in	_	
6-7	1069-1078	addiction	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[5]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[6]	
6-8	1079-1080	(	_	
6-9	1080-1083	ADD	_	
6-10	1083-1084	)	_	
6-11	1085-1088	and	_	
6-12	1089-1096	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-13	1097-1098	(	_	
6-14	1098-1101	CON	_	
6-15	1101-1102	)	_	
6-16	1103-1109	groups	_	
6-17	1109-1110	.	_	

#Text=The ADD group showed disruptions in global network connectivity.
7-1	1111-1114	The	_	
7-2	1115-1118	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[7]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[8]	
7-3	1119-1124	group	_	
7-4	1125-1131	showed	_	
7-5	1132-1143	disruptions	_	
7-6	1144-1146	in	_	
7-7	1147-1153	global	_	
7-8	1154-1161	network	_	
7-9	1162-1174	connectivity	_	
7-10	1174-1175	.	_	

#Text=Global network measures may be more sensitive than traditional voxel-wise analyses.
8-1	1176-1182	Global	_	
8-2	1183-1190	network	_	
8-3	1191-1199	measures	_	
8-4	1200-1203	may	_	
8-5	1204-1206	be	_	
8-6	1207-1211	more	_	
8-7	1212-1221	sensitive	_	
8-8	1222-1226	than	_	
8-9	1227-1238	traditional	_	
8-10	1239-1249	voxel-wise	_	
8-11	1250-1258	analyses	_	
8-12	1258-1259	.	_	

#Text=The prevalent spatial distribution of abnormalities reported in cognitive fMRI studies in addiction suggests there are extensive disruptions across whole brain networks.
9-1	1260-1263	The	_	
9-2	1264-1273	prevalent	_	
9-3	1274-1281	spatial	_	
9-4	1282-1294	distribution	_	
9-5	1295-1297	of	_	
9-6	1298-1311	abnormalities	_	
9-7	1312-1320	reported	_	
9-8	1321-1323	in	_	
9-9	1324-1333	cognitive	_	
9-10	1334-1338	fMRI	_	
9-11	1339-1346	studies	_	
9-12	1347-1349	in	_	
9-13	1350-1359	addiction	_	
9-14	1360-1368	suggests	_	
9-15	1369-1374	there	_	
9-16	1375-1378	are	_	
9-17	1379-1388	extensive	_	
9-18	1389-1400	disruptions	_	
9-19	1401-1407	across	_	
9-20	1408-1413	whole	_	
9-21	1414-1419	brain	_	
9-22	1420-1428	networks	_	
9-23	1428-1429	.	_	

#Text=Studies using resting state have reported disruptions in network connectivity in addiction, but these studies have not revealed characteristics of network functioning during critical psychological processes that are disrupted in addiction populations.
10-1	1430-1437	Studies	_	
10-2	1438-1443	using	_	
10-3	1444-1451	resting	_	
10-4	1452-1457	state	_	
10-5	1458-1462	have	_	
10-6	1463-1471	reported	_	
10-7	1472-1483	disruptions	_	
10-8	1484-1486	in	_	
10-9	1487-1494	network	_	
10-10	1495-1507	connectivity	_	
10-11	1508-1510	in	_	
10-12	1511-1520	addiction	_	
10-13	1520-1521	,	_	
10-14	1522-1525	but	_	
10-15	1526-1531	these	_	
10-16	1532-1539	studies	_	
10-17	1540-1544	have	_	
10-18	1545-1548	not	_	
10-19	1549-1557	revealed	_	
10-20	1558-1573	characteristics	_	
10-21	1574-1576	of	_	
10-22	1577-1584	network	_	
10-23	1585-1596	functioning	_	
10-24	1597-1603	during	_	
10-25	1604-1612	critical	_	
10-26	1613-1626	psychological	_	
10-27	1627-1636	processes	_	
10-28	1637-1641	that	_	
10-29	1642-1645	are	_	
10-30	1646-1655	disrupted	_	
10-31	1656-1658	in	_	
10-32	1659-1668	addiction	_	
10-33	1669-1680	populations	_	
10-34	1680-1681	.	_	

#Text=Analytic methods that can capture key features of whole brain networks during psychological processes may be more sensitive in revealing additional and widespread neural disturbances in addiction, that are the provisions for relapse risk, and targets for medication development.
11-1	1682-1690	Analytic	_	
11-2	1691-1698	methods	_	
11-3	1699-1703	that	_	
11-4	1704-1707	can	_	
11-5	1708-1715	capture	_	
11-6	1716-1719	key	_	
11-7	1720-1728	features	_	
11-8	1729-1731	of	_	
11-9	1732-1737	whole	_	
11-10	1738-1743	brain	_	
11-11	1744-1752	networks	_	
11-12	1753-1759	during	_	
11-13	1760-1773	psychological	_	
11-14	1774-1783	processes	_	
11-15	1784-1787	may	_	
11-16	1788-1790	be	_	
11-17	1791-1795	more	_	
11-18	1796-1805	sensitive	_	
11-19	1806-1808	in	_	
11-20	1809-1818	revealing	_	
11-21	1819-1829	additional	_	
11-22	1830-1833	and	_	
11-23	1834-1844	widespread	_	
11-24	1845-1851	neural	_	
11-25	1852-1864	disturbances	_	
11-26	1865-1867	in	_	
11-27	1868-1877	addiction	_	
11-28	1877-1878	,	_	
11-29	1879-1883	that	_	
11-30	1884-1887	are	_	
11-31	1888-1891	the	_	
11-32	1892-1902	provisions	_	
11-33	1903-1906	for	_	
11-34	1907-1914	relapse	_	
11-35	1915-1919	risk	_	
11-36	1919-1920	,	_	
11-37	1921-1924	and	_	
11-38	1925-1932	targets	_	
11-39	1933-1936	for	_	
11-40	1937-1947	medication	_	
11-41	1948-1959	development	_	
11-42	1959-1960	.	_	

#Text=The current study compared a substance addiction (ADD; n = 83) group in extended abstinence with a control (CON; n = 68) group on functional MRI (voxel-wise activation) and global network (connectivity) measures related to reward anticipation on a monetary incentive delay task.
12-1	1961-1964	The	_	
12-2	1965-1972	current	_	
12-3	1973-1978	study	_	
12-4	1979-1987	compared	_	
12-5	1988-1989	a	_	
12-6	1990-1999	substance	_	
12-7	2000-2009	addiction	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[10]	
12-8	2010-2011	(	_	
12-9	2011-2014	ADD	_	
12-10	2014-2015	;	_	
12-11	2016-2017	n	_	
12-12	2017-2018	 	_	
12-13	2018-2019	=	_	
12-14	2019-2020	 	_	
12-15	2020-2022	83	_	
12-16	2022-2023	)	_	
12-17	2024-2029	group	_	
12-18	2030-2032	in	_	
12-19	2033-2041	extended	_	
12-20	2042-2052	abstinence	_	
12-21	2053-2057	with	_	
12-22	2058-2059	a	_	
12-23	2060-2067	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
12-24	2068-2069	(	_	
12-25	2069-2072	CON	_	
12-26	2072-2073	;	_	
12-27	2074-2075	n	_	
12-28	2075-2076	 	_	
12-29	2076-2077	=	_	
12-30	2077-2078	 	_	
12-31	2078-2080	68	_	
12-32	2080-2081	)	_	
12-33	2082-2087	group	_	
12-34	2088-2090	on	_	
12-35	2091-2101	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
12-36	2102-2105	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[11]	
12-37	2106-2107	(	_	
12-38	2107-2117	voxel-wise	_	
12-39	2118-2128	activation	_	
12-40	2128-2129	)	_	
12-41	2130-2133	and	_	
12-42	2134-2140	global	_	
12-43	2141-2148	network	_	
12-44	2149-2150	(	_	
12-45	2150-2162	connectivity	_	
12-46	2162-2163	)	_	
12-47	2164-2172	measures	_	
12-48	2173-2180	related	_	
12-49	2181-2183	to	_	
12-50	2184-2190	reward	_	
12-51	2191-2203	anticipation	_	
12-52	2204-2206	on	_	
12-53	2207-2208	a	_	
12-54	2209-2217	monetary	_	
12-55	2218-2227	incentive	_	
12-56	2228-2233	delay	_	
12-57	2234-2238	task	_	
12-58	2238-2239	.	_	

#Text=In the absence of group differences on MID performance, the ADD group showed reduced activation predominantly across temporal and visual regions, but not across the striatum.
13-1	2240-2242	In	_	
13-2	2243-2246	the	_	
13-3	2247-2254	absence	_	
13-4	2255-2257	of	_	
13-5	2258-2263	group	_	
13-6	2264-2275	differences	_	
13-7	2276-2278	on	_	
13-8	2279-2282	MID	_	
13-9	2283-2294	performance	_	
13-10	2294-2295	,	_	
13-11	2296-2299	the	_	
13-12	2300-2303	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[12]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[13]	
13-13	2304-2309	group	_	
13-14	2310-2316	showed	_	
13-15	2317-2324	reduced	_	
13-16	2325-2335	activation	_	
13-17	2336-2349	predominantly	_	
13-18	2350-2356	across	_	
13-19	2357-2365	temporal	_	
13-20	2366-2369	and	_	
13-21	2370-2376	visual	_	
13-22	2377-2384	regions	_	
13-23	2384-2385	,	_	
13-24	2386-2389	but	_	
13-25	2390-2393	not	_	
13-26	2394-2400	across	_	
13-27	2401-2404	the	_	
13-28	2405-2413	striatum	_	
13-29	2413-2414	.	_	

#Text=The ADD group also showed disruptions in global network connectivity (lower clustering coefficient and higher characteristic path length), and significantly less connectivity across a sub-network comprising frontal, temporal, limbic and striatal nodes.
14-1	2415-2418	The	_	
14-2	2419-2422	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[14]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[15]	
14-3	2423-2428	group	_	
14-4	2429-2433	also	_	
14-5	2434-2440	showed	_	
14-6	2441-2452	disruptions	_	
14-7	2453-2455	in	_	
14-8	2456-2462	global	_	
14-9	2463-2470	network	_	
14-10	2471-2483	connectivity	_	
14-11	2484-2485	(	_	
14-12	2485-2490	lower	_	
14-13	2491-2501	clustering	_	
14-14	2502-2513	coefficient	_	
14-15	2514-2517	and	_	
14-16	2518-2524	higher	_	
14-17	2525-2539	characteristic	_	
14-18	2540-2544	path	_	
14-19	2545-2551	length	_	
14-20	2551-2552	)	_	
14-21	2552-2553	,	_	
14-22	2554-2557	and	_	
14-23	2558-2571	significantly	_	
14-24	2572-2576	less	_	
14-25	2577-2589	connectivity	_	
14-26	2590-2596	across	_	
14-27	2597-2598	a	_	
14-28	2599-2610	sub-network	_	
14-29	2611-2621	comprising	_	
14-30	2622-2629	frontal	_	
14-31	2629-2630	,	_	
14-32	2631-2639	temporal	_	
14-33	2639-2640	,	_	
14-34	2641-2647	limbic	_	
14-35	2648-2651	and	_	
14-36	2652-2660	striatal	_	
14-37	2661-2666	nodes	_	
14-38	2666-2667	.	_	

#Text=These results show that an addiction group in extended abstinence exhibit localised disruptions in brain activation, but more extensive disturbances in functional connectivity across whole brain networks.
15-1	2668-2673	These	_	
15-2	2674-2681	results	_	
15-3	2682-2686	show	_	
15-4	2687-2691	that	_	
15-5	2692-2694	an	_	
15-6	2695-2704	addiction	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[16]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[17]	
15-7	2705-2710	group	_	
15-8	2711-2713	in	_	
15-9	2714-2722	extended	_	
15-10	2723-2733	abstinence	_	
15-11	2734-2741	exhibit	_	
15-12	2742-2751	localised	_	
15-13	2752-2763	disruptions	_	
15-14	2764-2766	in	_	
15-15	2767-2772	brain	_	
15-16	2773-2783	activation	_	
15-17	2783-2784	,	_	
15-18	2785-2788	but	_	
15-19	2789-2793	more	_	
15-20	2794-2803	extensive	_	
15-21	2804-2816	disturbances	_	
15-22	2817-2819	in	_	
15-23	2820-2830	functional	_	
15-24	2831-2843	connectivity	_	
15-25	2844-2850	across	_	
15-26	2851-2856	whole	_	
15-27	2857-2862	brain	_	
15-28	2863-2871	networks	_	
15-29	2871-2872	.	_	

#Text=We propose that measures of global network functioning may be more sensitive in highlighting latent and more widespread neural disruptions during critical psychological processes in addiction and other psychiatric disorders.
16-1	2873-2875	We	_	
16-2	2876-2883	propose	_	
16-3	2884-2888	that	_	
16-4	2889-2897	measures	_	
16-5	2898-2900	of	_	
16-6	2901-2907	global	_	
16-7	2908-2915	network	_	
16-8	2916-2927	functioning	_	
16-9	2928-2931	may	_	
16-10	2932-2934	be	_	
16-11	2935-2939	more	_	
16-12	2940-2949	sensitive	_	
16-13	2950-2952	in	_	
16-14	2953-2965	highlighting	_	
16-15	2966-2972	latent	_	
16-16	2973-2976	and	_	
16-17	2977-2981	more	_	
16-18	2982-2992	widespread	_	
16-19	2993-2999	neural	_	
16-20	3000-3011	disruptions	_	
16-21	3012-3018	during	_	
16-22	3019-3027	critical	_	
16-23	3028-3041	psychological	_	
16-24	3042-3051	processes	_	
16-25	3052-3054	in	_	
16-26	3055-3064	addiction	_	
16-27	3065-3068	and	_	
16-28	3069-3074	other	_	
16-29	3075-3086	psychiatric	_	
16-30	3087-3096	disorders	_	
16-31	3096-3097	.	_	

#Text=Introduction
#Text=Reward processing is a psychological construct that has evolved to drive incentive-based learning and the development of goal-directed behaviours in humans.
17-1	3098-3110	Introduction	_	
17-2	3111-3117	Reward	_	
17-3	3118-3128	processing	_	
17-4	3129-3131	is	_	
17-5	3132-3133	a	_	
17-6	3134-3147	psychological	_	
17-7	3148-3157	construct	_	
17-8	3158-3162	that	_	
17-9	3163-3166	has	_	
17-10	3167-3174	evolved	_	
17-11	3175-3177	to	_	
17-12	3178-3183	drive	_	
17-13	3184-3199	incentive-based	_	
17-14	3200-3208	learning	_	
17-15	3209-3212	and	_	
17-16	3213-3216	the	_	
17-17	3217-3228	development	_	
17-18	3229-3231	of	_	
17-19	3232-3245	goal-directed	_	
17-20	3246-3256	behaviours	_	
17-21	3257-3259	in	_	
17-22	3260-3266	humans	_	
17-23	3266-3267	.	_	

#Text=Reward processing is mediated by a collection of subcortical and prefrontal cortical regions that are connected to form a complex neural network encoding various types of rewarding stimuli.
18-1	3268-3274	Reward	_	
18-2	3275-3285	processing	_	
18-3	3286-3288	is	_	
18-4	3289-3297	mediated	_	
18-5	3298-3300	by	_	
18-6	3301-3302	a	_	
18-7	3303-3313	collection	_	
18-8	3314-3316	of	_	
18-9	3317-3328	subcortical	_	
18-10	3329-3332	and	_	
18-11	3333-3343	prefrontal	_	
18-12	3344-3352	cortical	_	
18-13	3353-3360	regions	_	
18-14	3361-3365	that	_	
18-15	3366-3369	are	_	
18-16	3370-3379	connected	_	
18-17	3380-3382	to	_	
18-18	3383-3387	form	_	
18-19	3388-3389	a	_	
18-20	3390-3397	complex	_	
18-21	3398-3404	neural	_	
18-22	3405-3412	network	_	
18-23	3413-3421	encoding	_	
18-24	3422-3429	various	_	
18-25	3430-3435	types	_	
18-26	3436-3438	of	_	
18-27	3439-3448	rewarding	_	
18-28	3449-3456	stimuli	_	
18-29	3456-3457	.	_	

#Text=Substance addiction disorders are associated with disturbances within this reward network during the processing of non-drug rewards, and which are associated with drug relapse during abstinence.
19-1	3458-3467	Substance	_	
19-2	3468-3477	addiction	_	
19-3	3478-3487	disorders	_	
19-4	3488-3491	are	_	
19-5	3492-3502	associated	_	
19-6	3503-3507	with	_	
19-7	3508-3520	disturbances	_	
19-8	3521-3527	within	_	
19-9	3528-3532	this	_	
19-10	3533-3539	reward	_	
19-11	3540-3547	network	_	
19-12	3548-3554	during	_	
19-13	3555-3558	the	_	
19-14	3559-3569	processing	_	
19-15	3570-3572	of	_	
19-16	3573-3581	non-drug	_	
19-17	3582-3589	rewards	_	
19-18	3589-3590	,	_	
19-19	3591-3594	and	_	
19-20	3595-3600	which	_	
19-21	3601-3604	are	_	
19-22	3605-3615	associated	_	
19-23	3616-3620	with	_	
19-24	3621-3625	drug	_	
19-25	3626-3633	relapse	_	
19-26	3634-3640	during	_	
19-27	3641-3651	abstinence	_	
19-28	3651-3652	.	_	

#Text=Most studies in addiction populations, however, only probe regional differences in brain functioning, and do not attempt to elucidate features of global connectivity across networks that respond during certain psychological processes, such as reward.
20-1	3653-3657	Most	_	
20-2	3658-3665	studies	_	
20-3	3666-3668	in	_	
20-4	3669-3678	addiction	_	
20-5	3679-3690	populations	_	
20-6	3690-3691	,	_	
20-7	3692-3699	however	_	
20-8	3699-3700	,	_	
20-9	3701-3705	only	_	
20-10	3706-3711	probe	_	
20-11	3712-3720	regional	_	
20-12	3721-3732	differences	_	
20-13	3733-3735	in	_	
20-14	3736-3741	brain	_	
20-15	3742-3753	functioning	_	
20-16	3753-3754	,	_	
20-17	3755-3758	and	_	
20-18	3759-3761	do	_	
20-19	3762-3765	not	_	
20-20	3766-3773	attempt	_	
20-21	3774-3776	to	_	
20-22	3777-3786	elucidate	_	
20-23	3787-3795	features	_	
20-24	3796-3798	of	_	
20-25	3799-3805	global	_	
20-26	3806-3818	connectivity	_	
20-27	3819-3825	across	_	
20-28	3826-3834	networks	_	
20-29	3835-3839	that	_	
20-30	3840-3847	respond	_	
20-31	3848-3854	during	_	
20-32	3855-3862	certain	_	
20-33	3863-3876	psychological	_	
20-34	3877-3886	processes	_	
20-35	3886-3887	,	_	
20-36	3888-3892	such	_	
20-37	3893-3895	as	_	
20-38	3896-3902	reward	_	
20-39	3902-3903	.	_	

#Text=Differences in global network connectivity likely underlie the regional differences commonly reported in functional MRI studies in addiction disorders, and therefore, may be more sensitive in revealing widespread neural disturbances in addiction disorders.
21-1	3904-3915	Differences	_	
21-2	3916-3918	in	_	
21-3	3919-3925	global	_	
21-4	3926-3933	network	_	
21-5	3934-3946	connectivity	_	
21-6	3947-3953	likely	_	
21-7	3954-3962	underlie	_	
21-8	3963-3966	the	_	
21-9	3967-3975	regional	_	
21-10	3976-3987	differences	_	
21-11	3988-3996	commonly	_	
21-12	3997-4005	reported	_	
21-13	4006-4008	in	_	
21-14	4009-4019	functional	_	
21-15	4020-4023	MRI	_	
21-16	4024-4031	studies	_	
21-17	4032-4034	in	_	
21-18	4035-4044	addiction	_	
21-19	4045-4054	disorders	_	
21-20	4054-4055	,	_	
21-21	4056-4059	and	_	
21-22	4060-4069	therefore	_	
21-23	4069-4070	,	_	
21-24	4071-4074	may	_	
21-25	4075-4077	be	_	
21-26	4078-4082	more	_	
21-27	4083-4092	sensitive	_	
21-28	4093-4095	in	_	
21-29	4096-4105	revealing	_	
21-30	4106-4116	widespread	_	
21-31	4117-4123	neural	_	
21-32	4124-4136	disturbances	_	
21-33	4137-4139	in	_	
21-34	4140-4149	addiction	_	
21-35	4150-4159	disorders	_	
21-36	4159-4160	.	_	

#Text=Connectivity across brain networks can be probed by examining various characteristics that relate to their topology and functioning.
22-1	4161-4173	Connectivity	_	
22-2	4174-4180	across	_	
22-3	4181-4186	brain	_	
22-4	4187-4195	networks	_	
22-5	4196-4199	can	_	
22-6	4200-4202	be	_	
22-7	4203-4209	probed	_	
22-8	4210-4212	by	_	
22-9	4213-4222	examining	_	
22-10	4223-4230	various	_	
22-11	4231-4246	characteristics	_	
22-12	4247-4251	that	_	
22-13	4252-4258	relate	_	
22-14	4259-4261	to	_	
22-15	4262-4267	their	_	
22-16	4268-4276	topology	_	
22-17	4277-4280	and	_	
22-18	4281-4292	functioning	_	
22-19	4292-4293	.	_	

#Text=These methods have been used to capture brain network connectivity during resting state in psychiatric populations, including those with addiction disorders.
23-1	4294-4299	These	_	
23-2	4300-4307	methods	_	
23-3	4308-4312	have	_	
23-4	4313-4317	been	_	
23-5	4318-4322	used	_	
23-6	4323-4325	to	_	
23-7	4326-4333	capture	_	
23-8	4334-4339	brain	_	
23-9	4340-4347	network	_	
23-10	4348-4360	connectivity	_	
23-11	4361-4367	during	_	
23-12	4368-4375	resting	_	
23-13	4376-4381	state	_	
23-14	4382-4384	in	_	
23-15	4385-4396	psychiatric	_	
23-16	4397-4408	populations	_	
23-17	4408-4409	,	_	
23-18	4410-4419	including	_	
23-19	4420-4425	those	_	
23-20	4426-4430	with	_	
23-21	4431-4440	addiction	_	
23-22	4441-4450	disorders	_	
23-23	4450-4451	.	_	

#Text=These studies, however, have not been able to examine the characteristics of network functioning during critical psychological processes known to be disrupted in these populations.
24-1	4452-4457	These	_	
24-2	4458-4465	studies	_	
24-3	4465-4466	,	_	
24-4	4467-4474	however	_	
24-5	4474-4475	,	_	
24-6	4476-4480	have	_	
24-7	4481-4484	not	_	
24-8	4485-4489	been	_	
24-9	4490-4494	able	_	
24-10	4495-4497	to	_	
24-11	4498-4505	examine	_	
24-12	4506-4509	the	_	
24-13	4510-4525	characteristics	_	
24-14	4526-4528	of	_	
24-15	4529-4536	network	_	
24-16	4537-4548	functioning	_	
24-17	4549-4555	during	_	
24-18	4556-4564	critical	_	
24-19	4565-4578	psychological	_	
24-20	4579-4588	processes	_	
24-21	4589-4594	known	_	
24-22	4595-4597	to	_	
24-23	4598-4600	be	_	
24-24	4601-4610	disrupted	_	
24-25	4611-4613	in	_	
24-26	4614-4619	these	_	
24-27	4620-4631	populations	_	
24-28	4631-4632	.	_	

#Text=Studies examining connectivity during the psychological processes of cognitive control and reward, have been conducted, providing more precise measures of connectivity across networks that relate to these domains.
25-1	4633-4640	Studies	_	
25-2	4641-4650	examining	_	
25-3	4651-4663	connectivity	_	
25-4	4664-4670	during	_	
25-5	4671-4674	the	_	
25-6	4675-4688	psychological	_	
25-7	4689-4698	processes	_	
25-8	4699-4701	of	_	
25-9	4702-4711	cognitive	_	
25-10	4712-4719	control	_	
25-11	4720-4723	and	_	
25-12	4724-4730	reward	_	
25-13	4730-4731	,	_	
25-14	4732-4736	have	_	
25-15	4737-4741	been	_	
25-16	4742-4751	conducted	_	
25-17	4751-4752	,	_	
25-18	4753-4762	providing	_	
25-19	4763-4767	more	_	
25-20	4768-4775	precise	_	
25-21	4776-4784	measures	_	
25-22	4785-4787	of	_	
25-23	4788-4800	connectivity	_	
25-24	4801-4807	across	_	
25-25	4808-4816	networks	_	
25-26	4817-4821	that	_	
25-27	4822-4828	relate	_	
25-28	4829-4831	to	_	
25-29	4832-4837	these	_	
25-30	4838-4845	domains	_	
25-31	4845-4846	.	_	

#Text=Analytic methods that can reveal key features of brain network functioning during psychological processes may capture disruptions in connectivity that harbour the provisions for relapse risk in addiction disorders, and which may be clinical targets for medication development.
26-1	4847-4855	Analytic	_	
26-2	4856-4863	methods	_	
26-3	4864-4868	that	_	
26-4	4869-4872	can	_	
26-5	4873-4879	reveal	_	
26-6	4880-4883	key	_	
26-7	4884-4892	features	_	
26-8	4893-4895	of	_	
26-9	4896-4901	brain	_	
26-10	4902-4909	network	_	
26-11	4910-4921	functioning	_	
26-12	4922-4928	during	_	
26-13	4929-4942	psychological	_	
26-14	4943-4952	processes	_	
26-15	4953-4956	may	_	
26-16	4957-4964	capture	_	
26-17	4965-4976	disruptions	_	
26-18	4977-4979	in	_	
26-19	4980-4992	connectivity	_	
26-20	4993-4997	that	_	
26-21	4998-5005	harbour	_	
26-22	5006-5009	the	_	
26-23	5010-5020	provisions	_	
26-24	5021-5024	for	_	
26-25	5025-5032	relapse	_	
26-26	5033-5037	risk	_	
26-27	5038-5040	in	_	
26-28	5041-5050	addiction	_	
26-29	5051-5060	disorders	_	
26-30	5060-5061	,	_	
26-31	5062-5065	and	_	
26-32	5066-5071	which	_	
26-33	5072-5075	may	_	
26-34	5076-5078	be	_	
26-35	5079-5087	clinical	_	
26-36	5088-5095	targets	_	
26-37	5096-5099	for	_	
26-38	5100-5110	medication	_	
26-39	5111-5122	development	_	
26-40	5122-5123	.	_	

#Text=We have previously shown that abstinent substance-dependent populations demonstrate regional disturbances during reward processing, that likely represent disruptions in connectivity across global brain networks.
27-1	5124-5126	We	_	
27-2	5127-5131	have	_	
27-3	5132-5142	previously	_	
27-4	5143-5148	shown	_	
27-5	5149-5153	that	_	
27-6	5154-5163	abstinent	_	
27-7	5164-5183	substance-dependent	_	
27-8	5184-5195	populations	_	
27-9	5196-5207	demonstrate	_	
27-10	5208-5216	regional	_	
27-11	5217-5229	disturbances	_	
27-12	5230-5236	during	_	
27-13	5237-5243	reward	_	
27-14	5244-5254	processing	_	
27-15	5254-5255	,	_	
27-16	5256-5260	that	_	
27-17	5261-5267	likely	_	
27-18	5268-5277	represent	_	
27-19	5278-5289	disruptions	_	
27-20	5290-5292	in	_	
27-21	5293-5305	connectivity	_	
27-22	5306-5312	across	_	
27-23	5313-5319	global	_	
27-24	5320-5325	brain	_	
27-25	5326-5334	networks	_	
27-26	5334-5335	.	_	

#Text=This report documents a novel analytical approach that has attempted to identify differences in reward-related global network connectivity in an addiction population, an approach that departs from merely attempting to identify regional disturbances using common voxel-wise analyses.
28-1	5336-5340	This	_	
28-2	5341-5347	report	_	
28-3	5348-5357	documents	_	
28-4	5358-5359	a	_	
28-5	5360-5365	novel	_	
28-6	5366-5376	analytical	_	
28-7	5377-5385	approach	_	
28-8	5386-5390	that	_	
28-9	5391-5394	has	_	
28-10	5395-5404	attempted	_	
28-11	5405-5407	to	_	
28-12	5408-5416	identify	_	
28-13	5417-5428	differences	_	
28-14	5429-5431	in	_	
28-15	5432-5446	reward-related	_	
28-16	5447-5453	global	_	
28-17	5454-5461	network	_	
28-18	5462-5474	connectivity	_	
28-19	5475-5477	in	_	
28-20	5478-5480	an	_	
28-21	5481-5490	addiction	_	
28-22	5491-5501	population	_	
28-23	5501-5502	,	_	
28-24	5503-5505	an	_	
28-25	5506-5514	approach	_	
28-26	5515-5519	that	_	
28-27	5520-5527	departs	_	
28-28	5528-5532	from	_	
28-29	5533-5539	merely	_	
28-30	5540-5550	attempting	_	
28-31	5551-5553	to	_	
28-32	5554-5562	identify	_	
28-33	5563-5571	regional	_	
28-34	5572-5584	disturbances	_	
28-35	5585-5590	using	_	
28-36	5591-5597	common	_	
28-37	5598-5608	voxel-wise	_	
28-38	5609-5617	analyses	_	
28-39	5617-5618	.	_	

#Text=Here an addiction group in extended abstinence was compared with a control group on measures of voxel-wise and global network connectivity associated with reward anticipation on a monetary incentive delay task.
29-1	5619-5623	Here	_	
29-2	5624-5626	an	_	
29-3	5627-5636	addiction	_	
29-4	5637-5642	group	_	
29-5	5643-5645	in	_	
29-6	5646-5654	extended	_	
29-7	5655-5665	abstinence	_	
29-8	5666-5669	was	_	
29-9	5670-5678	compared	_	
29-10	5679-5683	with	_	
29-11	5684-5685	a	_	
29-12	5686-5693	control	_	
29-13	5694-5699	group	_	
29-14	5700-5702	on	_	
29-15	5703-5711	measures	_	
29-16	5712-5714	of	_	
29-17	5715-5725	voxel-wise	_	
29-18	5726-5729	and	_	
29-19	5730-5736	global	_	
29-20	5737-5744	network	_	
29-21	5745-5757	connectivity	_	
29-22	5758-5768	associated	_	
29-23	5769-5773	with	_	
29-24	5774-5780	reward	_	
29-25	5781-5793	anticipation	_	
29-26	5794-5796	on	_	
29-27	5797-5798	a	_	
29-28	5799-5807	monetary	_	
29-29	5808-5817	incentive	_	
29-30	5818-5823	delay	_	
29-31	5824-5828	task	_	
29-32	5828-5829	.	_	

#Text=We hypothesized that the addiction group would exhibit whole brain activation and global network connectivity disturbances, but that measures of connectivity would prove more sensitive to highlighting neural disturbances during reward processing in addiction.
30-1	5830-5832	We	_	
30-2	5833-5845	hypothesized	_	
30-3	5846-5850	that	_	
30-4	5851-5854	the	_	
30-5	5855-5864	addiction	_	
30-6	5865-5870	group	_	
30-7	5871-5876	would	_	
30-8	5877-5884	exhibit	_	
30-9	5885-5890	whole	_	
30-10	5891-5896	brain	_	
30-11	5897-5907	activation	_	
30-12	5908-5911	and	_	
30-13	5912-5918	global	_	
30-14	5919-5926	network	_	
30-15	5927-5939	connectivity	_	
30-16	5940-5952	disturbances	_	
30-17	5952-5953	,	_	
30-18	5954-5957	but	_	
30-19	5958-5962	that	_	
30-20	5963-5971	measures	_	
30-21	5972-5974	of	_	
30-22	5975-5987	connectivity	_	
30-23	5988-5993	would	_	
30-24	5994-5999	prove	_	
30-25	6000-6004	more	_	
30-26	6005-6014	sensitive	_	
30-27	6015-6017	to	_	
30-28	6018-6030	highlighting	_	
30-29	6031-6037	neural	_	
30-30	6038-6050	disturbances	_	
30-31	6051-6057	during	_	
30-32	6058-6064	reward	_	
30-33	6065-6075	processing	_	
30-34	6076-6078	in	_	
30-35	6079-6088	addiction	_	
30-36	6088-6089	.	_	

#Text=Material and methods
#Text=Participants
#Text=Sixty-eight control (CON: mean age 39.79 ± 1.22; 18 females, 50 males) and 83 addiction (ADD: mean age 40.05 ± 0.92; 16 females, 67 males) participants completed the current study.
31-1	6090-6098	Material	_	
31-2	6099-6102	and	_	
31-3	6103-6110	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
31-4	6111-6123	Participants	_	
31-5	6124-6135	Sixty-eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-6	6136-6143	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[19]	
31-7	6144-6145	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-8	6145-6148	CON	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-9	6148-6149	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-10	6150-6154	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-11	6155-6158	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-12	6159-6164	39.79	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-13	6164-6165	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-14	6165-6166	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-15	6166-6167	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-16	6167-6171	1.22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-17	6171-6172	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-18	6173-6175	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-19	6176-6183	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-20	6183-6184	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-21	6185-6187	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-22	6188-6193	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-23	6193-6194	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-24	6195-6198	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-25	6199-6201	83	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-26	6202-6211	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[20]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[21]	
31-27	6212-6213	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-28	6213-6216	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-29	6216-6217	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-30	6218-6222	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-31	6223-6226	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-32	6227-6232	40.05	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-33	6232-6233	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-34	6233-6234	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-35	6234-6235	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-36	6235-6239	0.92	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-37	6239-6240	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-38	6241-6243	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-39	6244-6251	females	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-40	6251-6252	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-41	6253-6255	67	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-42	6256-6261	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-43	6261-6262	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-44	6263-6275	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-45	6276-6285	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-46	6286-6289	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-47	6290-6297	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-48	6298-6303	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
31-49	6303-6304	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The current dataset was collected as part of a multi-centre study involving three study sites in the United Kingdom (Imperial College London, University of Cambridge and University of Manchester – ICCAM).
32-1	6305-6308	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-2	6309-6316	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-3	6317-6324	dataset	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-4	6325-6328	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-5	6329-6338	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-6	6339-6341	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-7	6342-6346	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-8	6347-6349	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-9	6350-6351	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-10	6352-6364	multi-centre	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-11	6365-6370	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-12	6371-6380	involving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-13	6381-6386	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-14	6387-6392	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-15	6393-6398	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-16	6399-6401	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-17	6402-6405	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-18	6406-6412	United	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-19	6413-6420	Kingdom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-20	6421-6422	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-21	6422-6430	Imperial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-22	6431-6438	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-23	6439-6445	London	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-24	6445-6446	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-25	6447-6457	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-26	6458-6460	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-27	6461-6470	Cambridge	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-28	6471-6474	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-29	6475-6485	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-30	6486-6488	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-31	6489-6499	Manchester	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-32	6500-6501	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-33	6502-6507	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-34	6507-6508	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
32-35	6508-6509	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=For a more detailed description of the ICCAM Platform, see) and.
33-1	6510-6513	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-2	6514-6515	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-3	6516-6520	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-4	6521-6529	detailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-5	6530-6541	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-6	6542-6544	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-7	6545-6548	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-8	6549-6554	ICCAM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-9	6555-6563	Platform	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-10	6563-6564	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-11	6565-6568	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-12	6568-6569	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-13	6570-6573	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
33-14	6573-6574	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Inclusion criteria were individuals who met DSM-IV measures for current or prior substance dependence (e.g., alcohol, cocaine, opiates).
34-1	6575-6584	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-2	6585-6593	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-3	6594-6598	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-4	6599-6610	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-5	6611-6614	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-6	6615-6618	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-7	6619-6625	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-8	6626-6634	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-9	6635-6638	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-10	6639-6646	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-11	6647-6649	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-12	6650-6655	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-13	6656-6665	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-14	6666-6676	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-15	6677-6678	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-16	6678-6681	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-17	6681-6682	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-18	6682-6683	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-19	6684-6691	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-20	6691-6692	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-21	6693-6700	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-22	6700-6701	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-23	6702-6709	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-24	6709-6710	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
34-25	6710-6711	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The ADD group consisted of 29 (35%) pure alcohol-dependent, 42 (50%) poly substance-dependent (e.g., alcohol and cocaine, cocaine and opiate) and 12 (15%) mono substance-dependent (e.g., cocaine, opiates) volunteers.
35-1	6712-6715	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-2	6716-6719	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[22]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[23]	
35-3	6720-6725	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-4	6726-6735	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-5	6736-6738	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-6	6739-6741	29	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-7	6742-6743	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-8	6743-6746	35%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-9	6746-6747	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-10	6748-6752	pure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-11	6753-6770	alcohol-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-12	6770-6771	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-13	6772-6774	42	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-14	6775-6776	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-15	6776-6779	50%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-16	6779-6780	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-17	6781-6785	poly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-18	6786-6805	substance-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-19	6806-6807	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-20	6807-6810	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-21	6810-6811	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-22	6811-6812	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-23	6813-6820	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-24	6821-6824	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-25	6825-6832	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-26	6832-6833	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-27	6834-6841	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-28	6842-6845	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-29	6846-6852	opiate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-30	6852-6853	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-31	6854-6857	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-32	6858-6860	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-33	6861-6862	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-34	6862-6865	15%	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-35	6865-6866	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-36	6867-6871	mono	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-37	6872-6891	substance-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-38	6892-6893	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-39	6893-6896	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-40	6896-6897	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-41	6897-6898	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-42	6899-6906	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-43	6906-6907	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-44	6908-6915	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-45	6915-6916	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-46	6917-6927	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
35-47	6927-6928	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=While addiction studies typically recruit volunteers in early abstinence, there was no upper limit in the current study.
36-1	6929-6934	While	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-2	6935-6944	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-3	6945-6952	studies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-4	6953-6962	typically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-5	6963-6970	recruit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-6	6971-6981	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-7	6982-6984	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-8	6985-6990	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-9	6991-7001	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-10	7001-7002	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-11	7003-7008	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-12	7009-7012	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-13	7013-7015	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-14	7016-7021	upper	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-15	7022-7027	limit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-16	7028-7030	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-17	7031-7034	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-18	7035-7042	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-19	7043-7048	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-20	7048-7049	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The mean abstinence length from alcohol in the current sample was 15.00 ± 3.50 months, while for cocaine and opiates it was 27.99 ± 3.72 and 39.04 ± 7.75 months, respectively.
37-1	7050-7053	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-2	7054-7058	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-3	7059-7069	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-4	7070-7076	length	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-5	7077-7081	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-6	7082-7089	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-7	7090-7092	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-8	7093-7096	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-9	7097-7104	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-10	7105-7111	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-11	7112-7115	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-12	7116-7121	15.00	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-13	7121-7122	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-14	7122-7123	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-15	7123-7124	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-16	7124-7128	3.50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-17	7128-7129	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-18	7129-7135	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-19	7135-7136	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-20	7137-7142	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-21	7143-7146	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-22	7147-7154	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-23	7155-7158	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-24	7159-7166	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-25	7167-7169	it	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-26	7170-7173	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-27	7174-7179	27.99	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-28	7179-7180	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-29	7180-7181	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-30	7181-7182	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-31	7182-7186	3.72	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-32	7187-7190	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-33	7191-7196	39.04	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-34	7196-7197	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-35	7197-7198	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-36	7198-7199	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-37	7199-7203	7.75	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-38	7203-7204	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-39	7204-7210	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-40	7210-7211	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-41	7212-7224	respectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
37-42	7224-7225	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Therefore, the current ADD group was made of a heterogenous sample with former substance-dependencies, and with variable levels of substance abstinence at the time of testing.
38-1	7226-7235	Therefore	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-2	7235-7236	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-3	7237-7240	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-4	7241-7248	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-5	7249-7252	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-6	7253-7258	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-7	7259-7262	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-8	7263-7267	made	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-9	7268-7270	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-10	7271-7272	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-11	7273-7285	heterogenous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-12	7286-7292	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-13	7293-7297	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-14	7298-7304	former	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-15	7305-7327	substance-dependencies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-16	7327-7328	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-17	7329-7332	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-18	7333-7337	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-19	7338-7346	variable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-20	7347-7353	levels	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-21	7354-7356	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-22	7357-7366	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-23	7367-7377	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-24	7378-7380	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-25	7381-7384	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-26	7385-7389	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-27	7390-7392	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-28	7393-7400	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
38-29	7400-7401	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=This meant that there was no substance dependence measure that was shared by all members of the ADD group.
39-1	7402-7406	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-2	7407-7412	meant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-3	7413-7417	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-4	7418-7423	there	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-5	7424-7427	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-6	7428-7430	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-7	7431-7440	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-8	7441-7451	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-9	7452-7459	measure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-10	7460-7464	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-11	7465-7468	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-12	7469-7475	shared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-13	7476-7478	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-14	7479-7482	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-15	7483-7490	members	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-16	7491-7493	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-17	7494-7497	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-18	7498-7501	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[24]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[25]	
39-19	7502-7507	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
39-20	7507-7508	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The CON group had no previous history of substance abuse, as assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and timeline follow-back.
40-1	7509-7512	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-2	7513-7516	CON	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]	
40-3	7517-7522	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-4	7523-7526	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-5	7527-7529	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-6	7530-7538	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-7	7539-7546	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-8	7547-7549	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-9	7550-7559	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-10	7560-7565	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-11	7565-7566	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-12	7567-7569	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-13	7570-7578	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-14	7579-7584	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-15	7585-7588	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-16	7589-7596	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-17	7596-7597	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-18	7598-7605	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-19	7606-7609	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-20	7610-7619	Substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-21	7620-7631	Involvement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-22	7632-7641	Screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-23	7642-7646	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-24	7647-7648	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-25	7648-7654	ASSIST	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-26	7654-7655	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[27]	
40-27	7656-7659	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-28	7660-7668	timeline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-29	7669-7680	follow-back	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
40-30	7680-7681	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=All participants were required to provide a negative breath alcohol test and a negative urine sample for various drugs of abuse on the day of testing (screening for the presence of amphetamines, benzodiazepines, cannabinoids, cocaine and opiates).
41-1	7682-7685	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-2	7686-7698	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-3	7699-7703	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-4	7704-7712	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-5	7713-7715	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-6	7716-7723	provide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-7	7724-7725	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-8	7726-7734	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-9	7735-7741	breath	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-10	7742-7749	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-11	7750-7754	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-12	7755-7758	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-13	7759-7760	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-14	7761-7769	negative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-15	7770-7775	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-16	7776-7782	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-17	7783-7786	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-18	7787-7794	various	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-19	7795-7800	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-20	7801-7803	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-21	7804-7809	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-22	7810-7812	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-23	7813-7816	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-24	7817-7820	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-25	7821-7823	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-26	7824-7831	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-27	7832-7833	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-28	7833-7842	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-29	7843-7846	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-30	7847-7850	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-31	7851-7859	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-32	7860-7862	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-33	7863-7875	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-34	7875-7876	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-35	7877-7892	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-36	7892-7893	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-37	7894-7906	cannabinoids	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-38	7906-7907	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-39	7908-7915	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-40	7916-7919	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-41	7920-7927	opiates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-42	7927-7928	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
41-43	7928-7929	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=The Mini-International Neuropsychiatric Interview (MINI) was administered to all participants by a trained psychiatrist to screen for the presence of Axis I psychiatric disorders that were part of the study exclusion criteria.
42-1	7930-7933	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-2	7934-7952	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-3	7953-7969	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-4	7970-7979	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-5	7980-7981	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-6	7981-7985	MINI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-7	7985-7986	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[28]	
42-8	7987-7990	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-9	7991-8003	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-10	8004-8006	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-11	8007-8010	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-12	8011-8023	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-13	8024-8026	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-14	8027-8028	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-15	8029-8036	trained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-16	8037-8049	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-17	8050-8052	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-18	8053-8059	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-19	8060-8063	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-20	8064-8067	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-21	8068-8076	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-22	8077-8079	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-23	8080-8084	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-24	8085-8086	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-25	8087-8098	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-26	8099-8108	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-27	8109-8113	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-28	8114-8118	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-29	8119-8123	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-30	8124-8126	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-31	8127-8130	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-32	8131-8136	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-33	8137-8146	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-34	8147-8155	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
42-35	8155-8156	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Exclusion criteria included 1) current use of regular prescription or non-prescription medication that could not be stopped; 2) current primary axis I diagnosis, past history of psychosis (unless drug-induced); 3) current or past history of enduring severe mental illness (e.g., schizophrenia, bipolar affective disorder); 4) other current or past psychiatric history that, in the opinion of a psychiatrist, contraindicated participation; 5) history or presence of a significant neurological diagnosis that may have influenced the outcome or analysis of the results; 6) claustrophobia or unable to lie still in the MRI scanner for up to 90 min and 7) presence of a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre-MRI questionnaire.
43-1	8157-8166	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-2	8167-8175	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-3	8176-8184	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-4	8185-8186	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-5	8186-8187	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-6	8188-8195	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-7	8196-8199	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-8	8200-8202	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-9	8203-8210	regular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-10	8211-8223	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-11	8224-8226	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-12	8227-8243	non-prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-13	8244-8254	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-14	8255-8259	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-15	8260-8265	could	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-16	8266-8269	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-17	8270-8272	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-18	8273-8280	stopped	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-19	8280-8281	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-20	8282-8283	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-21	8283-8284	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-22	8285-8292	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-23	8293-8300	primary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-24	8301-8305	axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-25	8306-8307	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-26	8308-8317	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-27	8317-8318	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-28	8319-8323	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-29	8324-8331	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-30	8332-8334	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-31	8335-8344	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-32	8345-8346	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-33	8346-8352	unless	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-34	8353-8365	drug-induced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-35	8365-8366	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-36	8366-8367	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-37	8368-8369	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-38	8369-8370	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-39	8371-8378	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-40	8379-8381	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-41	8382-8386	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-42	8387-8394	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-43	8395-8397	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-44	8398-8406	enduring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-45	8407-8413	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-46	8414-8420	mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-47	8421-8428	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-48	8429-8430	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-49	8430-8433	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-50	8433-8434	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-51	8434-8435	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-52	8436-8449	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-53	8449-8450	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-54	8451-8458	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-55	8459-8468	affective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-56	8469-8477	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-57	8477-8478	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-58	8478-8479	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-59	8480-8481	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-60	8481-8482	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-61	8483-8488	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-62	8489-8496	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-63	8497-8499	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-64	8500-8504	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-65	8505-8516	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-66	8517-8524	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-67	8525-8529	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-68	8529-8530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-69	8531-8533	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-70	8534-8537	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-71	8538-8545	opinion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-72	8546-8548	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-73	8549-8550	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-74	8551-8563	psychiatrist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-75	8563-8564	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-76	8565-8580	contraindicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-77	8581-8594	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-78	8594-8595	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-79	8596-8597	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-80	8597-8598	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-81	8599-8606	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-82	8607-8609	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-83	8610-8618	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-84	8619-8621	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-85	8622-8623	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-86	8624-8635	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-87	8636-8648	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-88	8649-8658	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-89	8659-8663	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-90	8664-8667	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-91	8668-8672	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-92	8673-8683	influenced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-93	8684-8687	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-94	8688-8695	outcome	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-95	8696-8698	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-96	8699-8707	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-97	8708-8710	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-98	8711-8714	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-99	8715-8722	results	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-100	8722-8723	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-101	8724-8725	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-102	8725-8726	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-103	8727-8741	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-104	8742-8744	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-105	8745-8751	unable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-106	8752-8754	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-107	8755-8758	lie	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-108	8759-8764	still	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-109	8765-8767	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-110	8768-8771	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-111	8772-8775	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-112	8776-8783	scanner	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-113	8784-8787	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-114	8788-8790	up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-115	8791-8793	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-116	8794-8796	90	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-117	8796-8797	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-118	8797-8800	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-119	8801-8804	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-120	8805-8806	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-121	8806-8807	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-122	8808-8816	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-123	8817-8819	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-124	8820-8821	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-125	8822-8829	cardiac	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-126	8830-8839	pacemaker	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-127	8839-8840	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-128	8841-8846	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-129	8847-8857	electronic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-130	8858-8864	device	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-131	8865-8867	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-132	8868-8873	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-133	8874-8877	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-134	8878-8894	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-135	8894-8895	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-136	8896-8905	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-137	8906-8915	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-138	8915-8916	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-139	8917-8919	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-140	8920-8928	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-141	8929-8931	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-142	8932-8933	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-143	8934-8942	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-144	8943-8950	pre-MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-145	8951-8964	questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[29]	
43-146	8964-8965	.	_	

#Text=Secondary or lifetime history of depression or anxiety was permitted in both the ADD and CON groups since these are very common psychiatric disorders.
44-1	8966-8975	Secondary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-2	8976-8978	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-3	8979-8987	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-4	8988-8995	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-5	8996-8998	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-6	8999-9009	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-7	9010-9012	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-8	9013-9020	anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-9	9021-9024	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-10	9025-9034	permitted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-11	9035-9037	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-12	9038-9042	both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-13	9043-9046	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-14	9047-9050	ADD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[31]|http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[32]	
44-15	9051-9054	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-16	9055-9058	CON	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[33]	
44-17	9059-9065	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-18	9066-9071	since	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-19	9072-9077	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-20	9078-9081	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-21	9082-9086	very	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-22	9087-9093	common	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-23	9094-9105	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-24	9106-9115	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	
44-25	9115-9116	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[30]	

#Text=All participants provided written informed consent.
45-1	9117-9120	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-2	9121-9133	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-3	9134-9142	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-4	9143-9150	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-5	9151-9159	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-6	9160-9167	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	
45-7	9167-9168	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[34]	

#Text=The study was conducted in accordance with the Declaration of Helsinki.
46-1	9169-9172	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-2	9173-9178	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-3	9179-9182	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-4	9183-9192	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-5	9193-9195	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-6	9196-9206	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-7	9207-9211	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-8	9212-9215	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-9	9216-9227	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-10	9228-9230	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-11	9231-9239	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	
46-12	9239-9240	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[35]	

#Text=Ethical approval was obtained from West London and Gene Therapy Advisory Committee National Research Ethics Service Committee (11/H0707/9) and relevant research governance and Participant Identification Centre (PIC) approvals obtained.
47-1	9241-9248	Ethical	_	
47-2	9249-9257	approval	_	
47-3	9258-9261	was	_	
47-4	9262-9270	obtained	_	
47-5	9271-9275	from	_	
47-6	9276-9280	West	_	
47-7	9281-9287	London	_	
47-8	9288-9291	and	_	
47-9	9292-9296	Gene	_	
47-10	9297-9304	Therapy	_	
47-11	9305-9313	Advisory	_	
47-12	9314-9323	Committee	_	
47-13	9324-9332	National	_	
47-14	9333-9341	Research	_	
47-15	9342-9348	Ethics	_	
47-16	9349-9356	Service	_	
47-17	9357-9366	Committee	_	
47-18	9367-9368	(	_	
47-19	9368-9370	11	_	
47-20	9370-9371	/	_	
47-21	9371-9376	H0707	_	
47-22	9376-9377	/	_	
47-23	9377-9378	9	_	
47-24	9378-9379	)	_	
47-25	9380-9383	and	_	
47-26	9384-9392	relevant	_	
47-27	9393-9401	research	_	
47-28	9402-9412	governance	_	
47-29	9413-9416	and	_	
47-30	9417-9428	Participant	_	
47-31	9429-9443	Identification	_	
47-32	9444-9450	Centre	_	
47-33	9451-9452	(	_	
47-34	9452-9455	PIC	_	
47-35	9455-9456	)	_	
47-36	9457-9466	approvals	_	
47-37	9467-9475	obtained	_	
47-38	9475-9476	.	_	

#Text=Monetary incentive delay task (MID)
#Text=We used a “monetary incentive delay task” (MID), which was based on that originally employed by Knutson, and which we have used to already publish data from the ICCAM platform.
48-1	9477-9485	Monetary	_	
48-2	9486-9495	incentive	_	
48-3	9496-9501	delay	_	
48-4	9502-9506	task	_	
48-5	9507-9508	(	_	
48-6	9508-9511	MID	_	
48-7	9511-9512	)	_	
48-8	9513-9515	We	_	
48-9	9516-9520	used	_	
48-10	9521-9522	a	_	
48-11	9523-9524	“	_	
48-12	9524-9532	monetary	_	
48-13	9533-9542	incentive	_	
48-14	9543-9548	delay	_	
48-15	9549-9553	task	_	
48-16	9553-9554	”	_	
48-17	9555-9556	(	_	
48-18	9556-9559	MID	_	
48-19	9559-9560	)	_	
48-20	9560-9561	,	_	
48-21	9562-9567	which	_	
48-22	9568-9571	was	_	
48-23	9572-9577	based	_	
48-24	9578-9580	on	_	
48-25	9581-9585	that	_	
48-26	9586-9596	originally	_	
48-27	9597-9605	employed	_	
48-28	9606-9608	by	_	
48-29	9609-9616	Knutson	_	
48-30	9616-9617	,	_	
48-31	9618-9621	and	_	
48-32	9622-9627	which	_	
48-33	9628-9630	we	_	
48-34	9631-9635	have	_	
48-35	9636-9640	used	_	
48-36	9641-9643	to	_	
48-37	9644-9651	already	_	
48-38	9652-9659	publish	_	
48-39	9660-9664	data	_	
48-40	9665-9669	from	_	
48-41	9670-9673	the	_	
48-42	9674-9679	ICCAM	_	
48-43	9680-9688	platform	_	
48-44	9688-9689	.	_	

#Text=At the beginning of each trial, participants viewed one of three symbols (a cue) that indicated the potential to gain fifty pence (square containing an ascending arrow), lose fifty pence (square containing a descending arrow) or experience no financial outcome (square containing a horizontal line - here referred to as a neutral trial).
49-1	9690-9692	At	_	
49-2	9693-9696	the	_	
49-3	9697-9706	beginning	_	
49-4	9707-9709	of	_	
49-5	9710-9714	each	_	
49-6	9715-9720	trial	_	
49-7	9720-9721	,	_	
49-8	9722-9734	participants	_	
49-9	9735-9741	viewed	_	
49-10	9742-9745	one	_	
49-11	9746-9748	of	_	
49-12	9749-9754	three	_	
49-13	9755-9762	symbols	_	
49-14	9763-9764	(	_	
49-15	9764-9765	a	_	
49-16	9766-9769	cue	_	
49-17	9769-9770	)	_	
49-18	9771-9775	that	_	
49-19	9776-9785	indicated	_	
49-20	9786-9789	the	_	
49-21	9790-9799	potential	_	
49-22	9800-9802	to	_	
49-23	9803-9807	gain	_	
49-24	9808-9813	fifty	_	
49-25	9814-9819	pence	_	
49-26	9820-9821	(	_	
49-27	9821-9827	square	_	
49-28	9828-9838	containing	_	
49-29	9839-9841	an	_	
49-30	9842-9851	ascending	_	
49-31	9852-9857	arrow	_	
49-32	9857-9858	)	_	
49-33	9858-9859	,	_	
49-34	9860-9864	lose	_	
49-35	9865-9870	fifty	_	
49-36	9871-9876	pence	_	
49-37	9877-9878	(	_	
49-38	9878-9884	square	_	
49-39	9885-9895	containing	_	
49-40	9896-9897	a	_	
49-41	9898-9908	descending	_	
49-42	9909-9914	arrow	_	
49-43	9914-9915	)	_	
49-44	9916-9918	or	_	
49-45	9919-9929	experience	_	
49-46	9930-9932	no	_	
49-47	9933-9942	financial	_	
49-48	9943-9950	outcome	_	
49-49	9951-9952	(	_	
49-50	9952-9958	square	_	
49-51	9959-9969	containing	_	
49-52	9970-9971	a	_	
49-53	9972-9982	horizontal	_	
49-54	9983-9987	line	_	
49-55	9988-9989	-	_	
49-56	9990-9994	here	_	
49-57	9995-10003	referred	_	
49-58	10004-10006	to	_	
49-59	10007-10009	as	_	
49-60	10010-10011	a	_	
49-61	10012-10019	neutral	_	
49-62	10020-10025	trial	_	
49-63	10025-10026	)	_	
49-64	10026-10027	.	_	

#Text=Each cue was presented for one second, with a variable duration (2–4 s) for the subsequent anticipation period.
50-1	10028-10032	Each	_	
50-2	10033-10036	cue	_	
50-3	10037-10040	was	_	
50-4	10041-10050	presented	_	
50-5	10051-10054	for	_	
50-6	10055-10058	one	_	
50-7	10059-10065	second	_	
50-8	10065-10066	,	_	
50-9	10067-10071	with	_	
50-10	10072-10073	a	_	
50-11	10074-10082	variable	_	
50-12	10083-10091	duration	_	
50-13	10092-10093	(	_	
50-14	10093-10094	2	_	
50-15	10094-10095	–	_	
50-16	10095-10096	4	_	
50-17	10096-10097	 	_	
50-18	10097-10098	s	_	
50-19	10098-10099	)	_	
50-20	10100-10103	for	_	
50-21	10104-10107	the	_	
50-22	10108-10118	subsequent	_	
50-23	10119-10131	anticipation	_	
50-24	10132-10138	period	_	
50-25	10138-10139	.	_	

#Text=Following the anticipation period, participants made a button press response upon the presentation of a visual target (star located within a circle).
51-1	10140-10149	Following	_	
51-2	10150-10153	the	_	
51-3	10154-10166	anticipation	_	
51-4	10167-10173	period	_	
51-5	10173-10174	,	_	
51-6	10175-10187	participants	_	
51-7	10188-10192	made	_	
51-8	10193-10194	a	_	
51-9	10195-10201	button	_	
51-10	10202-10207	press	_	
51-11	10208-10216	response	_	
51-12	10217-10221	upon	_	
51-13	10222-10225	the	_	
51-14	10226-10238	presentation	_	
51-15	10239-10241	of	_	
51-16	10242-10243	a	_	
51-17	10244-10250	visual	_	
51-18	10251-10257	target	_	
51-19	10258-10259	(	_	
51-20	10259-10263	star	_	
51-21	10264-10271	located	_	
51-22	10272-10278	within	_	
51-23	10279-10280	a	_	
51-24	10281-10287	circle	_	
51-25	10287-10288	)	_	
51-26	10288-10289	.	_	

#Text=Following their response to the visual target, participants received feedback (1.5 s) as to whether they were successful (“Hit”) or unsuccessful (“Miss”) on that trial and saw a running total of their winnings up to that point in the task.
52-1	10290-10299	Following	_	
52-2	10300-10305	their	_	
52-3	10306-10314	response	_	
52-4	10315-10317	to	_	
52-5	10318-10321	the	_	
52-6	10322-10328	visual	_	
52-7	10329-10335	target	_	
52-8	10335-10336	,	_	
52-9	10337-10349	participants	_	
52-10	10350-10358	received	_	
52-11	10359-10367	feedback	_	
52-12	10368-10369	(	_	
52-13	10369-10372	1.5	_	
52-14	10372-10373	 	_	
52-15	10373-10374	s	_	
52-16	10374-10375	)	_	
52-17	10376-10378	as	_	
52-18	10379-10381	to	_	
52-19	10382-10389	whether	_	
52-20	10390-10394	they	_	
52-21	10395-10399	were	_	
52-22	10400-10410	successful	_	
52-23	10411-10412	(	_	
52-24	10412-10413	“	_	
52-25	10413-10416	Hit	_	
52-26	10416-10417	”	_	
52-27	10417-10418	)	_	
52-28	10419-10421	or	_	
52-29	10422-10434	unsuccessful	_	
52-30	10435-10436	(	_	
52-31	10436-10437	“	_	
52-32	10437-10441	Miss	_	
52-33	10441-10442	”	_	
52-34	10442-10443	)	_	
52-35	10444-10446	on	_	
52-36	10447-10451	that	_	
52-37	10452-10457	trial	_	
52-38	10458-10461	and	_	
52-39	10462-10465	saw	_	
52-40	10466-10467	a	_	
52-41	10468-10475	running	_	
52-42	10476-10481	total	_	
52-43	10482-10484	of	_	
52-44	10485-10490	their	_	
52-45	10491-10499	winnings	_	
52-46	10500-10502	up	_	
52-47	10503-10505	to	_	
52-48	10506-10510	that	_	
52-49	10511-10516	point	_	
52-50	10517-10519	in	_	
52-51	10520-10523	the	_	
52-52	10524-10528	task	_	
52-53	10528-10529	.	_	

#Text=Following feedback, there was an end fixation period (3–5 s) before the commencement of the next trial.
53-1	10530-10539	Following	_	
53-2	10540-10548	feedback	_	
53-3	10548-10549	,	_	
53-4	10550-10555	there	_	
53-5	10556-10559	was	_	
53-6	10560-10562	an	_	
53-7	10563-10566	end	_	
53-8	10567-10575	fixation	_	
53-9	10576-10582	period	_	
53-10	10583-10584	(	_	
53-11	10584-10585	3	_	
53-12	10585-10586	–	_	
53-13	10586-10587	5	_	
53-14	10587-10588	 	_	
53-15	10588-10589	s	_	
53-16	10589-10590	)	_	
53-17	10591-10597	before	_	
53-18	10598-10601	the	_	
53-19	10602-10614	commencement	_	
53-20	10615-10617	of	_	
53-21	10618-10621	the	_	
53-22	10622-10626	next	_	
53-23	10627-10632	trial	_	
53-24	10632-10633	.	_	

#Text=Because the primary objective of ICCAM was to examine the neural correlates of reward anticipation, we chose to use a smaller number of loss trials in order to amplify the incentive salience of the gain trials during the task.
54-1	10634-10641	Because	_	
54-2	10642-10645	the	_	
54-3	10646-10653	primary	_	
54-4	10654-10663	objective	_	
54-5	10664-10666	of	_	
54-6	10667-10672	ICCAM	_	
54-7	10673-10676	was	_	
54-8	10677-10679	to	_	
54-9	10680-10687	examine	_	
54-10	10688-10691	the	_	
54-11	10692-10698	neural	_	
54-12	10699-10709	correlates	_	
54-13	10710-10712	of	_	
54-14	10713-10719	reward	_	
54-15	10720-10732	anticipation	_	
54-16	10732-10733	,	_	
54-17	10734-10736	we	_	
54-18	10737-10742	chose	_	
54-19	10743-10745	to	_	
54-20	10746-10749	use	_	
54-21	10750-10751	a	_	
54-22	10752-10759	smaller	_	
54-23	10760-10766	number	_	
54-24	10767-10769	of	_	
54-25	10770-10774	loss	_	
54-26	10775-10781	trials	_	
54-27	10782-10784	in	_	
54-28	10785-10790	order	_	
54-29	10791-10793	to	_	
54-30	10794-10801	amplify	_	
54-31	10802-10805	the	_	
54-32	10806-10815	incentive	_	
54-33	10816-10824	salience	_	
54-34	10825-10827	of	_	
54-35	10828-10831	the	_	
54-36	10832-10836	gain	_	
54-37	10837-10843	trials	_	
54-38	10844-10850	during	_	
54-39	10851-10854	the	_	
54-40	10855-10859	task	_	
54-41	10859-10860	.	_	

#Text=Consequently, there was a total of 18 gain, 6 lose and 18 neutral trials on each run of the task.
55-1	10861-10873	Consequently	_	
55-2	10873-10874	,	_	
55-3	10875-10880	there	_	
55-4	10881-10884	was	_	
55-5	10885-10886	a	_	
55-6	10887-10892	total	_	
55-7	10893-10895	of	_	
55-8	10896-10898	18	_	
55-9	10899-10903	gain	_	
55-10	10903-10904	,	_	
55-11	10905-10906	6	_	
55-12	10907-10911	lose	_	
55-13	10912-10915	and	_	
55-14	10916-10918	18	_	
55-15	10919-10926	neutral	_	
55-16	10927-10933	trials	_	
55-17	10934-10936	on	_	
55-18	10937-10941	each	_	
55-19	10942-10945	run	_	
55-20	10946-10948	of	_	
55-21	10949-10952	the	_	
55-22	10953-10957	task	_	
55-23	10957-10958	.	_	

#Text=The MID task was tailored to adapt to the visual target reaction time of each participant by using a staircase algorithm, such that the presentation of the visual target became shorter as performance improved during the experiment.
56-1	10959-10962	The	_	
56-2	10963-10966	MID	_	
56-3	10967-10971	task	_	
56-4	10972-10975	was	_	
56-5	10976-10984	tailored	_	
56-6	10985-10987	to	_	
56-7	10988-10993	adapt	_	
56-8	10994-10996	to	_	
56-9	10997-11000	the	_	
56-10	11001-11007	visual	_	
56-11	11008-11014	target	_	
56-12	11015-11023	reaction	_	
56-13	11024-11028	time	_	
56-14	11029-11031	of	_	
56-15	11032-11036	each	_	
56-16	11037-11048	participant	_	
56-17	11049-11051	by	_	
56-18	11052-11057	using	_	
56-19	11058-11059	a	_	
56-20	11060-11069	staircase	_	
56-21	11070-11079	algorithm	_	
56-22	11079-11080	,	_	
56-23	11081-11085	such	_	
56-24	11086-11090	that	_	
56-25	11091-11094	the	_	
56-26	11095-11107	presentation	_	
56-27	11108-11110	of	_	
56-28	11111-11114	the	_	
56-29	11115-11121	visual	_	
56-30	11122-11128	target	_	
56-31	11129-11135	became	_	
56-32	11136-11143	shorter	_	
56-33	11144-11146	as	_	
56-34	11147-11158	performance	_	
56-35	11159-11167	improved	_	
56-36	11168-11174	during	_	
56-37	11175-11178	the	_	
56-38	11179-11189	experiment	_	
56-39	11189-11190	.	_	

#Text=This enabled us to set a limit on the success rate of each participant (∼66%), which additionally served to incentivize participants to engage in the task.
57-1	11191-11195	This	_	
57-2	11196-11203	enabled	_	
57-3	11204-11206	us	_	
57-4	11207-11209	to	_	
57-5	11210-11213	set	_	
57-6	11214-11215	a	_	
57-7	11216-11221	limit	_	
57-8	11222-11224	on	_	
57-9	11225-11228	the	_	
57-10	11229-11236	success	_	
57-11	11237-11241	rate	_	
57-12	11242-11244	of	_	
57-13	11245-11249	each	_	
57-14	11250-11261	participant	_	
57-15	11262-11263	(	_	
57-16	11263-11264	∼	_	
57-17	11264-11267	66%	_	
57-18	11267-11268	)	_	
57-19	11268-11269	,	_	
57-20	11270-11275	which	_	
57-21	11276-11288	additionally	_	
57-22	11289-11295	served	_	
57-23	11296-11298	to	_	
57-24	11299-11310	incentivize	_	
57-25	11311-11323	participants	_	
57-26	11324-11326	to	_	
57-27	11327-11333	engage	_	
57-28	11334-11336	in	_	
57-29	11337-11340	the	_	
57-30	11341-11345	task	_	
57-31	11345-11346	.	_	

#Text=Participants were instructed to maximize their winnings and were told they would receive them at the end of the study.
58-1	11347-11359	Participants	_	
58-2	11360-11364	were	_	
58-3	11365-11375	instructed	_	
58-4	11376-11378	to	_	
58-5	11379-11387	maximize	_	
58-6	11388-11393	their	_	
58-7	11394-11402	winnings	_	
58-8	11403-11406	and	_	
58-9	11407-11411	were	_	
58-10	11412-11416	told	_	
58-11	11417-11421	they	_	
58-12	11422-11427	would	_	
58-13	11428-11435	receive	_	
58-14	11436-11440	them	_	
58-15	11441-11443	at	_	
58-16	11444-11447	the	_	
58-17	11448-11451	end	_	
58-18	11452-11454	of	_	
58-19	11455-11458	the	_	
58-20	11459-11464	study	_	
58-21	11464-11465	.	_	

#Text=Dependent measures were accuracy (percentage) and mean reaction time (milliseconds) to the visual target on each of the gain, lose and neutral trials, and the amount won (£) on the task.
59-1	11466-11475	Dependent	_	
59-2	11476-11484	measures	_	
59-3	11485-11489	were	_	
59-4	11490-11498	accuracy	_	
59-5	11499-11500	(	_	
59-6	11500-11510	percentage	_	
59-7	11510-11511	)	_	
59-8	11512-11515	and	_	
59-9	11516-11520	mean	_	
59-10	11521-11529	reaction	_	
59-11	11530-11534	time	_	
59-12	11535-11536	(	_	
59-13	11536-11548	milliseconds	_	
59-14	11548-11549	)	_	
59-15	11550-11552	to	_	
59-16	11553-11556	the	_	
59-17	11557-11563	visual	_	
59-18	11564-11570	target	_	
59-19	11571-11573	on	_	
59-20	11574-11578	each	_	
59-21	11579-11581	of	_	
59-22	11582-11585	the	_	
59-23	11586-11590	gain	_	
59-24	11590-11591	,	_	
59-25	11592-11596	lose	_	
59-26	11597-11600	and	_	
59-27	11601-11608	neutral	_	
59-28	11609-11615	trials	_	
59-29	11615-11616	,	_	
59-30	11617-11620	and	_	
59-31	11621-11624	the	_	
59-32	11625-11631	amount	_	
59-33	11632-11635	won	_	
59-34	11636-11637	(	_	
59-35	11637-11638	£	_	
59-36	11638-11639	)	_	
59-37	11640-11642	on	_	
59-38	11643-11646	the	_	
59-39	11647-11651	task	_	
59-40	11651-11652	.	_	

#Text=Participants completed two runs of the task (432 s each) during scanning.
60-1	11653-11665	Participants	_	
60-2	11666-11675	completed	_	
60-3	11676-11679	two	_	
60-4	11680-11684	runs	_	
60-5	11685-11687	of	_	
60-6	11688-11691	the	_	
60-7	11692-11696	task	_	
60-8	11697-11698	(	_	
60-9	11698-11701	432	_	
60-10	11701-11702	 	_	
60-11	11702-11703	s	_	
60-12	11704-11708	each	_	
60-13	11708-11709	)	_	
60-14	11710-11716	during	_	
60-15	11717-11725	scanning	_	
60-16	11725-11726	.	_	

#Text=The task was programmed using E-Prime version 2.0 (Psychology Software Tools, Pittsburgh, USA).
61-1	11727-11730	The	_	
61-2	11731-11735	task	_	
61-3	11736-11739	was	_	
61-4	11740-11750	programmed	_	
61-5	11751-11756	using	_	
61-6	11757-11764	E-Prime	_	
61-7	11765-11772	version	_	
61-8	11773-11776	2.0	_	
61-9	11777-11778	(	_	
61-10	11778-11788	Psychology	_	
61-11	11789-11797	Software	_	
61-12	11798-11803	Tools	_	
61-13	11803-11804	,	_	
61-14	11805-11815	Pittsburgh	_	
61-15	11815-11816	,	_	
61-16	11817-11820	USA	_	
61-17	11820-11821	)	_	
61-18	11821-11822	.	_	

#Text=Statistics
#Text=Group demographics were compared using simple independent samples t-test analyses.
62-1	11823-11833	Statistics	_	
62-2	11834-11839	Group	_	
62-3	11840-11852	demographics	_	
62-4	11853-11857	were	_	
62-5	11858-11866	compared	_	
62-6	11867-11872	using	_	
62-7	11873-11879	simple	_	
62-8	11880-11891	independent	_	
62-9	11892-11899	samples	_	
62-10	11900-11906	t-test	_	
62-11	11907-11915	analyses	_	
62-12	11915-11916	.	_	

#Text=For analyses conducted on MID performance, two (Group: CON vs.
63-1	11917-11920	For	_	
63-2	11921-11929	analyses	_	
63-3	11930-11939	conducted	_	
63-4	11940-11942	on	_	
63-5	11943-11946	MID	_	
63-6	11947-11958	performance	_	
63-7	11958-11959	,	_	
63-8	11960-11963	two	_	
63-9	11964-11965	(	_	
63-10	11965-11970	Group	_	
63-11	11970-11971	:	_	
63-12	11972-11975	CON	_	
63-13	11976-11978	vs	_	
63-14	11978-11979	.	_	

#Text=ADD) by two (Condition: Gain vs.
64-1	11980-11983	ADD	_	
64-2	11983-11984	)	_	
64-3	11985-11987	by	_	
64-4	11988-11991	two	_	
64-5	11992-11993	(	_	
64-6	11993-12002	Condition	_	
64-7	12002-12003	:	_	
64-8	12004-12008	Gain	_	
64-9	12009-12011	vs	_	
64-10	12011-12012	.	_	

#Text=Neutral) analyses of variance were conducted.
65-1	12013-12020	Neutral	_	
65-2	12020-12021	)	_	
65-3	12022-12030	analyses	_	
65-4	12031-12033	of	_	
65-5	12034-12042	variance	_	
65-6	12043-12047	were	_	
65-7	12048-12057	conducted	_	
65-8	12057-12058	.	_	

#Text=The CON and ADD groups were also compared on the lose accuracy and lose reaction time performance measures, as well as the amount of money won (£), using analyses of variance.
66-1	12059-12062	The	_	
66-2	12063-12066	CON	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
66-3	12067-12070	and	_	
66-4	12071-12074	ADD	http://maven.renci.org/NeuroBridge/neurobridge#Abstinent[36]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[37]	
66-5	12075-12081	groups	_	
66-6	12082-12086	were	_	
66-7	12087-12091	also	_	
66-8	12092-12100	compared	_	
66-9	12101-12103	on	_	
66-10	12104-12107	the	_	
66-11	12108-12112	lose	_	
66-12	12113-12121	accuracy	_	
66-13	12122-12125	and	_	
66-14	12126-12130	lose	_	
66-15	12131-12139	reaction	_	
66-16	12140-12144	time	_	
66-17	12145-12156	performance	_	
66-18	12157-12165	measures	_	
66-19	12165-12166	,	_	
66-20	12167-12169	as	_	
66-21	12170-12174	well	_	
66-22	12175-12177	as	_	
66-23	12178-12181	the	_	
66-24	12182-12188	amount	_	
66-25	12189-12191	of	_	
66-26	12192-12197	money	_	
66-27	12198-12201	won	_	
66-28	12202-12203	(	_	
66-29	12203-12204	£	_	
66-30	12204-12205	)	_	
66-31	12205-12206	,	_	
66-32	12207-12212	using	_	
66-33	12213-12221	analyses	_	
66-34	12222-12224	of	_	
66-35	12225-12233	variance	_	
66-36	12233-12234	.	_	

#Text=These analyses were conducted controlling for study site.
67-1	12235-12240	These	_	
67-2	12241-12249	analyses	_	
67-3	12250-12254	were	_	
67-4	12255-12264	conducted	_	
67-5	12265-12276	controlling	_	
67-6	12277-12280	for	_	
67-7	12281-12286	study	_	
67-8	12287-12291	site	_	
67-9	12291-12292	.	_	

#Text=For the graph measures (see below) we conducted two (Group: CON vs.
68-1	12293-12296	For	_	
68-2	12297-12300	the	_	
68-3	12301-12306	graph	_	
68-4	12307-12315	measures	_	
68-5	12316-12317	(	_	
68-6	12317-12320	see	_	
68-7	12321-12326	below	_	
68-8	12326-12327	)	_	
68-9	12328-12330	we	_	
68-10	12331-12340	conducted	_	
68-11	12341-12344	two	_	
68-12	12345-12346	(	_	
68-13	12346-12351	Group	_	
68-14	12351-12352	:	_	
68-15	12353-12356	CON	_	
68-16	12357-12359	vs	_	
68-17	12359-12360	.	_	

#Text=ADD) by five (1 ⩽ K ⩽ 5) analyses of variance, while also controlling for study site.
69-1	12361-12364	ADD	_	
69-2	12364-12365	)	_	
69-3	12366-12368	by	_	
69-4	12369-12373	five	_	
69-5	12374-12375	(	_	
69-6	12375-12376	1	_	
69-7	12376-12377	 	_	
69-8	12377-12378	⩽	_	
69-9	12378-12379	 	_	
69-10	12379-12380	K	_	
69-11	12380-12381	 	_	
69-12	12381-12382	⩽	_	
69-13	12382-12383	 	_	
69-14	12383-12384	5	_	
69-15	12384-12385	)	_	
69-16	12386-12394	analyses	_	
69-17	12395-12397	of	_	
69-18	12398-12406	variance	_	
69-19	12406-12407	,	_	
69-20	12408-12413	while	_	
69-21	12414-12418	also	_	
69-22	12419-12430	controlling	_	
69-23	12431-12434	for	_	
69-24	12435-12440	study	_	
69-25	12441-12445	site	_	
69-26	12445-12446	.	_	

#Text=All these analyses were conducted using permutation testing (5000 iterations) in the R statistical software package (www.R-project.org).
70-1	12447-12450	All	_	
70-2	12451-12456	these	_	
70-3	12457-12465	analyses	_	
70-4	12466-12470	were	_	
70-5	12471-12480	conducted	_	
70-6	12481-12486	using	_	
70-7	12487-12498	permutation	_	
70-8	12499-12506	testing	_	
70-9	12507-12508	(	_	
70-10	12508-12512	5000	_	
70-11	12513-12523	iterations	_	
70-12	12523-12524	)	_	
70-13	12525-12527	in	_	
70-14	12528-12531	the	_	
70-15	12532-12533	R	_	
70-16	12534-12545	statistical	_	
70-17	12546-12554	software	_	
70-18	12555-12562	package	_	
70-19	12563-12564	(	_	
70-20	12564-12581	www.R-project.org	_	
70-21	12581-12582	)	_	
70-22	12582-12583	.	_	

#Text=Functional MRI (fMRI) Data acquisition
#Text=The ICCAM platform was designed to allow the rapid testing across sites of multiple compounds relevant to addiction treatment.
71-1	12584-12594	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-2	12595-12598	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-3	12599-12600	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-4	12600-12604	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-5	12604-12605	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[38]	
71-6	12606-12610	Data	_	
71-7	12611-12622	acquisition	_	
71-8	12623-12626	The	_	
71-9	12627-12632	ICCAM	_	
71-10	12633-12641	platform	_	
71-11	12642-12645	was	_	
71-12	12646-12654	designed	_	
71-13	12655-12657	to	_	
71-14	12658-12663	allow	_	
71-15	12664-12667	the	_	
71-16	12668-12673	rapid	_	
71-17	12674-12681	testing	_	
71-18	12682-12688	across	_	
71-19	12689-12694	sites	_	
71-20	12695-12697	of	_	
71-21	12698-12706	multiple	_	
71-22	12707-12716	compounds	_	
71-23	12717-12725	relevant	_	
71-24	12726-12728	to	_	
71-25	12729-12738	addiction	_	
71-26	12739-12748	treatment	_	
71-27	12748-12749	.	_	

#Text=Imaging at multiple sites in parallel on the ICCAM platform accelerated study completion, through the sharing of expertise, infrastructure and capacity. 
72-1	12750-12757	Imaging	_	
72-2	12758-12760	at	_	
72-3	12761-12769	multiple	_	
72-4	12770-12775	sites	_	
72-5	12776-12778	in	_	
72-6	12779-12787	parallel	_	
72-7	12788-12790	on	_	
72-8	12791-12794	the	_	
72-9	12795-12800	ICCAM	_	
72-10	12801-12809	platform	_	
72-11	12810-12821	accelerated	_	
72-12	12822-12827	study	_	
72-13	12828-12838	completion	_	
72-14	12838-12839	,	_	
72-15	12840-12847	through	_	
72-16	12848-12851	the	_	
72-17	12852-12859	sharing	_	
72-18	12860-12862	of	_	
72-19	12863-12872	expertise	_	
72-20	12872-12873	,	_	
72-21	12874-12888	infrastructure	_	
72-22	12889-12892	and	_	
72-23	12893-12901	capacity	_	
72-24	12901-12902	.	_	
72-25	12902-12903	 	_	

#Text=For a more comprehensive description of data acquisition across the three sites on ICCAM, please see McGonigle et al.
73-1	12903-12906	For	_	
73-2	12907-12908	a	_	
73-3	12909-12913	more	_	
73-4	12914-12927	comprehensive	_	
73-5	12928-12939	description	_	
73-6	12940-12942	of	_	
73-7	12943-12947	data	_	
73-8	12948-12959	acquisition	_	
73-9	12960-12966	across	_	
73-10	12967-12970	the	_	
73-11	12971-12976	three	_	
73-12	12977-12982	sites	_	
73-13	12983-12985	on	_	
73-14	12986-12991	ICCAM	_	
73-15	12991-12992	,	_	
73-16	12993-12999	please	_	
73-17	13000-13003	see	_	
73-18	13004-13013	McGonigle	_	
73-19	13014-13016	et	_	
73-20	13017-13019	al	_	
73-21	13019-13020	.	_	

#Text=Briefly, all centres operated MRI machines with a main magnetic field of 3 T (T).
74-1	13021-13028	Briefly	_	
74-2	13028-13029	,	_	
74-3	13030-13033	all	_	
74-4	13034-13041	centres	_	
74-5	13042-13050	operated	_	
74-6	13051-13054	MRI	_	
74-7	13055-13063	machines	_	
74-8	13064-13068	with	_	
74-9	13069-13070	a	_	
74-10	13071-13075	main	_	
74-11	13076-13084	magnetic	_	
74-12	13085-13090	field	_	
74-13	13091-13093	of	_	
74-14	13094-13095	3	_	
74-15	13095-13096	 	_	
74-16	13096-13097	T	_	
74-17	13098-13099	(	_	
74-18	13099-13100	T	_	
74-19	13100-13101	)	_	
74-20	13101-13102	.	_	

#Text=Centres in London and Cambridge operated nominally identical 3 T Siemens Tim Trio systems running the syngo MR B17 software with a Siemens 32 channel receive-only phased-array head coil.
75-1	13103-13110	Centres	_	
75-2	13111-13113	in	_	
75-3	13114-13120	London	_	
75-4	13121-13124	and	_	
75-5	13125-13134	Cambridge	_	
75-6	13135-13143	operated	_	
75-7	13144-13153	nominally	_	
75-8	13154-13163	identical	_	
75-9	13164-13165	3	_	
75-10	13165-13166	 	_	
75-11	13166-13167	T	_	
75-12	13168-13175	Siemens	_	
75-13	13176-13179	Tim	_	
75-14	13180-13184	Trio	_	
75-15	13185-13192	systems	_	
75-16	13193-13200	running	_	
75-17	13201-13204	the	_	
75-18	13205-13210	syngo	_	
75-19	13211-13213	MR	_	
75-20	13214-13217	B17	_	
75-21	13218-13226	software	_	
75-22	13227-13231	with	_	
75-23	13232-13233	a	_	
75-24	13234-13241	Siemens	_	
75-25	13242-13244	32	_	
75-26	13245-13252	channel	_	
75-27	13253-13265	receive-only	_	
75-28	13266-13278	phased-array	_	
75-29	13279-13283	head	_	
75-30	13284-13288	coil	_	
75-31	13288-13289	.	_	

#Text=The Manchester centre operated a 3 T Philips Achieva running version 2.6.3.5 software and an 8 element SENSE head coil.
76-1	13290-13293	The	_	
76-2	13294-13304	Manchester	_	
76-3	13305-13311	centre	_	
76-4	13312-13320	operated	_	
76-5	13321-13322	a	_	
76-6	13323-13324	3	_	
76-7	13324-13325	 	_	
76-8	13325-13326	T	_	
76-9	13327-13334	Philips	_	
76-10	13335-13342	Achieva	_	
76-11	13343-13350	running	_	
76-12	13351-13358	version	_	
76-13	13359-13366	2.6.3.5	_	
76-14	13367-13375	software	_	
76-15	13376-13379	and	_	
76-16	13380-13382	an	_	
76-17	13383-13384	8	_	
76-18	13385-13392	element	_	
76-19	13393-13398	SENSE	_	
76-20	13399-13403	head	_	
76-21	13404-13408	coil	_	
76-22	13408-13409	.	_	

#Text=For anatomical images, 160 high-resolution T1-weighted anatomic MPRAGE axial images (FOV 256 mm, thickness 1.0 mm, voxel size 1.0 × 1.0 × 1.0) were acquired (total duration 303 s).
77-1	13410-13413	For	_	
77-2	13414-13424	anatomical	_	
77-3	13425-13431	images	_	
77-4	13431-13432	,	_	
77-5	13433-13436	160	_	
77-6	13437-13452	high-resolution	_	
77-7	13453-13455	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
77-8	13455-13456	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
77-9	13456-13464	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[39]	
77-10	13465-13473	anatomic	_	
77-11	13474-13480	MPRAGE	_	
77-12	13481-13486	axial	_	
77-13	13487-13493	images	_	
77-14	13494-13495	(	_	
77-15	13495-13498	FOV	_	
77-16	13499-13502	256	_	
77-17	13502-13503	 	_	
77-18	13503-13505	mm	_	
77-19	13505-13506	,	_	
77-20	13507-13516	thickness	_	
77-21	13517-13520	1.0	_	
77-22	13520-13521	 	_	
77-23	13521-13523	mm	_	
77-24	13523-13524	,	_	
77-25	13525-13530	voxel	_	
77-26	13531-13535	size	_	
77-27	13536-13539	1.0	_	
77-28	13539-13540	 	_	
77-29	13540-13541	×	_	
77-30	13541-13542	 	_	
77-31	13542-13545	1.0	_	
77-32	13545-13546	 	_	
77-33	13546-13547	×	_	
77-34	13547-13548	 	_	
77-35	13548-13551	1.0	_	
77-36	13551-13552	)	_	
77-37	13553-13557	were	_	
77-38	13558-13566	acquired	_	
77-39	13567-13568	(	_	
77-40	13568-13573	total	_	
77-41	13574-13582	duration	_	
77-42	13583-13586	303	_	
77-43	13586-13587	 	_	
77-44	13587-13588	s	_	
77-45	13588-13589	)	_	
77-46	13589-13590	.	_	

#Text=Functional data were acquired using a T2* weighted echo-planar imaging sequence collecting 36 non-contiguous (0% gap) 3.0 mm axial slices covering the entire brain (TE = 31 ms, TR = 2000 ms, FOV 225 mm, 64 × 64 mm matrix size in Fourier space).
78-1	13591-13601	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
78-2	13602-13606	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
78-3	13607-13611	were	_	
78-4	13612-13620	acquired	_	
78-5	13621-13626	using	_	
78-6	13627-13628	a	_	
78-7	13629-13631	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[41]	
78-8	13631-13632	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[41]	
78-9	13633-13641	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[41]	
78-10	13642-13653	echo-planar	_	
78-11	13654-13661	imaging	_	
78-12	13662-13670	sequence	_	
78-13	13671-13681	collecting	_	
78-14	13682-13684	36	_	
78-15	13685-13699	non-contiguous	_	
78-16	13700-13701	(	_	
78-17	13701-13703	0%	_	
78-18	13704-13707	gap	_	
78-19	13707-13708	)	_	
78-20	13709-13712	3.0	_	
78-21	13712-13713	 	_	
78-22	13713-13715	mm	_	
78-23	13716-13721	axial	_	
78-24	13722-13728	slices	_	
78-25	13729-13737	covering	_	
78-26	13738-13741	the	_	
78-27	13742-13748	entire	_	
78-28	13749-13754	brain	_	
78-29	13755-13756	(	_	
78-30	13756-13758	TE	_	
78-31	13758-13759	 	_	
78-32	13759-13760	=	_	
78-33	13760-13761	 	_	
78-34	13761-13763	31	_	
78-35	13763-13764	 	_	
78-36	13764-13766	ms	_	
78-37	13766-13767	,	_	
78-38	13768-13770	TR	_	
78-39	13770-13771	 	_	
78-40	13771-13772	=	_	
78-41	13772-13773	 	_	
78-42	13773-13777	2000	_	
78-43	13777-13778	 	_	
78-44	13778-13780	ms	_	
78-45	13780-13781	,	_	
78-46	13782-13785	FOV	_	
78-47	13786-13789	225	_	
78-48	13789-13790	 	_	
78-49	13790-13792	mm	_	
78-50	13792-13793	,	_	
78-51	13794-13796	64	_	
78-52	13796-13797	 	_	
78-53	13797-13798	×	_	
78-54	13798-13799	 	_	
78-55	13799-13801	64	_	
78-56	13801-13802	 	_	
78-57	13802-13804	mm	_	
78-58	13805-13811	matrix	_	
78-59	13812-13816	size	_	
78-60	13817-13819	in	_	
78-61	13820-13827	Fourier	_	
78-62	13828-13833	space	_	
78-63	13833-13834	)	_	
78-64	13834-13835	.	_	

#Text=Each run of the MID task produced a total of 216 volumes of functional MRI data.
#Text=fMRI Data analyses
#Text=Data pre-processing and statistical analysis were conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl).
79-1	13836-13840	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-2	13841-13844	run	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-3	13845-13847	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-4	13848-13851	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-5	13852-13855	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-6	13856-13860	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-7	13861-13869	produced	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-8	13870-13871	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-9	13872-13877	total	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-10	13878-13880	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-11	13881-13884	216	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-12	13885-13892	volumes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-13	13893-13895	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]	
79-14	13896-13906	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[43]	
79-15	13907-13910	MRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[43]	
79-16	13911-13915	data	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[42]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[43]	
79-17	13915-13916	.	_	
79-18	13917-13921	fMRI	_	
79-19	13922-13926	Data	_	
79-20	13927-13935	analyses	_	
79-21	13936-13940	Data	_	
79-22	13941-13955	pre-processing	_	
79-23	13956-13959	and	_	
79-24	13960-13971	statistical	_	
79-25	13972-13980	analysis	_	
79-26	13981-13985	were	_	
79-27	13986-13995	conducted	_	
79-28	13996-14001	using	_	
79-29	14002-14006	FEAT	_	
79-30	14007-14008	(	_	
79-31	14008-14012	fMRI	_	
79-32	14013-14019	Expert	_	
79-33	14020-14028	Analysis	_	
79-34	14029-14033	Tool	_	
79-35	14033-14034	)	_	
79-36	14035-14039	from	_	
79-37	14040-14043	the	_	
79-38	14044-14049	FMRIB	_	
79-39	14050-14058	Software	_	
79-40	14059-14066	Library	_	
79-41	14067-14068	(	_	
79-42	14068-14086	www.fmrib.ox.ac.uk	_	
79-43	14086-14087	/	_	
79-44	14087-14090	fsl	_	
79-45	14090-14091	)	_	
79-46	14091-14092	.	_	

#Text=Pre-statistical processing was as follows: motion correction utilizing FMRIB’s Linear Image Registration Tool (MCFLIRT; non-brain matter removal using Brain Extraction Tool (BET); spatial smoothing with a 5-mm full-width half maximum Gaussian kernel; mean-based intensity normalization; nonlinear high-pass temporal filtering (Gaussian-weighted least squares straight line fit, with sigma = 25.0 s).
80-1	14093-14108	Pre-statistical	_	
80-2	14109-14119	processing	_	
80-3	14120-14123	was	_	
80-4	14124-14126	as	_	
80-5	14127-14134	follows	_	
80-6	14134-14135	:	_	
80-7	14136-14142	motion	_	
80-8	14143-14153	correction	_	
80-9	14154-14163	utilizing	_	
80-10	14164-14169	FMRIB	_	
80-11	14169-14170	’	_	
80-12	14170-14171	s	_	
80-13	14172-14178	Linear	_	
80-14	14179-14184	Image	_	
80-15	14185-14197	Registration	_	
80-16	14198-14202	Tool	_	
80-17	14203-14204	(	_	
80-18	14204-14211	MCFLIRT	_	
80-19	14211-14212	;	_	
80-20	14213-14222	non-brain	_	
80-21	14223-14229	matter	_	
80-22	14230-14237	removal	_	
80-23	14238-14243	using	_	
80-24	14244-14249	Brain	_	
80-25	14250-14260	Extraction	_	
80-26	14261-14265	Tool	_	
80-27	14266-14267	(	_	
80-28	14267-14270	BET	_	
80-29	14270-14271	)	_	
80-30	14271-14272	;	_	
80-31	14273-14280	spatial	_	
80-32	14281-14290	smoothing	_	
80-33	14291-14295	with	_	
80-34	14296-14297	a	_	
80-35	14298-14299	5	_	
80-36	14299-14300	-	_	
80-37	14300-14302	mm	_	
80-38	14303-14313	full-width	_	
80-39	14314-14318	half	_	
80-40	14319-14326	maximum	_	
80-41	14327-14335	Gaussian	_	
80-42	14336-14342	kernel	_	
80-43	14342-14343	;	_	
80-44	14344-14354	mean-based	_	
80-45	14355-14364	intensity	_	
80-46	14365-14378	normalization	_	
80-47	14378-14379	;	_	
80-48	14380-14389	nonlinear	_	
80-49	14390-14399	high-pass	_	
80-50	14400-14408	temporal	_	
80-51	14409-14418	filtering	_	
80-52	14419-14420	(	_	
80-53	14420-14437	Gaussian-weighted	_	
80-54	14438-14443	least	_	
80-55	14444-14451	squares	_	
80-56	14452-14460	straight	_	
80-57	14461-14465	line	_	
80-58	14466-14469	fit	_	
80-59	14469-14470	,	_	
80-60	14471-14475	with	_	
80-61	14476-14481	sigma	_	
80-62	14481-14482	 	_	
80-63	14482-14483	=	_	
80-64	14483-14484	 	_	
80-65	14484-14488	25.0	_	
80-66	14488-14489	 	_	
80-67	14489-14490	s	_	
80-68	14490-14491	)	_	
80-69	14491-14492	.	_	

#Text=The six rigid body movement parameters were also included as regressors in the model in FSL FEAT.
81-1	14493-14496	The	_	
81-2	14497-14500	six	_	
81-3	14501-14506	rigid	_	
81-4	14507-14511	body	_	
81-5	14512-14520	movement	_	
81-6	14521-14531	parameters	_	
81-7	14532-14536	were	_	
81-8	14537-14541	also	_	
81-9	14542-14550	included	_	
81-10	14551-14553	as	_	
81-11	14554-14564	regressors	_	
81-12	14565-14567	in	_	
81-13	14568-14571	the	_	
81-14	14572-14577	model	_	
81-15	14578-14580	in	_	
81-16	14581-14584	FSL	_	
81-17	14585-14589	FEAT	_	
81-18	14589-14590	.	_	

#Text=For each participant, first level whole-brain mixed-effects analyses were performed by modelling the MID anticipation periods (i.e. gain, neutral) as explanatory variables within the context of the general linear model on a voxel-by-voxel basis (variable boxcar functions for the cue + variable anticipation period regressors were convolved with the haemodynamic response function).
82-1	14591-14594	For	_	
82-2	14595-14599	each	_	
82-3	14600-14611	participant	_	
82-4	14611-14612	,	_	
82-5	14613-14618	first	_	
82-6	14619-14624	level	_	
82-7	14625-14636	whole-brain	_	
82-8	14637-14650	mixed-effects	_	
82-9	14651-14659	analyses	_	
82-10	14660-14664	were	_	
82-11	14665-14674	performed	_	
82-12	14675-14677	by	_	
82-13	14678-14687	modelling	_	
82-14	14688-14691	the	_	
82-15	14692-14695	MID	_	
82-16	14696-14708	anticipation	_	
82-17	14709-14716	periods	_	
82-18	14717-14718	(	_	
82-19	14718-14721	i.e	_	
82-20	14721-14722	.	_	
82-21	14723-14727	gain	_	
82-22	14727-14728	,	_	
82-23	14729-14736	neutral	_	
82-24	14736-14737	)	_	
82-25	14738-14740	as	_	
82-26	14741-14752	explanatory	_	
82-27	14753-14762	variables	_	
82-28	14763-14769	within	_	
82-29	14770-14773	the	_	
82-30	14774-14781	context	_	
82-31	14782-14784	of	_	
82-32	14785-14788	the	_	
82-33	14789-14796	general	_	
82-34	14797-14803	linear	_	
82-35	14804-14809	model	_	
82-36	14810-14812	on	_	
82-37	14813-14814	a	_	
82-38	14815-14829	voxel-by-voxel	_	
82-39	14830-14835	basis	_	
82-40	14836-14837	(	_	
82-41	14837-14845	variable	_	
82-42	14846-14852	boxcar	_	
82-43	14853-14862	functions	_	
82-44	14863-14866	for	_	
82-45	14867-14870	the	_	
82-46	14871-14874	cue	_	
82-47	14874-14875	 	_	
82-48	14875-14876	+	_	
82-49	14876-14877	 	_	
82-50	14877-14885	variable	_	
82-51	14886-14898	anticipation	_	
82-52	14899-14905	period	_	
82-53	14906-14916	regressors	_	
82-54	14917-14921	were	_	
82-55	14922-14931	convolved	_	
82-56	14932-14936	with	_	
82-57	14937-14940	the	_	
82-58	14941-14953	haemodynamic	_	
82-59	14954-14962	response	_	
82-60	14963-14971	function	_	
82-61	14971-14972	)	_	
82-62	14972-14973	.	_	

#Text=The gain and neutral outcome periods (“Hit” and “Miss”) were regressed out of the functional time series as conditions of no interest for the analyses reported here.
83-1	14974-14977	The	_	
83-2	14978-14982	gain	_	
83-3	14983-14986	and	_	
83-4	14987-14994	neutral	_	
83-5	14995-15002	outcome	_	
83-6	15003-15010	periods	_	
83-7	15011-15012	(	_	
83-8	15012-15013	“	_	
83-9	15013-15016	Hit	_	
83-10	15016-15017	”	_	
83-11	15018-15021	and	_	
83-12	15022-15023	“	_	
83-13	15023-15027	Miss	_	
83-14	15027-15028	”	_	
83-15	15028-15029	)	_	
83-16	15030-15034	were	_	
83-17	15035-15044	regressed	_	
83-18	15045-15048	out	_	
83-19	15049-15051	of	_	
83-20	15052-15055	the	_	
83-21	15056-15066	functional	_	
83-22	15067-15071	time	_	
83-23	15072-15078	series	_	
83-24	15079-15081	as	_	
83-25	15082-15092	conditions	_	
83-26	15093-15095	of	_	
83-27	15096-15098	no	_	
83-28	15099-15107	interest	_	
83-29	15108-15111	for	_	
83-30	15112-15115	the	_	
83-31	15116-15124	analyses	_	
83-32	15125-15133	reported	_	
83-33	15134-15138	here	_	
83-34	15138-15139	.	_	

#Text=During these first level analyses, the gain anticipation > neutral anticipation contrast was formulated.
84-1	15140-15146	During	_	
84-2	15147-15152	these	_	
84-3	15153-15158	first	_	
84-4	15159-15164	level	_	
84-5	15165-15173	analyses	_	
84-6	15173-15174	,	_	
84-7	15175-15178	the	_	
84-8	15179-15183	gain	_	
84-9	15184-15196	anticipation	_	
84-10	15196-15197	 	_	
84-11	15197-15198	>	_	
84-12	15198-15199	 	_	
84-13	15199-15206	neutral	_	
84-14	15207-15219	anticipation	_	
84-15	15220-15228	contrast	_	
84-16	15229-15232	was	_	
84-17	15233-15243	formulated	_	
84-18	15243-15244	.	_	

#Text=Owing to the small number of loss trials in the current task, the lose cue + anticipation and outcome periods (“Hit” and “Miss”) were additionally regressed out of the functional time series as conditions of no interest.
85-1	15245-15250	Owing	_	
85-2	15251-15253	to	_	
85-3	15254-15257	the	_	
85-4	15258-15263	small	_	
85-5	15264-15270	number	_	
85-6	15271-15273	of	_	
85-7	15274-15278	loss	_	
85-8	15279-15285	trials	_	
85-9	15286-15288	in	_	
85-10	15289-15292	the	_	
85-11	15293-15300	current	_	
85-12	15301-15305	task	_	
85-13	15305-15306	,	_	
85-14	15307-15310	the	_	
85-15	15311-15315	lose	_	
85-16	15316-15319	cue	_	
85-17	15319-15320	 	_	
85-18	15320-15321	+	_	
85-19	15321-15322	 	_	
85-20	15322-15334	anticipation	_	
85-21	15335-15338	and	_	
85-22	15339-15346	outcome	_	
85-23	15347-15354	periods	_	
85-24	15355-15356	(	_	
85-25	15356-15357	“	_	
85-26	15357-15360	Hit	_	
85-27	15360-15361	”	_	
85-28	15362-15365	and	_	
85-29	15366-15367	“	_	
85-30	15367-15371	Miss	_	
85-31	15371-15372	”	_	
85-32	15372-15373	)	_	
85-33	15374-15378	were	_	
85-34	15379-15391	additionally	_	
85-35	15392-15401	regressed	_	
85-36	15402-15405	out	_	
85-37	15406-15408	of	_	
85-38	15409-15412	the	_	
85-39	15413-15423	functional	_	
85-40	15424-15428	time	_	
85-41	15429-15435	series	_	
85-42	15436-15438	as	_	
85-43	15439-15449	conditions	_	
85-44	15450-15452	of	_	
85-45	15453-15455	no	_	
85-46	15456-15464	interest	_	
85-47	15464-15465	.	_	

#Text=Therefore, the fewer number of lose trials on the MID task meant we were unable to examine voxel-wise group differences in loss anticipation.
86-1	15466-15475	Therefore	_	
86-2	15475-15476	,	_	
86-3	15477-15480	the	_	
86-4	15481-15486	fewer	_	
86-5	15487-15493	number	_	
86-6	15494-15496	of	_	
86-7	15497-15501	lose	_	
86-8	15502-15508	trials	_	
86-9	15509-15511	on	_	
86-10	15512-15515	the	_	
86-11	15516-15519	MID	_	
86-12	15520-15524	task	_	
86-13	15525-15530	meant	_	
86-14	15531-15533	we	_	
86-15	15534-15538	were	_	
86-16	15539-15545	unable	_	
86-17	15546-15548	to	_	
86-18	15549-15556	examine	_	
86-19	15557-15567	voxel-wise	_	
86-20	15568-15573	group	_	
86-21	15574-15585	differences	_	
86-22	15586-15588	in	_	
86-23	15589-15593	loss	_	
86-24	15594-15606	anticipation	_	
86-25	15606-15607	.	_	

#Text=The end fixation period of the task served as the implicit baseline.
87-1	15608-15611	The	_	
87-2	15612-15615	end	_	
87-3	15616-15624	fixation	_	
87-4	15625-15631	period	_	
87-5	15632-15634	of	_	
87-6	15635-15638	the	_	
87-7	15639-15643	task	_	
87-8	15644-15650	served	_	
87-9	15651-15653	as	_	
87-10	15654-15657	the	_	
87-11	15658-15666	implicit	_	
87-12	15667-15675	baseline	_	
87-13	15675-15676	.	_	

#Text=Registration was conducted through a two-step procedure, whereby EPI images were first registered to the high-resolution T1 structural image, then into standard (Montreal Neurological Institute, MNI avg152 template) space, with 12-parameter affine transformations.
88-1	15677-15689	Registration	_	
88-2	15690-15693	was	_	
88-3	15694-15703	conducted	_	
88-4	15704-15711	through	_	
88-5	15712-15713	a	_	
88-6	15714-15722	two-step	_	
88-7	15723-15732	procedure	_	
88-8	15732-15733	,	_	
88-9	15734-15741	whereby	_	
88-10	15742-15745	EPI	_	
88-11	15746-15752	images	_	
88-12	15753-15757	were	_	
88-13	15758-15763	first	_	
88-14	15764-15774	registered	_	
88-15	15775-15777	to	_	
88-16	15778-15781	the	_	
88-17	15782-15797	high-resolution	_	
88-18	15798-15800	T1	_	
88-19	15801-15811	structural	_	
88-20	15812-15817	image	_	
88-21	15817-15818	,	_	
88-22	15819-15823	then	_	
88-23	15824-15828	into	_	
88-24	15829-15837	standard	_	
88-25	15838-15839	(	_	
88-26	15839-15847	Montreal	_	
88-27	15848-15860	Neurological	_	
88-28	15861-15870	Institute	_	
88-29	15870-15871	,	_	
88-30	15872-15875	MNI	_	
88-31	15876-15882	avg152	_	
88-32	15883-15891	template	_	
88-33	15891-15892	)	_	
88-34	15893-15898	space	_	
88-35	15898-15899	,	_	
88-36	15900-15904	with	_	
88-37	15905-15907	12	_	
88-38	15907-15908	-	_	
88-39	15908-15917	parameter	_	
88-40	15918-15924	affine	_	
88-41	15925-15940	transformations	_	
88-42	15940-15941	.	_	

#Text=Higher-level (within group one-sample t-tests and between-group independent samples t-tests) were conducted on the gain anticipation > neutral anticipation contrast using the randomise programme in FSL.
89-1	15942-15954	Higher-level	_	
89-2	15955-15956	(	_	
89-3	15956-15962	within	_	
89-4	15963-15968	group	_	
89-5	15969-15979	one-sample	_	
89-6	15980-15987	t-tests	_	
89-7	15988-15991	and	_	
89-8	15992-16005	between-group	_	
89-9	16006-16017	independent	_	
89-10	16018-16025	samples	_	
89-11	16026-16033	t-tests	_	
89-12	16033-16034	)	_	
89-13	16035-16039	were	_	
89-14	16040-16049	conducted	_	
89-15	16050-16052	on	_	
89-16	16053-16056	the	_	
89-17	16057-16061	gain	_	
89-18	16062-16074	anticipation	_	
89-19	16074-16075	 	_	
89-20	16075-16076	>	_	
89-21	16076-16077	 	_	
89-22	16077-16084	neutral	_	
89-23	16085-16097	anticipation	_	
89-24	16098-16106	contrast	_	
89-25	16107-16112	using	_	
89-26	16113-16116	the	_	
89-27	16117-16126	randomise	_	
89-28	16127-16136	programme	_	
89-29	16137-16139	in	_	
89-30	16140-16143	FSL	_	
89-31	16143-16144	.	_	

#Text=Randomise employs a permutation approach through resampling.
90-1	16145-16154	Randomise	_	
90-2	16155-16162	employs	_	
90-3	16163-16164	a	_	
90-4	16165-16176	permutation	_	
90-5	16177-16185	approach	_	
90-6	16186-16193	through	_	
90-7	16194-16204	resampling	_	
90-8	16204-16205	.	_	

#Text=Significance (PFWE < 0.05) for the gain anticipation > neutral anticipation contrast on both the one-sample and independent samples t-tests was conducted taking a threshold-free cluster enhancement (TFCE) approach and using 5000 permutations.
91-1	16206-16218	Significance	_	
91-2	16219-16220	(	_	
91-3	16220-16224	PFWE	_	
91-4	16224-16225	 	_	
91-5	16225-16226	<	_	
91-6	16226-16227	 	_	
91-7	16227-16231	0.05	_	
91-8	16231-16232	)	_	
91-9	16233-16236	for	_	
91-10	16237-16240	the	_	
91-11	16241-16245	gain	_	
91-12	16246-16258	anticipation	_	
91-13	16258-16259	 	_	
91-14	16259-16260	>	_	
91-15	16260-16261	 	_	
91-16	16261-16268	neutral	_	
91-17	16269-16281	anticipation	_	
91-18	16282-16290	contrast	_	
91-19	16291-16293	on	_	
91-20	16294-16298	both	_	
91-21	16299-16302	the	_	
91-22	16303-16313	one-sample	_	
91-23	16314-16317	and	_	
91-24	16318-16329	independent	_	
91-25	16330-16337	samples	_	
91-26	16338-16345	t-tests	_	
91-27	16346-16349	was	_	
91-28	16350-16359	conducted	_	
91-29	16360-16366	taking	_	
91-30	16367-16368	a	_	
91-31	16369-16383	threshold-free	_	
91-32	16384-16391	cluster	_	
91-33	16392-16403	enhancement	_	
91-34	16404-16405	(	_	
91-35	16405-16409	TFCE	_	
91-36	16409-16410	)	_	
91-37	16411-16419	approach	_	
91-38	16420-16423	and	_	
91-39	16424-16429	using	_	
91-40	16430-16434	5000	_	
91-41	16435-16447	permutations	_	
91-42	16447-16448	.	_	

#Text=TFCE aims to maintain the sensitivity of cluster-based thresholding, while avoiding the arbitrary nature of threshold choice.
92-1	16449-16453	TFCE	_	
92-2	16454-16458	aims	_	
92-3	16459-16461	to	_	
92-4	16462-16470	maintain	_	
92-5	16471-16474	the	_	
92-6	16475-16486	sensitivity	_	
92-7	16487-16489	of	_	
92-8	16490-16503	cluster-based	_	
92-9	16504-16516	thresholding	_	
92-10	16516-16517	,	_	
92-11	16518-16523	while	_	
92-12	16524-16532	avoiding	_	
92-13	16533-16536	the	_	
92-14	16537-16546	arbitrary	_	
92-15	16547-16553	nature	_	
92-16	16554-16556	of	_	
92-17	16557-16566	threshold	_	
92-18	16567-16573	choice	_	
92-19	16573-16574	.	_	

#Text=Given the differences in scanners across the three sites, these analyses were conducted while also controlling for study site.
93-1	16575-16580	Given	_	
93-2	16581-16584	the	_	
93-3	16585-16596	differences	_	
93-4	16597-16599	in	_	
93-5	16600-16608	scanners	_	
93-6	16609-16615	across	_	
93-7	16616-16619	the	_	
93-8	16620-16625	three	_	
93-9	16626-16631	sites	_	
93-10	16631-16632	,	_	
93-11	16633-16638	these	_	
93-12	16639-16647	analyses	_	
93-13	16648-16652	were	_	
93-14	16653-16662	conducted	_	
93-15	16663-16668	while	_	
93-16	16669-16673	also	_	
93-17	16674-16685	controlling	_	
93-18	16686-16689	for	_	
93-19	16690-16695	study	_	
93-20	16696-16700	site	_	
93-21	16700-16701	.	_	

#Text=Trial-Wise beta value image analyses
#Text=Data pre-processing was also initially conducted using FEAT (fMRI Expert Analysis Tool) from the FMRIB Software Library (www.fmrib.ox.ac.uk/fsl) as described above.
94-1	16702-16712	Trial-Wise	_	
94-2	16713-16717	beta	_	
94-3	16718-16723	value	_	
94-4	16724-16729	image	_	
94-5	16730-16738	analyses	_	
94-6	16739-16743	Data	_	
94-7	16744-16758	pre-processing	_	
94-8	16759-16762	was	_	
94-9	16763-16767	also	_	
94-10	16768-16777	initially	_	
94-11	16778-16787	conducted	_	
94-12	16788-16793	using	_	
94-13	16794-16798	FEAT	_	
94-14	16799-16800	(	_	
94-15	16800-16804	fMRI	_	
94-16	16805-16811	Expert	_	
94-17	16812-16820	Analysis	_	
94-18	16821-16825	Tool	_	
94-19	16825-16826	)	_	
94-20	16827-16831	from	_	
94-21	16832-16835	the	_	
94-22	16836-16841	FMRIB	_	
94-23	16842-16850	Software	_	
94-24	16851-16858	Library	_	
94-25	16859-16860	(	_	
94-26	16860-16878	www.fmrib.ox.ac.uk	_	
94-27	16878-16879	/	_	
94-28	16879-16882	fsl	_	
94-29	16882-16883	)	_	
94-30	16884-16886	as	_	
94-31	16887-16896	described	_	
94-32	16897-16902	above	_	
94-33	16902-16903	.	_	

#Text=For each participant, each individual gain and neutral anticipation epoch (cue + variable anticipation period) was separately modelled within the context of the general linear model.
95-1	16904-16907	For	_	
95-2	16908-16912	each	_	
95-3	16913-16924	participant	_	
95-4	16924-16925	,	_	
95-5	16926-16930	each	_	
95-6	16931-16941	individual	_	
95-7	16942-16946	gain	_	
95-8	16947-16950	and	_	
95-9	16951-16958	neutral	_	
95-10	16959-16971	anticipation	_	
95-11	16972-16977	epoch	_	
95-12	16978-16979	(	_	
95-13	16979-16982	cue	_	
95-14	16982-16983	 	_	
95-15	16983-16984	+	_	
95-16	16984-16985	 	_	
95-17	16985-16993	variable	_	
95-18	16994-17006	anticipation	_	
95-19	17007-17013	period	_	
95-20	17013-17014	)	_	
95-21	17015-17018	was	_	
95-22	17019-17029	separately	_	
95-23	17030-17038	modelled	_	
95-24	17039-17045	within	_	
95-25	17046-17049	the	_	
95-26	17050-17057	context	_	
95-27	17058-17060	of	_	
95-28	17061-17064	the	_	
95-29	17065-17072	general	_	
95-30	17073-17079	linear	_	
95-31	17080-17085	model	_	
95-32	17085-17086	.	_	

#Text=This approach yielded a total of 18 unique beta value images for each of the gain and neutral anticipation conditions on each run of the MID task.
96-1	17087-17091	This	_	
96-2	17092-17100	approach	_	
96-3	17101-17108	yielded	_	
96-4	17109-17110	a	_	
96-5	17111-17116	total	_	
96-6	17117-17119	of	_	
96-7	17120-17122	18	_	
96-8	17123-17129	unique	_	
96-9	17130-17134	beta	_	
96-10	17135-17140	value	_	
96-11	17141-17147	images	_	
96-12	17148-17151	for	_	
96-13	17152-17156	each	_	
96-14	17157-17159	of	_	
96-15	17160-17163	the	_	
96-16	17164-17168	gain	_	
96-17	17169-17172	and	_	
96-18	17173-17180	neutral	_	
96-19	17181-17193	anticipation	_	
96-20	17194-17204	conditions	_	
96-21	17205-17207	on	_	
96-22	17208-17212	each	_	
96-23	17213-17216	run	_	
96-24	17217-17219	of	_	
96-25	17220-17223	the	_	
96-26	17224-17227	MID	_	
96-27	17228-17232	task	_	
96-28	17232-17233	.	_	

#Text=This meant that each voxel-wise beta value image reflected the magnitude of the hemodynamic response evoked by each of the gain and neutral anticipation epochs.
97-1	17234-17238	This	_	
97-2	17239-17244	meant	_	
97-3	17245-17249	that	_	
97-4	17250-17254	each	_	
97-5	17255-17265	voxel-wise	_	
97-6	17266-17270	beta	_	
97-7	17271-17276	value	_	
97-8	17277-17282	image	_	
97-9	17283-17292	reflected	_	
97-10	17293-17296	the	_	
97-11	17297-17306	magnitude	_	
97-12	17307-17309	of	_	
97-13	17310-17313	the	_	
97-14	17314-17325	hemodynamic	_	
97-15	17326-17334	response	_	
97-16	17335-17341	evoked	_	
97-17	17342-17344	by	_	
97-18	17345-17349	each	_	
97-19	17350-17352	of	_	
97-20	17353-17356	the	_	
97-21	17357-17361	gain	_	
97-22	17362-17365	and	_	
97-23	17366-17373	neutral	_	
97-24	17374-17386	anticipation	_	
97-25	17387-17393	epochs	_	
97-26	17393-17394	.	_	

#Text=Each beta value image for each MID run was then subsequently registered into standard (MNI avg152 template) space before being concatenated to generate a beta value “trial-wise” (e.g., gain anticipation) time series.
98-1	17395-17399	Each	_	
98-2	17400-17404	beta	_	
98-3	17405-17410	value	_	
98-4	17411-17416	image	_	
98-5	17417-17420	for	_	
98-6	17421-17425	each	_	
98-7	17426-17429	MID	_	
98-8	17430-17433	run	_	
98-9	17434-17437	was	_	
98-10	17438-17442	then	_	
98-11	17443-17455	subsequently	_	
98-12	17456-17466	registered	_	
98-13	17467-17471	into	_	
98-14	17472-17480	standard	_	
98-15	17481-17482	(	_	
98-16	17482-17485	MNI	_	
98-17	17486-17492	avg152	_	
98-18	17493-17501	template	_	
98-19	17501-17502	)	_	
98-20	17503-17508	space	_	
98-21	17509-17515	before	_	
98-22	17516-17521	being	_	
98-23	17522-17534	concatenated	_	
98-24	17535-17537	to	_	
98-25	17538-17546	generate	_	
98-26	17547-17548	a	_	
98-27	17549-17553	beta	_	
98-28	17554-17559	value	_	
98-29	17560-17561	“	_	
98-30	17561-17571	trial-wise	_	
98-31	17571-17572	”	_	
98-32	17573-17574	(	_	
98-33	17574-17577	e.g	_	
98-34	17577-17578	.	_	
98-35	17578-17579	,	_	
98-36	17580-17584	gain	_	
98-37	17585-17597	anticipation	_	
98-38	17597-17598	)	_	
98-39	17599-17603	time	_	
98-40	17604-17610	series	_	
98-41	17610-17611	.	_	

#Text=Each beta value trial-wise time series for each MID run was further concatenated across runs to generate a single beta value trial-wise time series for the gain and neutral MID anticipation conditions.
99-1	17612-17616	Each	_	
99-2	17617-17621	beta	_	
99-3	17622-17627	value	_	
99-4	17628-17638	trial-wise	_	
99-5	17639-17643	time	_	
99-6	17644-17650	series	_	
99-7	17651-17654	for	_	
99-8	17655-17659	each	_	
99-9	17660-17663	MID	_	
99-10	17664-17667	run	_	
99-11	17668-17671	was	_	
99-12	17672-17679	further	_	
99-13	17680-17692	concatenated	_	
99-14	17693-17699	across	_	
99-15	17700-17704	runs	_	
99-16	17705-17707	to	_	
99-17	17708-17716	generate	_	
99-18	17717-17718	a	_	
99-19	17719-17725	single	_	
99-20	17726-17730	beta	_	
99-21	17731-17736	value	_	
99-22	17737-17747	trial-wise	_	
99-23	17748-17752	time	_	
99-24	17753-17759	series	_	
99-25	17760-17763	for	_	
99-26	17764-17767	the	_	
99-27	17768-17772	gain	_	
99-28	17773-17776	and	_	
99-29	17777-17784	neutral	_	
99-30	17785-17788	MID	_	
99-31	17789-17801	anticipation	_	
99-32	17802-17812	conditions	_	
99-33	17812-17813	.	_	

#Text=This procedure yielded a thirty-six beta value trial-wise time series image for each participant for the gain and neutral anticipation conditions.
100-1	17814-17818	This	_	
100-2	17819-17828	procedure	_	
100-3	17829-17836	yielded	_	
100-4	17837-17838	a	_	
100-5	17839-17849	thirty-six	_	
100-6	17850-17854	beta	_	
100-7	17855-17860	value	_	
100-8	17861-17871	trial-wise	_	
100-9	17872-17876	time	_	
100-10	17877-17883	series	_	
100-11	17884-17889	image	_	
100-12	17890-17893	for	_	
100-13	17894-17898	each	_	
100-14	17899-17910	participant	_	
100-15	17911-17914	for	_	
100-16	17915-17918	the	_	
100-17	17919-17923	gain	_	
100-18	17924-17927	and	_	
100-19	17928-17935	neutral	_	
100-20	17936-17948	anticipation	_	
100-21	17949-17959	conditions	_	
100-22	17959-17960	.	_	

#Text=The neutral trial-wise time series was then simply subtracted from the gain trial-wise time series to yield a gain anticipation > neutral anticipation contrast time series (see Supplementary Fig. 1).
101-1	17961-17964	The	_	
101-2	17965-17972	neutral	_	
101-3	17973-17983	trial-wise	_	
101-4	17984-17988	time	_	
101-5	17989-17995	series	_	
101-6	17996-17999	was	_	
101-7	18000-18004	then	_	
101-8	18005-18011	simply	_	
101-9	18012-18022	subtracted	_	
101-10	18023-18027	from	_	
101-11	18028-18031	the	_	
101-12	18032-18036	gain	_	
101-13	18037-18047	trial-wise	_	
101-14	18048-18052	time	_	
101-15	18053-18059	series	_	
101-16	18060-18062	to	_	
101-17	18063-18068	yield	_	
101-18	18069-18070	a	_	
101-19	18071-18075	gain	_	
101-20	18076-18088	anticipation	_	
101-21	18088-18089	 	_	
101-22	18089-18090	>	_	
101-23	18090-18091	 	_	
101-24	18091-18098	neutral	_	
101-25	18099-18111	anticipation	_	
101-26	18112-18120	contrast	_	
101-27	18121-18125	time	_	
101-28	18126-18132	series	_	
101-29	18133-18134	(	_	
101-30	18134-18137	see	_	
101-31	18138-18151	Supplementary	_	
101-32	18152-18155	Fig	_	
101-33	18155-18156	.	_	
101-34	18157-18158	1	_	
101-35	18158-18159	)	_	
101-36	18159-18160	.	_	

#Text=This beta value trial-wise time series method has been previously used to examine connectivity during cognitive tasks, including the MID task.
102-1	18161-18165	This	_	
102-2	18166-18170	beta	_	
102-3	18171-18176	value	_	
102-4	18177-18187	trial-wise	_	
102-5	18188-18192	time	_	
102-6	18193-18199	series	_	
102-7	18200-18206	method	_	
102-8	18207-18210	has	_	
102-9	18211-18215	been	_	
102-10	18216-18226	previously	_	
102-11	18227-18231	used	_	
102-12	18232-18234	to	_	
102-13	18235-18242	examine	_	
102-14	18243-18255	connectivity	_	
102-15	18256-18262	during	_	
102-16	18263-18272	cognitive	_	
102-17	18273-18278	tasks	_	
102-18	18278-18279	,	_	
102-19	18280-18289	including	_	
102-20	18290-18293	the	_	
102-21	18294-18297	MID	_	
102-22	18298-18302	task	_	
102-23	18302-18303	.	_	

#Text=The small, variable (performance-dependent) number of events for the outcome periods (“hits” and “misses”), and the small number of loss trials in the task, meant that we could not generate trial-wise beta value images for these events.
103-1	18304-18307	The	_	
103-2	18308-18313	small	_	
103-3	18313-18314	,	_	
103-4	18315-18323	variable	_	
103-5	18324-18325	(	_	
103-6	18325-18346	performance-dependent	_	
103-7	18346-18347	)	_	
103-8	18348-18354	number	_	
103-9	18355-18357	of	_	
103-10	18358-18364	events	_	
103-11	18365-18368	for	_	
103-12	18369-18372	the	_	
103-13	18373-18380	outcome	_	
103-14	18381-18388	periods	_	
103-15	18389-18390	(	_	
103-16	18390-18391	“	_	
103-17	18391-18395	hits	_	
103-18	18395-18396	”	_	
103-19	18397-18400	and	_	
103-20	18401-18402	“	_	
103-21	18402-18408	misses	_	
103-22	18408-18409	”	_	
103-23	18409-18410	)	_	
103-24	18410-18411	,	_	
103-25	18412-18415	and	_	
103-26	18416-18419	the	_	
103-27	18420-18425	small	_	
103-28	18426-18432	number	_	
103-29	18433-18435	of	_	
103-30	18436-18440	loss	_	
103-31	18441-18447	trials	_	
103-32	18448-18450	in	_	
103-33	18451-18454	the	_	
103-34	18455-18459	task	_	
103-35	18459-18460	,	_	
103-36	18461-18466	meant	_	
103-37	18467-18471	that	_	
103-38	18472-18474	we	_	
103-39	18475-18480	could	_	
103-40	18481-18484	not	_	
103-41	18485-18493	generate	_	
103-42	18494-18504	trial-wise	_	
103-43	18505-18509	beta	_	
103-44	18510-18515	value	_	
103-45	18516-18522	images	_	
103-46	18523-18526	for	_	
103-47	18527-18532	these	_	
103-48	18533-18539	events	_	
103-49	18539-18540	.	_	

#Text=Therefore, gain and neutral outcome (well as lose anticipation and outcome) events were regressed out of the functional time series as conditions of no interest during the first level analyses.
104-1	18541-18550	Therefore	_	
104-2	18550-18551	,	_	
104-3	18552-18556	gain	_	
104-4	18557-18560	and	_	
104-5	18561-18568	neutral	_	
104-6	18569-18576	outcome	_	
104-7	18577-18578	(	_	
104-8	18578-18582	well	_	
104-9	18583-18585	as	_	
104-10	18586-18590	lose	_	
104-11	18591-18603	anticipation	_	
104-12	18604-18607	and	_	
104-13	18608-18615	outcome	_	
104-14	18615-18616	)	_	
104-15	18617-18623	events	_	
104-16	18624-18628	were	_	
104-17	18629-18638	regressed	_	
104-18	18639-18642	out	_	
104-19	18643-18645	of	_	
104-20	18646-18649	the	_	
104-21	18650-18660	functional	_	
104-22	18661-18665	time	_	
104-23	18666-18672	series	_	
104-24	18673-18675	as	_	
104-25	18676-18686	conditions	_	
104-26	18687-18689	of	_	
104-27	18690-18692	no	_	
104-28	18693-18701	interest	_	
104-29	18702-18708	during	_	
104-30	18709-18712	the	_	
104-31	18713-18718	first	_	
104-32	18719-18724	level	_	
104-33	18725-18733	analyses	_	
104-34	18733-18734	.	_	

#Text=This meant that the same end fixation period of the task also served as the implicit baseline for these analyses.
105-1	18735-18739	This	_	
105-2	18740-18745	meant	_	
105-3	18746-18750	that	_	
105-4	18751-18754	the	_	
105-5	18755-18759	same	_	
105-6	18760-18763	end	_	
105-7	18764-18772	fixation	_	
105-8	18773-18779	period	_	
105-9	18780-18782	of	_	
105-10	18783-18786	the	_	
105-11	18787-18791	task	_	
105-12	18792-18796	also	_	
105-13	18797-18803	served	_	
105-14	18804-18806	as	_	
105-15	18807-18810	the	_	
105-16	18811-18819	implicit	_	
105-17	18820-18828	baseline	_	
105-18	18829-18832	for	_	
105-19	18833-18838	these	_	
105-20	18839-18847	analyses	_	
105-21	18847-18848	.	_	

#Text=Time series Extraction and correlation matrices
#Text=Using the Harvard-Oxford atlas (96 cortical and 14 subcortical nodes/regions) as our connectome of interest, we used the fslmeants programme to extract the mean beta value time series from each of 110 anatomical regions of interest (ROI) for the gain anticipation > neutral contrast beta image for each participant.
106-1	18849-18853	Time	_	
106-2	18854-18860	series	_	
106-3	18861-18871	Extraction	_	
106-4	18872-18875	and	_	
106-5	18876-18887	correlation	_	
106-6	18888-18896	matrices	_	
106-7	18897-18902	Using	_	
106-8	18903-18906	the	_	
106-9	18907-18921	Harvard-Oxford	_	
106-10	18922-18927	atlas	_	
106-11	18928-18929	(	_	
106-12	18929-18931	96	_	
106-13	18932-18940	cortical	_	
106-14	18941-18944	and	_	
106-15	18945-18947	14	_	
106-16	18948-18959	subcortical	_	
106-17	18960-18965	nodes	_	
106-18	18965-18966	/	_	
106-19	18966-18973	regions	_	
106-20	18973-18974	)	_	
106-21	18975-18977	as	_	
106-22	18978-18981	our	_	
106-23	18982-18992	connectome	_	
106-24	18993-18995	of	_	
106-25	18996-19004	interest	_	
106-26	19004-19005	,	_	
106-27	19006-19008	we	_	
106-28	19009-19013	used	_	
106-29	19014-19017	the	_	
106-30	19018-19027	fslmeants	_	
106-31	19028-19037	programme	_	
106-32	19038-19040	to	_	
106-33	19041-19048	extract	_	
106-34	19049-19052	the	_	
106-35	19053-19057	mean	_	
106-36	19058-19062	beta	_	
106-37	19063-19068	value	_	
106-38	19069-19073	time	_	
106-39	19074-19080	series	_	
106-40	19081-19085	from	_	
106-41	19086-19090	each	_	
106-42	19091-19093	of	_	
106-43	19094-19097	110	_	
106-44	19098-19108	anatomical	_	
106-45	19109-19116	regions	_	
106-46	19117-19119	of	_	
106-47	19120-19128	interest	_	
106-48	19129-19130	(	_	
106-49	19130-19133	ROI	_	
106-50	19133-19134	)	_	
106-51	19135-19138	for	_	
106-52	19139-19142	the	_	
106-53	19143-19147	gain	_	
106-54	19148-19160	anticipation	_	
106-55	19160-19161	 	_	
106-56	19161-19162	>	_	
106-57	19162-19163	 	_	
106-58	19163-19170	neutral	_	
106-59	19171-19179	contrast	_	
106-60	19180-19184	beta	_	
106-61	19185-19190	image	_	
106-62	19191-19194	for	_	
106-63	19195-19199	each	_	
106-64	19200-19211	participant	_	
106-65	19211-19212	.	_	

#Text=Using these mean ROI time series outputs, we then conducted Pearson correlation coefficient analyses to construct whole brain ROI‐to‐ROI pairwise matrices (see Supplementary Fig. 1).
107-1	19213-19218	Using	_	
107-2	19219-19224	these	_	
107-3	19225-19229	mean	_	
107-4	19230-19233	ROI	_	
107-5	19234-19238	time	_	
107-6	19239-19245	series	_	
107-7	19246-19253	outputs	_	
107-8	19253-19254	,	_	
107-9	19255-19257	we	_	
107-10	19258-19262	then	_	
107-11	19263-19272	conducted	_	
107-12	19273-19280	Pearson	_	
107-13	19281-19292	correlation	_	
107-14	19293-19304	coefficient	_	
107-15	19305-19313	analyses	_	
107-16	19314-19316	to	_	
107-17	19317-19326	construct	_	
107-18	19327-19332	whole	_	
107-19	19333-19338	brain	_	
107-20	19339-19349	ROI‐to‐ROI	_	
107-21	19350-19358	pairwise	_	
107-22	19359-19367	matrices	_	
107-23	19368-19369	(	_	
107-24	19369-19372	see	_	
107-25	19373-19386	Supplementary	_	
107-26	19387-19390	Fig	_	
107-27	19390-19391	.	_	
107-28	19392-19393	1	_	
107-29	19393-19394	)	_	
107-30	19394-19395	.	_	

#Text=Each matrix was made up of 5995 (=N*(N − 1)/2, with N = 110 nodes) pairwise connections (edges).
108-1	19396-19400	Each	_	
108-2	19401-19407	matrix	_	
108-3	19408-19411	was	_	
108-4	19412-19416	made	_	
108-5	19417-19419	up	_	
108-6	19420-19422	of	_	
108-7	19423-19427	5995	_	
108-8	19428-19429	(	_	
108-9	19429-19430	=	_	
108-10	19430-19431	N	_	
108-11	19431-19432	*	_	
108-12	19432-19433	(	_	
108-13	19433-19434	N	_	
108-14	19434-19435	 	_	
108-15	19435-19436	−	_	
108-16	19436-19437	 	_	
108-17	19437-19438	1	_	
108-18	19438-19439	)	_	
108-19	19439-19440	/	_	
108-20	19440-19441	2	_	
108-21	19441-19442	,	_	
108-22	19443-19447	with	_	
108-23	19448-19449	N	_	
108-24	19449-19450	 	_	
108-25	19450-19451	=	_	
108-26	19451-19452	 	_	
108-27	19452-19455	110	_	
108-28	19456-19461	nodes	_	
108-29	19461-19462	)	_	
108-30	19463-19471	pairwise	_	
108-31	19472-19483	connections	_	
108-32	19484-19485	(	_	
108-33	19485-19490	edges	_	
108-34	19490-19491	)	_	
108-35	19491-19492	.	_	

#Text=These matrices were generated in MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States) and used to compare network connectivity between the CON and ADD groups (see below).
109-1	19493-19498	These	_	
109-2	19499-19507	matrices	_	
109-3	19508-19512	were	_	
109-4	19513-19522	generated	_	
109-5	19523-19525	in	_	
109-6	19526-19532	MATLAB	_	
109-7	19533-19534	(	_	
109-8	19534-19537	The	_	
109-9	19538-19547	MathWorks	_	
109-10	19547-19548	,	_	
109-11	19549-19552	Inc	_	
109-12	19552-19553	.	_	
109-13	19553-19554	,	_	
109-14	19555-19561	Natick	_	
109-15	19561-19562	,	_	
109-16	19563-19576	Massachusetts	_	
109-17	19576-19577	,	_	
109-18	19578-19584	United	_	
109-19	19585-19591	States	_	
109-20	19591-19592	)	_	
109-21	19593-19596	and	_	
109-22	19597-19601	used	_	
109-23	19602-19604	to	_	
109-24	19605-19612	compare	_	
109-25	19613-19620	network	_	
109-26	19621-19633	connectivity	_	
109-27	19634-19641	between	_	
109-28	19642-19645	the	_	
109-29	19646-19649	CON	_	
109-30	19650-19653	and	_	
109-31	19654-19657	ADD	_	
109-32	19658-19664	groups	_	
109-33	19665-19666	(	_	
109-34	19666-19669	see	_	
109-35	19670-19675	below	_	
109-36	19675-19676	)	_	
109-37	19676-19677	.	_	

#Text=Graph measures
#Text=Global (characteristic path length and clustering coefficient) graph measures were estimated from each correlation matrix using the GraphVar (www.rfmri.org/GraphVar) toolbox for functional brain connectivity in MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
110-1	19678-19683	Graph	_	
110-2	19684-19692	measures	_	
110-3	19693-19699	Global	_	
110-4	19700-19701	(	_	
110-5	19701-19715	characteristic	_	
110-6	19716-19720	path	_	
110-7	19721-19727	length	_	
110-8	19728-19731	and	_	
110-9	19732-19742	clustering	_	
110-10	19743-19754	coefficient	_	
110-11	19754-19755	)	_	
110-12	19756-19761	graph	_	
110-13	19762-19770	measures	_	
110-14	19771-19775	were	_	
110-15	19776-19785	estimated	_	
110-16	19786-19790	from	_	
110-17	19791-19795	each	_	
110-18	19796-19807	correlation	_	
110-19	19808-19814	matrix	_	
110-20	19815-19820	using	_	
110-21	19821-19824	the	_	
110-22	19825-19833	GraphVar	_	
110-23	19834-19835	(	_	
110-24	19835-19848	www.rfmri.org	_	
110-25	19848-19849	/	_	
110-26	19849-19857	GraphVar	_	
110-27	19857-19858	)	_	
110-28	19859-19866	toolbox	_	
110-29	19867-19870	for	_	
110-30	19871-19881	functional	_	
110-31	19882-19887	brain	_	
110-32	19888-19900	connectivity	_	
110-33	19901-19903	in	_	
110-34	19904-19910	MATLAB	_	
110-35	19911-19912	(	_	
110-36	19912-19915	The	_	
110-37	19916-19925	MathWorks	_	
110-38	19925-19926	,	_	
110-39	19927-19930	Inc	_	
110-40	19930-19931	.	_	
110-41	19931-19932	,	_	
110-42	19933-19939	Natick	_	
110-43	19939-19940	,	_	
110-44	19941-19954	Massachusetts	_	
110-45	19954-19955	,	_	
110-46	19956-19962	United	_	
110-47	19963-19969	States	_	
110-48	19969-19970	)	_	
110-49	19970-19971	.	_	

#Text=More detailed descriptions of brain network graph measures can be found elsewhere, but we will briefly describe these metrics here.
111-1	19972-19976	More	_	
111-2	19977-19985	detailed	_	
111-3	19986-19998	descriptions	_	
111-4	19999-20001	of	_	
111-5	20002-20007	brain	_	
111-6	20008-20015	network	_	
111-7	20016-20021	graph	_	
111-8	20022-20030	measures	_	
111-9	20031-20034	can	_	
111-10	20035-20037	be	_	
111-11	20038-20043	found	_	
111-12	20044-20053	elsewhere	_	
111-13	20053-20054	,	_	
111-14	20055-20058	but	_	
111-15	20059-20061	we	_	
111-16	20062-20066	will	_	
111-17	20067-20074	briefly	_	
111-18	20075-20083	describe	_	
111-19	20084-20089	these	_	
111-20	20090-20097	metrics	_	
111-21	20098-20102	here	_	
111-22	20102-20103	.	_	

#Text=Characteristic path length is the minimum number of edges that must be traversed to go from one node (brain region) to another in a network.
112-1	20104-20118	Characteristic	_	
112-2	20119-20123	path	_	
112-3	20124-20130	length	_	
112-4	20131-20133	is	_	
112-5	20134-20137	the	_	
112-6	20138-20145	minimum	_	
112-7	20146-20152	number	_	
112-8	20153-20155	of	_	
112-9	20156-20161	edges	_	
112-10	20162-20166	that	_	
112-11	20167-20171	must	_	
112-12	20172-20174	be	_	
112-13	20175-20184	traversed	_	
112-14	20185-20187	to	_	
112-15	20188-20190	go	_	
112-16	20191-20195	from	_	
112-17	20196-20199	one	_	
112-18	20200-20204	node	_	
112-19	20205-20206	(	_	
112-20	20206-20211	brain	_	
112-21	20212-20218	region	_	
112-22	20218-20219	)	_	
112-23	20220-20222	to	_	
112-24	20223-20230	another	_	
112-25	20231-20233	in	_	
112-26	20234-20235	a	_	
112-27	20236-20243	network	_	
112-28	20243-20244	.	_	

#Text=For a pair of nodes that are nearest neighbours, the path length is 1.
113-1	20245-20248	For	_	
113-2	20249-20250	a	_	
113-3	20251-20255	pair	_	
113-4	20256-20258	of	_	
113-5	20259-20264	nodes	_	
113-6	20265-20269	that	_	
113-7	20270-20273	are	_	
113-8	20274-20281	nearest	_	
113-9	20282-20292	neighbours	_	
113-10	20292-20293	,	_	
113-11	20294-20297	the	_	
113-12	20298-20302	path	_	
113-13	20303-20309	length	_	
113-14	20310-20312	is	_	
113-15	20313-20314	1	_	
113-16	20314-20315	.	_	

#Text=The clustering coefficient, by contrast, quantifies the density of connections between the nearest neighbour of a node, and describes how segregated the network is.
114-1	20316-20319	The	_	
114-2	20320-20330	clustering	_	
114-3	20331-20342	coefficient	_	
114-4	20342-20343	,	_	
114-5	20344-20346	by	_	
114-6	20347-20355	contrast	_	
114-7	20355-20356	,	_	
114-8	20357-20367	quantifies	_	
114-9	20368-20371	the	_	
114-10	20372-20379	density	_	
114-11	20380-20382	of	_	
114-12	20383-20394	connections	_	
114-13	20395-20402	between	_	
114-14	20403-20406	the	_	
114-15	20407-20414	nearest	_	
114-16	20415-20424	neighbour	_	
114-17	20425-20427	of	_	
114-18	20428-20429	a	_	
114-19	20430-20434	node	_	
114-20	20434-20435	,	_	
114-21	20436-20439	and	_	
114-22	20440-20449	describes	_	
114-23	20450-20453	how	_	
114-24	20454-20464	segregated	_	
114-25	20465-20468	the	_	
114-26	20469-20476	network	_	
114-27	20477-20479	is	_	
114-28	20479-20480	.	_	

#Text=The path and clustering measures are first estimated at each node of the connectome before an average (global value) is computed for the entire connectome for each participant’s correlation matrix.
115-1	20481-20484	The	_	
115-2	20485-20489	path	_	
115-3	20490-20493	and	_	
115-4	20494-20504	clustering	_	
115-5	20505-20513	measures	_	
115-6	20514-20517	are	_	
115-7	20518-20523	first	_	
115-8	20524-20533	estimated	_	
115-9	20534-20536	at	_	
115-10	20537-20541	each	_	
115-11	20542-20546	node	_	
115-12	20547-20549	of	_	
115-13	20550-20553	the	_	
115-14	20554-20564	connectome	_	
115-15	20565-20571	before	_	
115-16	20572-20574	an	_	
115-17	20575-20582	average	_	
115-18	20583-20584	(	_	
115-19	20584-20590	global	_	
115-20	20591-20596	value	_	
115-21	20596-20597	)	_	
115-22	20598-20600	is	_	
115-23	20601-20609	computed	_	
115-24	20610-20613	for	_	
115-25	20614-20617	the	_	
115-26	20618-20624	entire	_	
115-27	20625-20635	connectome	_	
115-28	20636-20639	for	_	
115-29	20640-20644	each	_	
115-30	20645-20656	participant	_	
115-31	20656-20657	’	_	
115-32	20657-20658	s	_	
115-33	20659-20670	correlation	_	
115-34	20671-20677	matrix	_	
115-35	20677-20678	.	_	

#Text=Graph measures for each participant were then estimated by thresholding each matrix at a selection of proportional cost (K) thresholds – i.e. thresholds that retain only a percentage of the strongest connections (edges) in the network.
116-1	20679-20684	Graph	_	
116-2	20685-20693	measures	_	
116-3	20694-20697	for	_	
116-4	20698-20702	each	_	
116-5	20703-20714	participant	_	
116-6	20715-20719	were	_	
116-7	20720-20724	then	_	
116-8	20725-20734	estimated	_	
116-9	20735-20737	by	_	
116-10	20738-20750	thresholding	_	
116-11	20751-20755	each	_	
116-12	20756-20762	matrix	_	
116-13	20763-20765	at	_	
116-14	20766-20767	a	_	
116-15	20768-20777	selection	_	
116-16	20778-20780	of	_	
116-17	20781-20793	proportional	_	
116-18	20794-20798	cost	_	
116-19	20799-20800	(	_	
116-20	20800-20801	K	_	
116-21	20801-20802	)	_	
116-22	20803-20813	thresholds	_	
116-23	20814-20815	–	_	
116-24	20816-20819	i.e	_	
116-25	20819-20820	.	_	
116-26	20821-20831	thresholds	_	
116-27	20832-20836	that	_	
116-28	20837-20843	retain	_	
116-29	20844-20848	only	_	
116-30	20849-20850	a	_	
116-31	20851-20861	percentage	_	
116-32	20862-20864	of	_	
116-33	20865-20868	the	_	
116-34	20869-20878	strongest	_	
116-35	20879-20890	connections	_	
116-36	20891-20892	(	_	
116-37	20892-20897	edges	_	
116-38	20897-20898	)	_	
116-39	20899-20901	in	_	
116-40	20902-20905	the	_	
116-41	20906-20913	network	_	
116-42	20913-20914	.	_	

#Text=Biological networks are represented by sparse connections, however, and thresholding is a necessary step to extract the appropriate topological properties of networks.
117-1	20915-20925	Biological	_	
117-2	20926-20934	networks	_	
117-3	20935-20938	are	_	
117-4	20939-20950	represented	_	
117-5	20951-20953	by	_	
117-6	20954-20960	sparse	_	
117-7	20961-20972	connections	_	
117-8	20972-20973	,	_	
117-9	20974-20981	however	_	
117-10	20981-20982	,	_	
117-11	20983-20986	and	_	
117-12	20987-20999	thresholding	_	
117-13	21000-21002	is	_	
117-14	21003-21004	a	_	
117-15	21005-21014	necessary	_	
117-16	21015-21019	step	_	
117-17	21020-21022	to	_	
117-18	21023-21030	extract	_	
117-19	21031-21034	the	_	
117-20	21035-21046	appropriate	_	
117-21	21047-21058	topological	_	
117-22	21059-21069	properties	_	
117-23	21070-21072	of	_	
117-24	21073-21081	networks	_	
117-25	21081-21082	.	_	

#Text=Because graph measures can also be sensitive to threshold value, we have reported our measures across a range of K thresholds (1 ⩽ K ⩽ 5, increments of 1).
118-1	21083-21090	Because	_	
118-2	21091-21096	graph	_	
118-3	21097-21105	measures	_	
118-4	21106-21109	can	_	
118-5	21110-21114	also	_	
118-6	21115-21117	be	_	
118-7	21118-21127	sensitive	_	
118-8	21128-21130	to	_	
118-9	21131-21140	threshold	_	
118-10	21141-21146	value	_	
118-11	21146-21147	,	_	
118-12	21148-21150	we	_	
118-13	21151-21155	have	_	
118-14	21156-21164	reported	_	
118-15	21165-21168	our	_	
118-16	21169-21177	measures	_	
118-17	21178-21184	across	_	
118-18	21185-21186	a	_	
118-19	21187-21192	range	_	
118-20	21193-21195	of	_	
118-21	21196-21197	K	_	
118-22	21198-21208	thresholds	_	
118-23	21209-21210	(	_	
118-24	21210-21211	1	_	
118-25	21211-21212	 	_	
118-26	21212-21213	⩽	_	
118-27	21213-21214	 	_	
118-28	21214-21215	K	_	
118-29	21215-21216	 	_	
118-30	21216-21217	⩽	_	
118-31	21217-21218	 	_	
118-32	21218-21219	5	_	
118-33	21219-21220	,	_	
118-34	21221-21231	increments	_	
118-35	21232-21234	of	_	
118-36	21235-21236	1	_	
118-37	21236-21237	)	_	
118-38	21237-21238	.	_	

#Text=Here K represents the percentage (e.g., 1 = 10%) number of edges in each matrix that are maintained following thresholding.
119-1	21239-21243	Here	_	
119-2	21244-21245	K	_	
119-3	21246-21256	represents	_	
119-4	21257-21260	the	_	
119-5	21261-21271	percentage	_	
119-6	21272-21273	(	_	
119-7	21273-21276	e.g	_	
119-8	21276-21277	.	_	
119-9	21277-21278	,	_	
119-10	21279-21280	1	_	
119-11	21280-21281	 	_	
119-12	21281-21282	=	_	
119-13	21282-21283	 	_	
119-14	21283-21286	10%	_	
119-15	21286-21287	)	_	
119-16	21288-21294	number	_	
119-17	21295-21297	of	_	
119-18	21298-21303	edges	_	
119-19	21304-21306	in	_	
119-20	21307-21311	each	_	
119-21	21312-21318	matrix	_	
119-22	21319-21323	that	_	
119-23	21324-21327	are	_	
119-24	21328-21338	maintained	_	
119-25	21339-21348	following	_	
119-26	21349-21361	thresholding	_	
119-27	21361-21362	.	_	

#Text=We employed a range of thresholds to represent the lower and upper bound of a small-world system, and that preserve only the strongest functional connections for efficient parallel information processing at a relatively low wiring cost.
120-1	21363-21365	We	_	
120-2	21366-21374	employed	_	
120-3	21375-21376	a	_	
120-4	21377-21382	range	_	
120-5	21383-21385	of	_	
120-6	21386-21396	thresholds	_	
120-7	21397-21399	to	_	
120-8	21400-21409	represent	_	
120-9	21410-21413	the	_	
120-10	21414-21419	lower	_	
120-11	21420-21423	and	_	
120-12	21424-21429	upper	_	
120-13	21430-21435	bound	_	
120-14	21436-21438	of	_	
120-15	21439-21440	a	_	
120-16	21441-21452	small-world	_	
120-17	21453-21459	system	_	
120-18	21459-21460	,	_	
120-19	21461-21464	and	_	
120-20	21465-21469	that	_	
120-21	21470-21478	preserve	_	
120-22	21479-21483	only	_	
120-23	21484-21487	the	_	
120-24	21488-21497	strongest	_	
120-25	21498-21508	functional	_	
120-26	21509-21520	connections	_	
120-27	21521-21524	for	_	
120-28	21525-21534	efficient	_	
120-29	21535-21543	parallel	_	
120-30	21544-21555	information	_	
120-31	21556-21566	processing	_	
120-32	21567-21569	at	_	
120-33	21570-21571	a	_	
120-34	21572-21582	relatively	_	
120-35	21583-21586	low	_	
120-36	21587-21593	wiring	_	
120-37	21594-21598	cost	_	
120-38	21598-21599	.	_	

#Text=All graph measures were computed from matrices in their weighted form following this thresholding procedure.
121-1	21600-21603	All	_	
121-2	21604-21609	graph	_	
121-3	21610-21618	measures	_	
121-4	21619-21623	were	_	
121-5	21624-21632	computed	_	
121-6	21633-21637	from	_	
121-7	21638-21646	matrices	_	
121-8	21647-21649	in	_	
121-9	21650-21655	their	_	
121-10	21656-21664	weighted	_	
121-11	21665-21669	form	_	
121-12	21670-21679	following	_	
121-13	21680-21684	this	_	
121-14	21685-21697	thresholding	_	
121-15	21698-21707	procedure	_	
121-16	21707-21708	.	_	

#Text=Functional connectivity
#Text=Group comparisons in ROI‐to‐ROI connectivity across matrices were assessed using the Networks Based Statistics (NBS) Toolbox for MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States).
122-1	21709-21719	Functional	_	
122-2	21720-21732	connectivity	_	
122-3	21733-21738	Group	_	
122-4	21739-21750	comparisons	_	
122-5	21751-21753	in	_	
122-6	21754-21764	ROI‐to‐ROI	_	
122-7	21765-21777	connectivity	_	
122-8	21778-21784	across	_	
122-9	21785-21793	matrices	_	
122-10	21794-21798	were	_	
122-11	21799-21807	assessed	_	
122-12	21808-21813	using	_	
122-13	21814-21817	the	_	
122-14	21818-21826	Networks	_	
122-15	21827-21832	Based	_	
122-16	21833-21843	Statistics	_	
122-17	21844-21845	(	_	
122-18	21845-21848	NBS	_	
122-19	21848-21849	)	_	
122-20	21850-21857	Toolbox	_	
122-21	21858-21861	for	_	
122-22	21862-21868	MATLAB	_	
122-23	21869-21870	(	_	
122-24	21870-21873	The	_	
122-25	21874-21883	MathWorks	_	
122-26	21883-21884	,	_	
122-27	21885-21888	Inc	_	
122-28	21888-21889	.	_	
122-29	21889-21890	,	_	
122-30	21891-21897	Natick	_	
122-31	21897-21898	,	_	
122-32	21899-21912	Massachusetts	_	
122-33	21912-21913	,	_	
122-34	21914-21920	United	_	
122-35	21921-21927	States	_	
122-36	21927-21928	)	_	
122-37	21928-21929	.	_	

#Text=Comparisons between the CON and ADD groups were conducted to identify those nodes across the connectome that showed differences in connectivity.
123-1	21930-21941	Comparisons	_	
123-2	21942-21949	between	_	
123-3	21950-21953	the	_	
123-4	21954-21957	CON	_	
123-5	21958-21961	and	_	
123-6	21962-21965	ADD	_	
123-7	21966-21972	groups	_	
123-8	21973-21977	were	_	
123-9	21978-21987	conducted	_	
123-10	21988-21990	to	_	
123-11	21991-21999	identify	_	
123-12	22000-22005	those	_	
123-13	22006-22011	nodes	_	
123-14	22012-22018	across	_	
123-15	22019-22022	the	_	
123-16	22023-22033	connectome	_	
123-17	22034-22038	that	_	
123-18	22039-22045	showed	_	
123-19	22046-22057	differences	_	
123-20	22058-22060	in	_	
123-21	22061-22073	connectivity	_	
123-22	22073-22074	.	_	

#Text=Independent groups t-tests were first performed to test for a between-group difference in the correlation coefficients at each of the 110 × (110–1)/2 = 5995 regional pairings.
124-1	22075-22086	Independent	_	
124-2	22087-22093	groups	_	
124-3	22094-22101	t-tests	_	
124-4	22102-22106	were	_	
124-5	22107-22112	first	_	
124-6	22113-22122	performed	_	
124-7	22123-22125	to	_	
124-8	22126-22130	test	_	
124-9	22131-22134	for	_	
124-10	22135-22136	a	_	
124-11	22137-22150	between-group	_	
124-12	22151-22161	difference	_	
124-13	22162-22164	in	_	
124-14	22165-22168	the	_	
124-15	22169-22180	correlation	_	
124-16	22181-22193	coefficients	_	
124-17	22194-22196	at	_	
124-18	22197-22201	each	_	
124-19	22202-22204	of	_	
124-20	22205-22208	the	_	
124-21	22209-22212	110	_	
124-22	22212-22213	 	_	
124-23	22213-22214	×	_	
124-24	22214-22215	 	_	
124-25	22215-22216	(	_	
124-26	22216-22219	110	_	
124-27	22219-22220	–	_	
124-28	22220-22221	1	_	
124-29	22221-22222	)	_	
124-30	22222-22223	/	_	
124-31	22223-22224	2	_	
124-32	22224-22225	 	_	
124-33	22225-22226	=	_	
124-34	22226-22227	 	_	
124-35	22227-22231	5995	_	
124-36	22232-22240	regional	_	
124-37	22241-22249	pairings	_	
124-38	22249-22250	.	_	

#Text=Graph sub-components were identified among the connections using a t-statistic threshold t > 3.1.
125-1	22251-22256	Graph	_	
125-2	22257-22271	sub-components	_	
125-3	22272-22276	were	_	
125-4	22277-22287	identified	_	
125-5	22288-22293	among	_	
125-6	22294-22297	the	_	
125-7	22298-22309	connections	_	
125-8	22310-22315	using	_	
125-9	22316-22317	a	_	
125-10	22318-22329	t-statistic	_	
125-11	22330-22339	threshold	_	
125-12	22340-22341	t	_	
125-13	22341-22342	 	_	
125-14	22342-22343	>	_	
125-15	22343-22344	 	_	
125-16	22344-22347	3.1	_	
125-17	22347-22348	.	_	

#Text=From here, a family-wise error (FWE) corrected p-value (p < 0.05) was calculated for the size of each resulting component using permutation testing (5000 permutations).
126-1	22349-22353	From	_	
126-2	22354-22358	here	_	
126-3	22358-22359	,	_	
126-4	22360-22361	a	_	
126-5	22362-22373	family-wise	_	
126-6	22374-22379	error	_	
126-7	22380-22381	(	_	
126-8	22381-22384	FWE	_	
126-9	22384-22385	)	_	
126-10	22386-22395	corrected	_	
126-11	22396-22403	p-value	_	
126-12	22404-22405	(	_	
126-13	22405-22406	p	_	
126-14	22406-22407	 	_	
126-15	22407-22408	<	_	
126-16	22408-22409	 	_	
126-17	22409-22413	0.05	_	
126-18	22413-22414	)	_	
126-19	22415-22418	was	_	
126-20	22419-22429	calculated	_	
126-21	22430-22433	for	_	
126-22	22434-22437	the	_	
126-23	22438-22442	size	_	
126-24	22443-22445	of	_	
126-25	22446-22450	each	_	
126-26	22451-22460	resulting	_	
126-27	22461-22470	component	_	
126-28	22471-22476	using	_	
126-29	22477-22488	permutation	_	
126-30	22489-22496	testing	_	
126-31	22497-22498	(	_	
126-32	22498-22502	5000	_	
126-33	22503-22515	permutations	_	
126-34	22515-22516	)	_	
126-35	22516-22517	.	_	

#Text=Two (CON > ADD and ADD > CON) analyses were conducted independently on the gain anticipation > neutral anticipation contrast matrices.
127-1	22518-22521	Two	_	
127-2	22522-22523	(	_	
127-3	22523-22526	CON	_	
127-4	22526-22527	 	_	
127-5	22527-22528	>	_	
127-6	22528-22529	 	_	
127-7	22529-22532	ADD	_	
127-8	22533-22536	and	_	
127-9	22537-22540	ADD	_	
127-10	22540-22541	 	_	
127-11	22541-22542	>	_	
127-12	22542-22543	 	_	
127-13	22543-22546	CON	_	
127-14	22546-22547	)	_	
127-15	22548-22556	analyses	_	
127-16	22557-22561	were	_	
127-17	22562-22571	conducted	_	
127-18	22572-22585	independently	_	
127-19	22586-22588	on	_	
127-20	22589-22592	the	_	
127-21	22593-22597	gain	_	
127-22	22598-22610	anticipation	_	
127-23	22610-22611	 	_	
127-24	22611-22612	>	_	
127-25	22612-22613	 	_	
127-26	22613-22620	neutral	_	
127-27	22621-22633	anticipation	_	
127-28	22634-22642	contrast	_	
127-29	22643-22651	matrices	_	
127-30	22651-22652	.	_	

#Text=Given the differences in scanners across the three sites, these NBS analyses were conducted while controlling for study site.
128-1	22653-22658	Given	_	
128-2	22659-22662	the	_	
128-3	22663-22674	differences	_	
128-4	22675-22677	in	_	
128-5	22678-22686	scanners	_	
128-6	22687-22693	across	_	
128-7	22694-22697	the	_	
128-8	22698-22703	three	_	
128-9	22704-22709	sites	_	
128-10	22709-22710	,	_	
128-11	22711-22716	these	_	
128-12	22717-22720	NBS	_	
128-13	22721-22729	analyses	_	
128-14	22730-22734	were	_	
128-15	22735-22744	conducted	_	
128-16	22745-22750	while	_	
128-17	22751-22762	controlling	_	
128-18	22763-22766	for	_	
128-19	22767-22772	study	_	
128-20	22773-22777	site	_	
128-21	22777-22778	.	_	

#Text=NBS has previously been used to identify specific networks of nodes across a connectome that differ between clinical populations during different psychological processes.
129-1	22779-22782	NBS	_	
129-2	22783-22786	has	_	
129-3	22787-22797	previously	_	
129-4	22798-22802	been	_	
129-5	22803-22807	used	_	
129-6	22808-22810	to	_	
129-7	22811-22819	identify	_	
129-8	22820-22828	specific	_	
129-9	22829-22837	networks	_	
129-10	22838-22840	of	_	
129-11	22841-22846	nodes	_	
129-12	22847-22853	across	_	
129-13	22854-22855	a	_	
129-14	22856-22866	connectome	_	
129-15	22867-22871	that	_	
129-16	22872-22878	differ	_	
129-17	22879-22886	between	_	
129-18	22887-22895	clinical	_	
129-19	22896-22907	populations	_	
129-20	22908-22914	during	_	
129-21	22915-22924	different	_	
129-22	22925-22938	psychological	_	
129-23	22939-22948	processes	_	
129-24	22948-22949	.	_	

#Text=Network visualisation
#Text=Networks that emerged from group comparisons in NBS were visualised and presented using brain connectivity maps and circular connectograms using the NeuroMArVL software (www.immersive.erc.monash.edu.au/neuromarvl).
130-1	22950-22957	Network	_	
130-2	22958-22971	visualisation	_	
130-3	22972-22980	Networks	_	
130-4	22981-22985	that	_	
130-5	22986-22993	emerged	_	
130-6	22994-22998	from	_	
130-7	22999-23004	group	_	
130-8	23005-23016	comparisons	_	
130-9	23017-23019	in	_	
130-10	23020-23023	NBS	_	
130-11	23024-23028	were	_	
130-12	23029-23039	visualised	_	
130-13	23040-23043	and	_	
130-14	23044-23053	presented	_	
130-15	23054-23059	using	_	
130-16	23060-23065	brain	_	
130-17	23066-23078	connectivity	_	
130-18	23079-23083	maps	_	
130-19	23084-23087	and	_	
130-20	23088-23096	circular	_	
130-21	23097-23110	connectograms	_	
130-22	23111-23116	using	_	
130-23	23117-23120	the	_	
130-24	23121-23131	NeuroMArVL	_	
130-25	23132-23140	software	_	
130-26	23141-23142	(	_	
130-27	23142-23173	www.immersive.erc.monash.edu.au	_	
130-28	23173-23174	/	_	
130-29	23174-23184	neuromarvl	_	
130-30	23184-23185	)	_	
130-31	23185-23186	.	_	

#Text=Results
#Text=Demographics
#Text=Table 1 (supplementary section) shows the demographic and substance use measures for the CON and ADD groups.
131-1	23187-23194	Results	_	
131-2	23195-23207	Demographics	_	
131-3	23208-23213	Table	_	
131-4	23214-23215	1	_	
131-5	23216-23217	(	_	
131-6	23217-23230	supplementary	_	
131-7	23231-23238	section	_	
131-8	23238-23239	)	_	
131-9	23240-23245	shows	_	
131-10	23246-23249	the	_	
131-11	23250-23261	demographic	_	
131-12	23262-23265	and	_	
131-13	23266-23275	substance	_	
131-14	23276-23279	use	_	
131-15	23280-23288	measures	_	
131-16	23289-23292	for	_	
131-17	23293-23296	the	_	
131-18	23297-23300	CON	_	
131-19	23301-23304	and	_	
131-20	23305-23308	ADD	_	
131-21	23309-23315	groups	_	
131-22	23315-23316	.	_	

#Text=The groups were balanced for gender and age, but did significantly differ on other measures, such as reported education, IQ, anxiety, depression, MINI score, and the number of participants who were nicotine-dependent.
132-1	23317-23320	The	_	
132-2	23321-23327	groups	_	
132-3	23328-23332	were	_	
132-4	23333-23341	balanced	_	
132-5	23342-23345	for	_	
132-6	23346-23352	gender	_	
132-7	23353-23356	and	_	
132-8	23357-23360	age	_	
132-9	23360-23361	,	_	
132-10	23362-23365	but	_	
132-11	23366-23369	did	_	
132-12	23370-23383	significantly	_	
132-13	23384-23390	differ	_	
132-14	23391-23393	on	_	
132-15	23394-23399	other	_	
132-16	23400-23408	measures	_	
132-17	23408-23409	,	_	
132-18	23410-23414	such	_	
132-19	23415-23417	as	_	
132-20	23418-23426	reported	_	
132-21	23427-23436	education	_	
132-22	23436-23437	,	_	
132-23	23438-23440	IQ	_	
132-24	23440-23441	,	_	
132-25	23442-23449	anxiety	_	
132-26	23449-23450	,	_	
132-27	23451-23461	depression	_	
132-28	23461-23462	,	_	
132-29	23463-23467	MINI	_	
132-30	23468-23473	score	_	
132-31	23473-23474	,	_	
132-32	23475-23478	and	_	
132-33	23479-23482	the	_	
132-34	23483-23489	number	_	
132-35	23490-23492	of	_	
132-36	23493-23505	participants	_	
132-37	23506-23509	who	_	
132-38	23510-23514	were	_	
132-39	23515-23533	nicotine-dependent	_	
132-40	23533-23534	.	_	

#Text=While we cannot dismiss the potential influence of these demographic differences on brain activation changes or connectivity during reward anticipation, we did not use any of these variables as covariates in any of the analyses reported.
133-1	23535-23540	While	_	
133-2	23541-23543	we	_	
133-3	23544-23550	cannot	_	
133-4	23551-23558	dismiss	_	
133-5	23559-23562	the	_	
133-6	23563-23572	potential	_	
133-7	23573-23582	influence	_	
133-8	23583-23585	of	_	
133-9	23586-23591	these	_	
133-10	23592-23603	demographic	_	
133-11	23604-23615	differences	_	
133-12	23616-23618	on	_	
133-13	23619-23624	brain	_	
133-14	23625-23635	activation	_	
133-15	23636-23643	changes	_	
133-16	23644-23646	or	_	
133-17	23647-23659	connectivity	_	
133-18	23660-23666	during	_	
133-19	23667-23673	reward	_	
133-20	23674-23686	anticipation	_	
133-21	23686-23687	,	_	
133-22	23688-23690	we	_	
133-23	23691-23694	did	_	
133-24	23695-23698	not	_	
133-25	23699-23702	use	_	
133-26	23703-23706	any	_	
133-27	23707-23709	of	_	
133-28	23710-23715	these	_	
133-29	23716-23725	variables	_	
133-30	23726-23728	as	_	
133-31	23729-23739	covariates	_	
133-32	23740-23742	in	_	
133-33	23743-23746	any	_	
133-34	23747-23749	of	_	
133-35	23750-23753	the	_	
133-36	23754-23762	analyses	_	
133-37	23763-23771	reported	_	
133-38	23771-23772	.	_	

#Text=MID task
#Text=MID performance results for the CON and ADD group showing a) mean accuracy (**p < 0.01 Gain > Neutral); b) mean reaction time (**p < 0.01 Gain < Neutral); c) mean lose accuracy and d) mean lose reaction time.
134-1	23773-23776	MID	_	
134-2	23777-23781	task	_	
134-3	23782-23785	MID	_	
134-4	23786-23797	performance	_	
134-5	23798-23805	results	_	
134-6	23806-23809	for	_	
134-7	23810-23813	the	_	
134-8	23814-23817	CON	_	
134-9	23818-23821	and	_	
134-10	23822-23825	ADD	_	
134-11	23826-23831	group	_	
134-12	23832-23839	showing	_	
134-13	23840-23841	a	_	
134-14	23841-23842	)	_	
134-15	23843-23847	mean	_	
134-16	23848-23856	accuracy	_	
134-17	23857-23858	(	_	
134-18	23858-23859	*	_	
134-19	23859-23860	*	_	
134-20	23860-23861	p	_	
134-21	23861-23862	 	_	
134-22	23862-23863	<	_	
134-23	23863-23864	 	_	
134-24	23864-23868	0.01	_	
134-25	23869-23873	Gain	_	
134-26	23873-23874	 	_	
134-27	23874-23875	>	_	
134-28	23875-23876	 	_	
134-29	23876-23883	Neutral	_	
134-30	23883-23884	)	_	
134-31	23884-23885	;	_	
134-32	23886-23887	b	_	
134-33	23887-23888	)	_	
134-34	23889-23893	mean	_	
134-35	23894-23902	reaction	_	
134-36	23903-23907	time	_	
134-37	23908-23909	(	_	
134-38	23909-23910	*	_	
134-39	23910-23911	*	_	
134-40	23911-23912	p	_	
134-41	23912-23913	 	_	
134-42	23913-23914	<	_	
134-43	23914-23915	 	_	
134-44	23915-23919	0.01	_	
134-45	23920-23924	Gain	_	
134-46	23924-23925	 	_	
134-47	23925-23926	<	_	
134-48	23926-23927	 	_	
134-49	23927-23934	Neutral	_	
134-50	23934-23935	)	_	
134-51	23935-23936	;	_	
134-52	23937-23938	c	_	
134-53	23938-23939	)	_	
134-54	23940-23944	mean	_	
134-55	23945-23949	lose	_	
134-56	23950-23958	accuracy	_	
134-57	23959-23962	and	_	
134-58	23963-23964	d	_	
134-59	23964-23965	)	_	
134-60	23966-23970	mean	_	
134-61	23971-23975	lose	_	
134-62	23976-23984	reaction	_	
134-63	23985-23989	time	_	
134-64	23989-23990	.	_	

#Text=Data were analysed with permutation analyses of variance (5000 permutations), controlling for study site.
135-1	23991-23995	Data	_	
135-2	23996-24000	were	_	
135-3	24001-24009	analysed	_	
135-4	24010-24014	with	_	
135-5	24015-24026	permutation	_	
135-6	24027-24035	analyses	_	
135-7	24036-24038	of	_	
135-8	24039-24047	variance	_	
135-9	24048-24049	(	_	
135-10	24049-24053	5000	_	
135-11	24054-24066	permutations	_	
135-12	24066-24067	)	_	
135-13	24067-24068	,	_	
135-14	24069-24080	controlling	_	
135-15	24081-24084	for	_	
135-16	24085-24090	study	_	
135-17	24091-24095	site	_	
135-18	24095-24096	.	_	

#Text=Data are expressed as means and standard error means.
136-1	24097-24101	Data	_	
136-2	24102-24105	are	_	
136-3	24106-24115	expressed	_	
136-4	24116-24118	as	_	
136-5	24119-24124	means	_	
136-6	24125-24128	and	_	
136-7	24129-24137	standard	_	
136-8	24138-24143	error	_	
136-9	24144-24149	means	_	
136-10	24149-24150	.	_	

#Text=Two (Group: CON vs.
137-1	24151-24154	Two	_	
137-2	24155-24156	(	_	
137-3	24156-24161	Group	_	
137-4	24161-24162	:	_	
137-5	24163-24166	CON	_	
137-6	24167-24169	vs	_	
137-7	24169-24170	.	_	

#Text=ADD) by two (Condition: Gain vs.
138-1	24171-24174	ADD	_	
138-2	24174-24175	)	_	
138-3	24176-24178	by	_	
138-4	24179-24182	two	_	
138-5	24183-24184	(	_	
138-6	24184-24193	Condition	_	
138-7	24193-24194	:	_	
138-8	24195-24199	Gain	_	
138-9	24200-24202	vs	_	
138-10	24202-24203	.	_	

#Text=Neutral) permutation analyses of variance showed only a significant effect of condition for MID accuracy (F = 7.8, p < 0.01 - Gain > Neutral) and MID reaction time (F = 8.49, p < 0.01 - Gain < Neutral - Fig. 1a and b).
139-1	24204-24211	Neutral	_	
139-2	24211-24212	)	_	
139-3	24213-24224	permutation	_	
139-4	24225-24233	analyses	_	
139-5	24234-24236	of	_	
139-6	24237-24245	variance	_	
139-7	24246-24252	showed	_	
139-8	24253-24257	only	_	
139-9	24258-24259	a	_	
139-10	24260-24271	significant	_	
139-11	24272-24278	effect	_	
139-12	24279-24281	of	_	
139-13	24282-24291	condition	_	
139-14	24292-24295	for	_	
139-15	24296-24299	MID	_	
139-16	24300-24308	accuracy	_	
139-17	24309-24310	(	_	
139-18	24310-24311	F	_	
139-19	24311-24312	 	_	
139-20	24312-24313	=	_	
139-21	24313-24314	 	_	
139-22	24314-24317	7.8	_	
139-23	24317-24318	,	_	
139-24	24319-24320	p	_	
139-25	24320-24321	 	_	
139-26	24321-24322	<	_	
139-27	24322-24323	 	_	
139-28	24323-24327	0.01	_	
139-29	24328-24329	-	_	
139-30	24330-24334	Gain	_	
139-31	24334-24335	 	_	
139-32	24335-24336	>	_	
139-33	24336-24337	 	_	
139-34	24337-24344	Neutral	_	
139-35	24344-24345	)	_	
139-36	24346-24349	and	_	
139-37	24350-24353	MID	_	
139-38	24354-24362	reaction	_	
139-39	24363-24367	time	_	
139-40	24368-24369	(	_	
139-41	24369-24370	F	_	
139-42	24370-24371	 	_	
139-43	24371-24372	=	_	
139-44	24372-24373	 	_	
139-45	24373-24377	8.49	_	
139-46	24377-24378	,	_	
139-47	24379-24380	p	_	
139-48	24380-24381	 	_	
139-49	24381-24382	<	_	
139-50	24382-24383	 	_	
139-51	24383-24387	0.01	_	
139-52	24388-24389	-	_	
139-53	24390-24394	Gain	_	
139-54	24394-24395	 	_	
139-55	24395-24396	<	_	
139-56	24396-24397	 	_	
139-57	24397-24404	Neutral	_	
139-58	24405-24406	-	_	
139-59	24407-24410	Fig	_	
139-60	24410-24411	.	_	
139-61	24412-24414	1a	_	
139-62	24415-24418	and	_	
139-63	24419-24420	b	_	
139-64	24420-24421	)	_	
139-65	24421-24422	.	_	

#Text=Permutation analyses did not reveal any significant effect of group on the MID lose accuracy (F = 0.01, p = 0.94) or reaction time (F = 0.09, p = 0.77) measures (Fig. 1c and d), or the amount won (£) on the task (F = 0.45, p = 0.50).
140-1	24423-24434	Permutation	_	
140-2	24435-24443	analyses	_	
140-3	24444-24447	did	_	
140-4	24448-24451	not	_	
140-5	24452-24458	reveal	_	
140-6	24459-24462	any	_	
140-7	24463-24474	significant	_	
140-8	24475-24481	effect	_	
140-9	24482-24484	of	_	
140-10	24485-24490	group	_	
140-11	24491-24493	on	_	
140-12	24494-24497	the	_	
140-13	24498-24501	MID	_	
140-14	24502-24506	lose	_	
140-15	24507-24515	accuracy	_	
140-16	24516-24517	(	_	
140-17	24517-24518	F	_	
140-18	24518-24519	 	_	
140-19	24519-24520	=	_	
140-20	24520-24521	 	_	
140-21	24521-24525	0.01	_	
140-22	24525-24526	,	_	
140-23	24527-24528	p	_	
140-24	24528-24529	 	_	
140-25	24529-24530	=	_	
140-26	24530-24531	 	_	
140-27	24531-24535	0.94	_	
140-28	24535-24536	)	_	
140-29	24537-24539	or	_	
140-30	24540-24548	reaction	_	
140-31	24549-24553	time	_	
140-32	24554-24555	(	_	
140-33	24555-24556	F	_	
140-34	24556-24557	 	_	
140-35	24557-24558	=	_	
140-36	24558-24559	 	_	
140-37	24559-24563	0.09	_	
140-38	24563-24564	,	_	
140-39	24565-24566	p	_	
140-40	24566-24567	 	_	
140-41	24567-24568	=	_	
140-42	24568-24569	 	_	
140-43	24569-24573	0.77	_	
140-44	24573-24574	)	_	
140-45	24575-24583	measures	_	
140-46	24584-24585	(	_	
140-47	24585-24588	Fig	_	
140-48	24588-24589	.	_	
140-49	24590-24592	1c	_	
140-50	24593-24596	and	_	
140-51	24597-24598	d	_	
140-52	24598-24599	)	_	
140-53	24599-24600	,	_	
140-54	24601-24603	or	_	
140-55	24604-24607	the	_	
140-56	24608-24614	amount	_	
140-57	24615-24618	won	_	
140-58	24619-24620	(	_	
140-59	24620-24621	£	_	
140-60	24621-24622	)	_	
140-61	24623-24625	on	_	
140-62	24626-24629	the	_	
140-63	24630-24634	task	_	
140-64	24635-24636	(	_	
140-65	24636-24637	F	_	
140-66	24637-24638	 	_	
140-67	24638-24639	=	_	
140-68	24639-24640	 	_	
140-69	24640-24644	0.45	_	
140-70	24644-24645	,	_	
140-71	24646-24647	p	_	
140-72	24647-24648	 	_	
140-73	24648-24649	=	_	
140-74	24649-24650	 	_	
140-75	24650-24654	0.50	_	
140-76	24654-24655	)	_	
140-77	24655-24656	.	_	

#Text=These results suggest that the CON and ADD groups were well matched with respect to MID performance, while also validating the task with respect to its effects on instrumental responding for monetary reward.
#Text=fMRI
#Text=Permutation independent samples t-test analyses showing that ADD < CON group activation differences on the MID gain anticipation > neutral anticipation contrast.
141-1	24657-24662	These	_	
141-2	24663-24670	results	_	
141-3	24671-24678	suggest	_	
141-4	24679-24683	that	_	
141-5	24684-24687	the	_	
141-6	24688-24691	CON	_	
141-7	24692-24695	and	_	
141-8	24696-24699	ADD	_	
141-9	24700-24706	groups	_	
141-10	24707-24711	were	_	
141-11	24712-24716	well	_	
141-12	24717-24724	matched	_	
141-13	24725-24729	with	_	
141-14	24730-24737	respect	_	
141-15	24738-24740	to	_	
141-16	24741-24744	MID	_	
141-17	24745-24756	performance	_	
141-18	24756-24757	,	_	
141-19	24758-24763	while	_	
141-20	24764-24768	also	_	
141-21	24769-24779	validating	_	
141-22	24780-24783	the	_	
141-23	24784-24788	task	_	
141-24	24789-24793	with	_	
141-25	24794-24801	respect	_	
141-26	24802-24804	to	_	
141-27	24805-24808	its	_	
141-28	24809-24816	effects	_	
141-29	24817-24819	on	_	
141-30	24820-24832	instrumental	_	
141-31	24833-24843	responding	_	
141-32	24844-24847	for	_	
141-33	24848-24856	monetary	_	
141-34	24857-24863	reward	_	
141-35	24863-24864	.	_	
141-36	24865-24869	fMRI	_	
141-37	24870-24881	Permutation	_	
141-38	24882-24893	independent	_	
141-39	24894-24901	samples	_	
141-40	24902-24908	t-test	_	
141-41	24909-24917	analyses	_	
141-42	24918-24925	showing	_	
141-43	24926-24930	that	_	
141-44	24931-24934	ADD	_	
141-45	24934-24935	 	_	
141-46	24935-24936	<	_	
141-47	24936-24937	 	_	
141-48	24937-24940	CON	_	
141-49	24941-24946	group	_	
141-50	24947-24957	activation	_	
141-51	24958-24969	differences	_	
141-52	24970-24972	on	_	
141-53	24973-24976	the	_	
141-54	24977-24980	MID	_	
141-55	24981-24985	gain	_	
141-56	24986-24998	anticipation	_	
141-57	24998-24999	 	_	
141-58	24999-25000	>	_	
141-59	25000-25001	 	_	
141-60	25001-25008	neutral	_	
141-61	25009-25021	anticipation	_	
141-62	25022-25030	contrast	_	
141-63	25030-25031	.	_	

#Text=Images were produced after 5000 permutations in randomise using TFCE (PFWE < 0.05), controlling for study site.
142-1	25032-25038	Images	_	
142-2	25039-25043	were	_	
142-3	25044-25052	produced	_	
142-4	25053-25058	after	_	
142-5	25059-25063	5000	_	
142-6	25064-25076	permutations	_	
142-7	25077-25079	in	_	
142-8	25080-25089	randomise	_	
142-9	25090-25095	using	_	
142-10	25096-25100	TFCE	_	
142-11	25101-25102	(	_	
142-12	25102-25106	PFWE	_	
142-13	25106-25107	 	_	
142-14	25107-25108	<	_	
142-15	25108-25109	 	_	
142-16	25109-25113	0.05	_	
142-17	25113-25114	)	_	
142-18	25114-25115	,	_	
142-19	25116-25127	controlling	_	
142-20	25128-25131	for	_	
142-21	25132-25137	study	_	
142-22	25138-25142	site	_	
142-23	25142-25143	.	_	

#Text=The bar corresponds to PFWE < 0.05 and lower. 
143-1	25144-25147	The	_	
143-2	25148-25151	bar	_	
143-3	25152-25163	corresponds	_	
143-4	25164-25166	to	_	
143-5	25167-25171	PFWE	_	
143-6	25171-25172	 	_	
143-7	25172-25173	<	_	
143-8	25173-25174	 	_	
143-9	25174-25178	0.05	_	
143-10	25179-25182	and	_	
143-11	25183-25188	lower	_	
143-12	25188-25189	.	_	
143-13	25189-25190	 	_	

#Text=The structural image represents the MNI152 average normal brain with corresponding horizontal coordinates (inferior–superior).
144-1	25190-25193	The	_	
144-2	25194-25204	structural	_	
144-3	25205-25210	image	_	
144-4	25211-25221	represents	_	
144-5	25222-25225	the	_	
144-6	25226-25232	MNI152	_	
144-7	25233-25240	average	_	
144-8	25241-25247	normal	_	
144-9	25248-25253	brain	_	
144-10	25254-25258	with	_	
144-11	25259-25272	corresponding	_	
144-12	25273-25283	horizontal	_	
144-13	25284-25295	coordinates	_	
144-14	25296-25297	(	_	
144-15	25297-25314	inferior–superior	_	
144-16	25314-25315	)	_	
144-17	25315-25316	.	_	

#Text=R = right hemisphere.
145-1	25317-25318	R	_	
145-2	25318-25319	 	_	
145-3	25319-25320	=	_	
145-4	25320-25321	 	_	
145-5	25321-25326	right	_	
145-6	25327-25337	hemisphere	_	
145-7	25337-25338	.	_	

#Text=One-sample permutation t-test analyses showed that both the CON and ADD groups activated a mostly frontostriatal network of regions for gain anticipation > neutral anticipation contrast (TFCE, PFWE < 0.05) – although these activation changes were weaker in the ADD group (see Supplementary Fig. 2).
146-1	25339-25349	One-sample	_	
146-2	25350-25361	permutation	_	
146-3	25362-25368	t-test	_	
146-4	25369-25377	analyses	_	
146-5	25378-25384	showed	_	
146-6	25385-25389	that	_	
146-7	25390-25394	both	_	
146-8	25395-25398	the	_	
146-9	25399-25402	CON	_	
146-10	25403-25406	and	_	
146-11	25407-25410	ADD	_	
146-12	25411-25417	groups	_	
146-13	25418-25427	activated	_	
146-14	25428-25429	a	_	
146-15	25430-25436	mostly	_	
146-16	25437-25451	frontostriatal	_	
146-17	25452-25459	network	_	
146-18	25460-25462	of	_	
146-19	25463-25470	regions	_	
146-20	25471-25474	for	_	
146-21	25475-25479	gain	_	
146-22	25480-25492	anticipation	_	
146-23	25492-25493	 	_	
146-24	25493-25494	>	_	
146-25	25494-25495	 	_	
146-26	25495-25502	neutral	_	
146-27	25503-25515	anticipation	_	
146-28	25516-25524	contrast	_	
146-29	25525-25526	(	_	
146-30	25526-25530	TFCE	_	
146-31	25530-25531	,	_	
146-32	25532-25536	PFWE	_	
146-33	25536-25537	 	_	
146-34	25537-25538	<	_	
146-35	25538-25539	 	_	
146-36	25539-25543	0.05	_	
146-37	25543-25544	)	_	
146-38	25545-25546	–	_	
146-39	25547-25555	although	_	
146-40	25556-25561	these	_	
146-41	25562-25572	activation	_	
146-42	25573-25580	changes	_	
146-43	25581-25585	were	_	
146-44	25586-25592	weaker	_	
146-45	25593-25595	in	_	
146-46	25596-25599	the	_	
146-47	25600-25603	ADD	_	
146-48	25604-25609	group	_	
146-49	25610-25611	(	_	
146-50	25611-25614	see	_	
146-51	25615-25628	Supplementary	_	
146-52	25629-25632	Fig	_	
146-53	25632-25633	.	_	
146-54	25634-25635	2	_	
146-55	25635-25636	)	_	
146-56	25636-25637	.	_	

#Text=Independent samples permutation t-test analyses on the same contrast detected significant differences between the two groups.
147-1	25638-25649	Independent	_	
147-2	25650-25657	samples	_	
147-3	25658-25669	permutation	_	
147-4	25670-25676	t-test	_	
147-5	25677-25685	analyses	_	
147-6	25686-25688	on	_	
147-7	25689-25692	the	_	
147-8	25693-25697	same	_	
147-9	25698-25706	contrast	_	
147-10	25707-25715	detected	_	
147-11	25716-25727	significant	_	
147-12	25728-25739	differences	_	
147-13	25740-25747	between	_	
147-14	25748-25751	the	_	
147-15	25752-25755	two	_	
147-16	25756-25762	groups	_	
147-17	25762-25763	.	_	

#Text=The ADD group showed significantly less activation change compared with the CON group (TFCE, PFWE < 0.05), particularly across temporal (including the amygdala, hippocampus) and visual regions.
148-1	25764-25767	The	_	
148-2	25768-25771	ADD	_	
148-3	25772-25777	group	_	
148-4	25778-25784	showed	_	
148-5	25785-25798	significantly	_	
148-6	25799-25803	less	_	
148-7	25804-25814	activation	_	
148-8	25815-25821	change	_	
148-9	25822-25830	compared	_	
148-10	25831-25835	with	_	
148-11	25836-25839	the	_	
148-12	25840-25843	CON	_	
148-13	25844-25849	group	_	
148-14	25850-25851	(	_	
148-15	25851-25855	TFCE	_	
148-16	25855-25856	,	_	
148-17	25857-25861	PFWE	_	
148-18	25861-25862	 	_	
148-19	25862-25863	<	_	
148-20	25863-25864	 	_	
148-21	25864-25868	0.05	_	
148-22	25868-25869	)	_	
148-23	25869-25870	,	_	
148-24	25871-25883	particularly	_	
148-25	25884-25890	across	_	
148-26	25891-25899	temporal	_	
148-27	25900-25901	(	_	
148-28	25901-25910	including	_	
148-29	25911-25914	the	_	
148-30	25915-25923	amygdala	_	
148-31	25923-25924	,	_	
148-32	25925-25936	hippocampus	_	
148-33	25936-25937	)	_	
148-34	25938-25941	and	_	
148-35	25942-25948	visual	_	
148-36	25949-25956	regions	_	
148-37	25956-25957	.	_	

#Text=There were also less pronounced differences across frontal (insula, inferior frontal gyrus) and limbic-associated (anterior cingulate gyrus, thalamus) regions (Fig. 2).
149-1	25958-25963	There	_	
149-2	25964-25968	were	_	
149-3	25969-25973	also	_	
149-4	25974-25978	less	_	
149-5	25979-25989	pronounced	_	
149-6	25990-26001	differences	_	
149-7	26002-26008	across	_	
149-8	26009-26016	frontal	_	
149-9	26017-26018	(	_	
149-10	26018-26024	insula	_	
149-11	26024-26025	,	_	
149-12	26026-26034	inferior	_	
149-13	26035-26042	frontal	_	
149-14	26043-26048	gyrus	_	
149-15	26048-26049	)	_	
149-16	26050-26053	and	_	
149-17	26054-26071	limbic-associated	_	
149-18	26072-26073	(	_	
149-19	26073-26081	anterior	_	
149-20	26082-26091	cingulate	_	
149-21	26092-26097	gyrus	_	
149-22	26097-26098	,	_	
149-23	26099-26107	thalamus	_	
149-24	26107-26108	)	_	
149-25	26109-26116	regions	_	
149-26	26117-26118	(	_	
149-27	26118-26121	Fig	_	
149-28	26121-26122	.	_	
149-29	26123-26124	2	_	
149-30	26124-26125	)	_	
149-31	26125-26126	.	_	

#Text=These between groups analyses, however, did not reveal any differences in activation change across striatal regions.
150-1	26127-26132	These	_	
150-2	26133-26140	between	_	
150-3	26141-26147	groups	_	
150-4	26148-26156	analyses	_	
150-5	26156-26157	,	_	
150-6	26158-26165	however	_	
150-7	26165-26166	,	_	
150-8	26167-26170	did	_	
150-9	26171-26174	not	_	
150-10	26175-26181	reveal	_	
150-11	26182-26185	any	_	
150-12	26186-26197	differences	_	
150-13	26198-26200	in	_	
150-14	26201-26211	activation	_	
150-15	26212-26218	change	_	
150-16	26219-26225	across	_	
150-17	26226-26234	striatal	_	
150-18	26235-26242	regions	_	
150-19	26242-26243	.	_	

#Text=Graph measures
#Text=Global network differences between groups showing a) clustering (***p < 0.001, ADD < CON) and b) path length (**p < 0.01, ADD > CON) during the gain > neutral contrast of the MID task.
151-1	26244-26249	Graph	_	
151-2	26250-26258	measures	_	
151-3	26259-26265	Global	_	
151-4	26266-26273	network	_	
151-5	26274-26285	differences	_	
151-6	26286-26293	between	_	
151-7	26294-26300	groups	_	
151-8	26301-26308	showing	_	
151-9	26309-26310	a	_	
151-10	26310-26311	)	_	
151-11	26312-26322	clustering	_	
151-12	26323-26324	(	_	
151-13	26324-26325	*	_	
151-14	26325-26326	*	_	
151-15	26326-26327	*	_	
151-16	26327-26328	p	_	
151-17	26328-26329	 	_	
151-18	26329-26330	<	_	
151-19	26330-26331	 	_	
151-20	26331-26336	0.001	_	
151-21	26336-26337	,	_	
151-22	26338-26341	ADD	_	
151-23	26341-26342	 	_	
151-24	26342-26343	<	_	
151-25	26343-26344	 	_	
151-26	26344-26347	CON	_	
151-27	26347-26348	)	_	
151-28	26349-26352	and	_	
151-29	26353-26354	b	_	
151-30	26354-26355	)	_	
151-31	26356-26360	path	_	
151-32	26361-26367	length	_	
151-33	26368-26369	(	_	
151-34	26369-26370	*	_	
151-35	26370-26371	*	_	
151-36	26371-26372	p	_	
151-37	26372-26373	 	_	
151-38	26373-26374	<	_	
151-39	26374-26375	 	_	
151-40	26375-26379	0.01	_	
151-41	26379-26380	,	_	
151-42	26381-26384	ADD	_	
151-43	26384-26385	 	_	
151-44	26385-26386	>	_	
151-45	26386-26387	 	_	
151-46	26387-26390	CON	_	
151-47	26390-26391	)	_	
151-48	26392-26398	during	_	
151-49	26399-26402	the	_	
151-50	26403-26407	gain	_	
151-51	26407-26408	 	_	
151-52	26408-26409	>	_	
151-53	26409-26410	 	_	
151-54	26410-26417	neutral	_	
151-55	26418-26426	contrast	_	
151-56	26427-26429	of	_	
151-57	26430-26433	the	_	
151-58	26434-26437	MID	_	
151-59	26438-26442	task	_	
151-60	26442-26443	.	_	

#Text=Data were analysed using two (group: CON vs.
152-1	26444-26448	Data	_	
152-2	26449-26453	were	_	
152-3	26454-26462	analysed	_	
152-4	26463-26468	using	_	
152-5	26469-26472	two	_	
152-6	26473-26474	(	_	
152-7	26474-26479	group	_	
152-8	26479-26480	:	_	
152-9	26481-26484	CON	_	
152-10	26485-26487	vs	_	
152-11	26487-26488	.	_	

#Text=ADD) × five (1 ⩽ K ⩽ 5) permutation anova analyses, controlling for study site.
153-1	26489-26492	ADD	_	
153-2	26492-26493	)	_	
153-3	26493-26494	 	_	
153-4	26494-26495	×	_	
153-5	26495-26496	 	_	
153-6	26496-26500	five	_	
153-7	26501-26502	(	_	
153-8	26502-26503	1	_	
153-9	26503-26504	 	_	
153-10	26504-26505	⩽	_	
153-11	26505-26506	 	_	
153-12	26506-26507	K	_	
153-13	26507-26508	 	_	
153-14	26508-26509	⩽	_	
153-15	26509-26510	 	_	
153-16	26510-26511	5	_	
153-17	26511-26512	)	_	
153-18	26513-26524	permutation	_	
153-19	26525-26530	anova	_	
153-20	26531-26539	analyses	_	
153-21	26539-26540	,	_	
153-22	26541-26552	controlling	_	
153-23	26553-26556	for	_	
153-24	26557-26562	study	_	
153-25	26563-26567	site	_	
153-26	26567-26568	.	_	

#Text=Data are expressed as means and standard error means.
154-1	26569-26573	Data	_	
154-2	26574-26577	are	_	
154-3	26578-26587	expressed	_	
154-4	26588-26590	as	_	
154-5	26591-26596	means	_	
154-6	26597-26600	and	_	
154-7	26601-26609	standard	_	
154-8	26610-26615	error	_	
154-9	26616-26621	means	_	
154-10	26621-26622	.	_	

#Text=The results from all permutation tests are provided in the Supplementary results section.
155-1	26623-26626	The	_	
155-2	26627-26634	results	_	
155-3	26635-26639	from	_	
155-4	26640-26643	all	_	
155-5	26644-26655	permutation	_	
155-6	26656-26661	tests	_	
155-7	26662-26665	are	_	
155-8	26666-26674	provided	_	
155-9	26675-26677	in	_	
155-10	26678-26681	the	_	
155-11	26682-26695	Supplementary	_	
155-12	26696-26703	results	_	
155-13	26704-26711	section	_	
155-14	26711-26712	.	_	

#Text=Here we report only the main effects of Group.
156-1	26713-26717	Here	_	
156-2	26718-26720	we	_	
156-3	26721-26727	report	_	
156-4	26728-26732	only	_	
156-5	26733-26736	the	_	
156-6	26737-26741	main	_	
156-7	26742-26749	effects	_	
156-8	26750-26752	of	_	
156-9	26753-26758	Group	_	
156-10	26758-26759	.	_	

#Text=Two (Group: CON vs.
157-1	26760-26763	Two	_	
157-2	26764-26765	(	_	
157-3	26765-26770	Group	_	
157-4	26770-26771	:	_	
157-5	26772-26775	CON	_	
157-6	26776-26778	vs	_	
157-7	26778-26779	.	_	

#Text=ADD) by five (1 ⩽ K ⩽ 5) permutation analyses of variance showed a significant effect of Group on both the clustering coefficient (F = 29.98, p < 0.001 - ADD < CON) and characteristic path length (F = 7.30, p < 0.001 – ADD > CON) measures (Fig. 3a and b).
158-1	26780-26783	ADD	_	
158-2	26783-26784	)	_	
158-3	26785-26787	by	_	
158-4	26788-26792	five	_	
158-5	26793-26794	(	_	
158-6	26794-26795	1	_	
158-7	26795-26796	 	_	
158-8	26796-26797	⩽	_	
158-9	26797-26798	 	_	
158-10	26798-26799	K	_	
158-11	26799-26800	 	_	
158-12	26800-26801	⩽	_	
158-13	26801-26802	 	_	
158-14	26802-26803	5	_	
158-15	26803-26804	)	_	
158-16	26805-26816	permutation	_	
158-17	26817-26825	analyses	_	
158-18	26826-26828	of	_	
158-19	26829-26837	variance	_	
158-20	26838-26844	showed	_	
158-21	26845-26846	a	_	
158-22	26847-26858	significant	_	
158-23	26859-26865	effect	_	
158-24	26866-26868	of	_	
158-25	26869-26874	Group	_	
158-26	26875-26877	on	_	
158-27	26878-26882	both	_	
158-28	26883-26886	the	_	
158-29	26887-26897	clustering	_	
158-30	26898-26909	coefficient	_	
158-31	26910-26911	(	_	
158-32	26911-26912	F	_	
158-33	26912-26913	 	_	
158-34	26913-26914	=	_	
158-35	26914-26915	 	_	
158-36	26915-26920	29.98	_	
158-37	26920-26921	,	_	
158-38	26922-26923	p	_	
158-39	26923-26924	 	_	
158-40	26924-26925	<	_	
158-41	26925-26926	 	_	
158-42	26926-26931	0.001	_	
158-43	26932-26933	-	_	
158-44	26934-26937	ADD	_	
158-45	26937-26938	 	_	
158-46	26938-26939	<	_	
158-47	26939-26940	 	_	
158-48	26940-26943	CON	_	
158-49	26943-26944	)	_	
158-50	26945-26948	and	_	
158-51	26949-26963	characteristic	_	
158-52	26964-26968	path	_	
158-53	26969-26975	length	_	
158-54	26976-26977	(	_	
158-55	26977-26978	F	_	
158-56	26978-26979	 	_	
158-57	26979-26980	=	_	
158-58	26980-26981	 	_	
158-59	26981-26985	7.30	_	
158-60	26985-26986	,	_	
158-61	26987-26988	p	_	
158-62	26988-26989	 	_	
158-63	26989-26990	<	_	
158-64	26990-26991	 	_	
158-65	26991-26996	0.001	_	
158-66	26997-26998	–	_	
158-67	26999-27002	ADD	_	
158-68	27002-27003	 	_	
158-69	27003-27004	>	_	
158-70	27004-27005	 	_	
158-71	27005-27008	CON	_	
158-72	27008-27009	)	_	
158-73	27010-27018	measures	_	
158-74	27019-27020	(	_	
158-75	27020-27023	Fig	_	
158-76	27023-27024	.	_	
158-77	27025-27027	3a	_	
158-78	27028-27031	and	_	
158-79	27032-27033	b	_	
158-80	27033-27034	)	_	
158-81	27034-27035	.	_	

#Text=Functional connectivity
#Text=Non-parametric network based statistics (NBS) analysis results showing a graph sub-component comprising 153 edges (p < 0.01) where the ADD group demonstrated significantly less connectivity compared to the CON group during the gain > neutral anticipation contrast of the MID task.
159-1	27036-27046	Functional	_	
159-2	27047-27059	connectivity	_	
159-3	27060-27074	Non-parametric	_	
159-4	27075-27082	network	_	
159-5	27083-27088	based	_	
159-6	27089-27099	statistics	_	
159-7	27100-27101	(	_	
159-8	27101-27104	NBS	_	
159-9	27104-27105	)	_	
159-10	27106-27114	analysis	_	
159-11	27115-27122	results	_	
159-12	27123-27130	showing	_	
159-13	27131-27132	a	_	
159-14	27133-27138	graph	_	
159-15	27139-27152	sub-component	_	
159-16	27153-27163	comprising	_	
159-17	27164-27167	153	_	
159-18	27168-27173	edges	_	
159-19	27174-27175	(	_	
159-20	27175-27176	p	_	
159-21	27176-27177	 	_	
159-22	27177-27178	<	_	
159-23	27178-27179	 	_	
159-24	27179-27183	0.01	_	
159-25	27183-27184	)	_	
159-26	27185-27190	where	_	
159-27	27191-27194	the	_	
159-28	27195-27198	ADD	_	
159-29	27199-27204	group	_	
159-30	27205-27217	demonstrated	_	
159-31	27218-27231	significantly	_	
159-32	27232-27236	less	_	
159-33	27237-27249	connectivity	_	
159-34	27250-27258	compared	_	
159-35	27259-27261	to	_	
159-36	27262-27265	the	_	
159-37	27266-27269	CON	_	
159-38	27270-27275	group	_	
159-39	27276-27282	during	_	
159-40	27283-27286	the	_	
159-41	27287-27291	gain	_	
159-42	27291-27292	 	_	
159-43	27292-27293	>	_	
159-44	27293-27294	 	_	
159-45	27294-27301	neutral	_	
159-46	27302-27314	anticipation	_	
159-47	27315-27323	contrast	_	
159-48	27324-27326	of	_	
159-49	27327-27330	the	_	
159-50	27331-27334	MID	_	
159-51	27335-27339	task	_	
159-52	27339-27340	.	_	

#Text=Graph sub-components were identified among all node pairwise connections with a t-statistic threshold of t > 3.1, corrected for multiple comparisons, while controlling for study site using permutation (5000) analyses.
160-1	27341-27346	Graph	_	
160-2	27347-27361	sub-components	_	
160-3	27362-27366	were	_	
160-4	27367-27377	identified	_	
160-5	27378-27383	among	_	
160-6	27384-27387	all	_	
160-7	27388-27392	node	_	
160-8	27393-27401	pairwise	_	
160-9	27402-27413	connections	_	
160-10	27414-27418	with	_	
160-11	27419-27420	a	_	
160-12	27421-27432	t-statistic	_	
160-13	27433-27442	threshold	_	
160-14	27443-27445	of	_	
160-15	27446-27447	t	_	
160-16	27447-27448	 	_	
160-17	27448-27449	>	_	
160-18	27449-27450	 	_	
160-19	27450-27453	3.1	_	
160-20	27453-27454	,	_	
160-21	27455-27464	corrected	_	
160-22	27465-27468	for	_	
160-23	27469-27477	multiple	_	
160-24	27478-27489	comparisons	_	
160-25	27489-27490	,	_	
160-26	27491-27496	while	_	
160-27	27497-27508	controlling	_	
160-28	27509-27512	for	_	
160-29	27513-27518	study	_	
160-30	27519-27523	site	_	
160-31	27524-27529	using	_	
160-32	27530-27541	permutation	_	
160-33	27542-27543	(	_	
160-34	27543-27547	5000	_	
160-35	27547-27548	)	_	
160-36	27549-27557	analyses	_	
160-37	27557-27558	.	_	

#Text=Reductions in connectivity in the ADD group are represented by a) brain connectivity maps and b) a circular connectogram.
161-1	27559-27569	Reductions	_	
161-2	27570-27572	in	_	
161-3	27573-27585	connectivity	_	
161-4	27586-27588	in	_	
161-5	27589-27592	the	_	
161-6	27593-27596	ADD	_	
161-7	27597-27602	group	_	
161-8	27603-27606	are	_	
161-9	27607-27618	represented	_	
161-10	27619-27621	by	_	
161-11	27622-27623	a	_	
161-12	27623-27624	)	_	
161-13	27625-27630	brain	_	
161-14	27631-27643	connectivity	_	
161-15	27644-27648	maps	_	
161-16	27649-27652	and	_	
161-17	27653-27654	b	_	
161-18	27654-27655	)	_	
161-19	27656-27657	a	_	
161-20	27658-27666	circular	_	
161-21	27667-27679	connectogram	_	
161-22	27679-27680	.	_	

#Text=Brain regions are grouped on the connectogram circumference according to lobes and centres in the left and right hemispheres (left frontal [dark blue]; left temporal [light blue]; left parietal [dark orange], left occipital [light orange]); left limbic [dark green]; right frontal [light green]; right temporal [dark red]; right parietal [pink]; right occipital [dark purple]; right limbic [light purple]; left striatal [dark brown] and right striatal [light brown].
162-1	27681-27686	Brain	_	
162-2	27687-27694	regions	_	
162-3	27695-27698	are	_	
162-4	27699-27706	grouped	_	
162-5	27707-27709	on	_	
162-6	27710-27713	the	_	
162-7	27714-27726	connectogram	_	
162-8	27727-27740	circumference	_	
162-9	27741-27750	according	_	
162-10	27751-27753	to	_	
162-11	27754-27759	lobes	_	
162-12	27760-27763	and	_	
162-13	27764-27771	centres	_	
162-14	27772-27774	in	_	
162-15	27775-27778	the	_	
162-16	27779-27783	left	_	
162-17	27784-27787	and	_	
162-18	27788-27793	right	_	
162-19	27794-27805	hemispheres	_	
162-20	27806-27807	(	_	
162-21	27807-27811	left	_	
162-22	27812-27819	frontal	_	
162-23	27820-27821	[	_	
162-24	27821-27825	dark	_	
162-25	27826-27830	blue	_	
162-26	27830-27831	]	_	
162-27	27831-27832	;	_	
162-28	27833-27837	left	_	
162-29	27838-27846	temporal	_	
162-30	27847-27848	[	_	
162-31	27848-27853	light	_	
162-32	27854-27858	blue	_	
162-33	27858-27859	]	_	
162-34	27859-27860	;	_	
162-35	27861-27865	left	_	
162-36	27866-27874	parietal	_	
162-37	27875-27876	[	_	
162-38	27876-27880	dark	_	
162-39	27881-27887	orange	_	
162-40	27887-27888	]	_	
162-41	27888-27889	,	_	
162-42	27890-27894	left	_	
162-43	27895-27904	occipital	_	
162-44	27905-27906	[	_	
162-45	27906-27911	light	_	
162-46	27912-27918	orange	_	
162-47	27918-27919	]	_	
162-48	27919-27920	)	_	
162-49	27920-27921	;	_	
162-50	27922-27926	left	_	
162-51	27927-27933	limbic	_	
162-52	27934-27935	[	_	
162-53	27935-27939	dark	_	
162-54	27940-27945	green	_	
162-55	27945-27946	]	_	
162-56	27946-27947	;	_	
162-57	27948-27953	right	_	
162-58	27954-27961	frontal	_	
162-59	27962-27963	[	_	
162-60	27963-27968	light	_	
162-61	27969-27974	green	_	
162-62	27974-27975	]	_	
162-63	27975-27976	;	_	
162-64	27977-27982	right	_	
162-65	27983-27991	temporal	_	
162-66	27992-27993	[	_	
162-67	27993-27997	dark	_	
162-68	27998-28001	red	_	
162-69	28001-28002	]	_	
162-70	28002-28003	;	_	
162-71	28004-28009	right	_	
162-72	28010-28018	parietal	_	
162-73	28019-28020	[	_	
162-74	28020-28024	pink	_	
162-75	28024-28025	]	_	
162-76	28025-28026	;	_	
162-77	28027-28032	right	_	
162-78	28033-28042	occipital	_	
162-79	28043-28044	[	_	
162-80	28044-28048	dark	_	
162-81	28049-28055	purple	_	
162-82	28055-28056	]	_	
162-83	28056-28057	;	_	
162-84	28058-28063	right	_	
162-85	28064-28070	limbic	_	
162-86	28071-28072	[	_	
162-87	28072-28077	light	_	
162-88	28078-28084	purple	_	
162-89	28084-28085	]	_	
162-90	28085-28086	;	_	
162-91	28087-28091	left	_	
162-92	28092-28100	striatal	_	
162-93	28101-28102	[	_	
162-94	28102-28106	dark	_	
162-95	28107-28112	brown	_	
162-96	28112-28113	]	_	
162-97	28114-28117	and	_	
162-98	28118-28123	right	_	
162-99	28124-28132	striatal	_	
162-100	28133-28134	[	_	
162-101	28134-28139	light	_	
162-102	28140-28145	brown	_	
162-103	28145-28146	]	_	
162-104	28146-28147	.	_	

#Text=Brain connectivity maps and the circular connectogram were generated using NeuroMArVL (http://immersive.erc.monash.edu.au/neuromarvl).
163-1	28148-28153	Brain	_	
163-2	28154-28166	connectivity	_	
163-3	28167-28171	maps	_	
163-4	28172-28175	and	_	
163-5	28176-28179	the	_	
163-6	28180-28188	circular	_	
163-7	28189-28201	connectogram	_	
163-8	28202-28206	were	_	
163-9	28207-28216	generated	_	
163-10	28217-28222	using	_	
163-11	28223-28233	NeuroMArVL	_	
163-12	28234-28235	(	_	
163-13	28235-28239	http	_	
163-14	28239-28240	:	_	
163-15	28240-28241	/	_	
163-16	28241-28242	/	_	
163-17	28242-28269	immersive.erc.monash.edu.au	_	
163-18	28269-28270	/	_	
163-19	28270-28280	neuromarvl	_	
163-20	28280-28281	)	_	
163-21	28281-28282	.	_	

#Text=(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
164-1	28283-28284	(	_	
164-2	28284-28287	For	_	
164-3	28288-28302	interpretation	_	
164-4	28303-28305	of	_	
164-5	28306-28309	the	_	
164-6	28310-28320	references	_	
164-7	28321-28323	to	_	
164-8	28324-28330	colour	_	
164-9	28331-28333	in	_	
164-10	28334-28338	this	_	
164-11	28339-28345	figure	_	
164-12	28346-28352	legend	_	
164-13	28352-28353	,	_	
164-14	28354-28357	the	_	
164-15	28358-28364	reader	_	
164-16	28365-28367	is	_	
164-17	28368-28376	referred	_	
164-18	28377-28379	to	_	
164-19	28380-28383	the	_	
164-20	28384-28387	web	_	
164-21	28388-28395	version	_	
164-22	28396-28398	of	_	
164-23	28399-28403	this	_	
164-24	28404-28411	article	_	
164-25	28411-28412	.	_	
164-26	28412-28413	)	_	

#Text=The network based statistics (NBS) analyses detected a graph sub-network comprising 153 edges between 59 nodes of the connectome where the ADD group demonstrated significantly less connectivity (p < 0.01) compared with the CON group.
165-1	28414-28417	The	_	
165-2	28418-28425	network	_	
165-3	28426-28431	based	_	
165-4	28432-28442	statistics	_	
165-5	28443-28444	(	_	
165-6	28444-28447	NBS	_	
165-7	28447-28448	)	_	
165-8	28449-28457	analyses	_	
165-9	28458-28466	detected	_	
165-10	28467-28468	a	_	
165-11	28469-28474	graph	_	
165-12	28475-28486	sub-network	_	
165-13	28487-28497	comprising	_	
165-14	28498-28501	153	_	
165-15	28502-28507	edges	_	
165-16	28508-28515	between	_	
165-17	28516-28518	59	_	
165-18	28519-28524	nodes	_	
165-19	28525-28527	of	_	
165-20	28528-28531	the	_	
165-21	28532-28542	connectome	_	
165-22	28543-28548	where	_	
165-23	28549-28552	the	_	
165-24	28553-28556	ADD	_	
165-25	28557-28562	group	_	
165-26	28563-28575	demonstrated	_	
165-27	28576-28589	significantly	_	
165-28	28590-28594	less	_	
165-29	28595-28607	connectivity	_	
165-30	28608-28609	(	_	
165-31	28609-28610	p	_	
165-32	28610-28611	 	_	
165-33	28611-28612	<	_	
165-34	28612-28613	 	_	
165-35	28613-28617	0.01	_	
165-36	28617-28618	)	_	
165-37	28619-28627	compared	_	
165-38	28628-28632	with	_	
165-39	28633-28636	the	_	
165-40	28637-28640	CON	_	
165-41	28641-28646	group	_	
165-42	28646-28647	.	_	

#Text=These differences in connectivity were mostly intra-hemispheric (55%), the majority (38%) being in the right hemisphere.
166-1	28648-28653	These	_	
166-2	28654-28665	differences	_	
166-3	28666-28668	in	_	
166-4	28669-28681	connectivity	_	
166-5	28682-28686	were	_	
166-6	28687-28693	mostly	_	
166-7	28694-28711	intra-hemispheric	_	
166-8	28712-28713	(	_	
166-9	28713-28716	55%	_	
166-10	28716-28717	)	_	
166-11	28717-28718	,	_	
166-12	28719-28722	the	_	
166-13	28723-28731	majority	_	
166-14	28732-28733	(	_	
166-15	28733-28736	38%	_	
166-16	28736-28737	)	_	
166-17	28738-28743	being	_	
166-18	28744-28746	in	_	
166-19	28747-28750	the	_	
166-20	28751-28756	right	_	
166-21	28757-28767	hemisphere	_	
166-22	28767-28768	.	_	

#Text=The anatomical distribution of these connectivity differences between the two groups involved frontal (insula, inferior frontal gyrus, orbitofrontal cortex), limbic-associated (anterior cingulate gyrus, thalamus), visual (lateral occipital cortex, lingual gyrus, intracalcarine cortex); and unlike the voxel-wise analyses, striatal (accumbens, caudate, pallidum) regions (Fig. 4).
167-1	28769-28772	The	_	
167-2	28773-28783	anatomical	_	
167-3	28784-28796	distribution	_	
167-4	28797-28799	of	_	
167-5	28800-28805	these	_	
167-6	28806-28818	connectivity	_	
167-7	28819-28830	differences	_	
167-8	28831-28838	between	_	
167-9	28839-28842	the	_	
167-10	28843-28846	two	_	
167-11	28847-28853	groups	_	
167-12	28854-28862	involved	_	
167-13	28863-28870	frontal	_	
167-14	28871-28872	(	_	
167-15	28872-28878	insula	_	
167-16	28878-28879	,	_	
167-17	28880-28888	inferior	_	
167-18	28889-28896	frontal	_	
167-19	28897-28902	gyrus	_	
167-20	28902-28903	,	_	
167-21	28904-28917	orbitofrontal	_	
167-22	28918-28924	cortex	_	
167-23	28924-28925	)	_	
167-24	28925-28926	,	_	
167-25	28927-28944	limbic-associated	_	
167-26	28945-28946	(	_	
167-27	28946-28954	anterior	_	
167-28	28955-28964	cingulate	_	
167-29	28965-28970	gyrus	_	
167-30	28970-28971	,	_	
167-31	28972-28980	thalamus	_	
167-32	28980-28981	)	_	
167-33	28981-28982	,	_	
167-34	28983-28989	visual	_	
167-35	28990-28991	(	_	
167-36	28991-28998	lateral	_	
167-37	28999-29008	occipital	_	
167-38	29009-29015	cortex	_	
167-39	29015-29016	,	_	
167-40	29017-29024	lingual	_	
167-41	29025-29030	gyrus	_	
167-42	29030-29031	,	_	
167-43	29032-29046	intracalcarine	_	
167-44	29047-29053	cortex	_	
167-45	29053-29054	)	_	
167-46	29054-29055	;	_	
167-47	29056-29059	and	_	
167-48	29060-29066	unlike	_	
167-49	29067-29070	the	_	
167-50	29071-29081	voxel-wise	_	
167-51	29082-29090	analyses	_	
167-52	29090-29091	,	_	
167-53	29092-29100	striatal	_	
167-54	29101-29102	(	_	
167-55	29102-29111	accumbens	_	
167-56	29111-29112	,	_	
167-57	29113-29120	caudate	_	
167-58	29120-29121	,	_	
167-59	29122-29130	pallidum	_	
167-60	29130-29131	)	_	
167-61	29132-29139	regions	_	
167-62	29140-29141	(	_	
167-63	29141-29144	Fig	_	
167-64	29144-29145	.	_	
167-65	29146-29147	4	_	
167-66	29147-29148	)	_	
167-67	29148-29149	.	_	

#Text=Discussion
#Text=We compared a control (CON) and an addiction (ADD) group in extended abstinence on behavioural and neural measures of a Monetary Incentive Delay (MID) task.
168-1	29150-29160	Discussion	_	
168-2	29161-29163	We	_	
168-3	29164-29172	compared	_	
168-4	29173-29174	a	_	
168-5	29175-29182	control	_	
168-6	29183-29184	(	_	
168-7	29184-29187	CON	_	
168-8	29187-29188	)	_	
168-9	29189-29192	and	_	
168-10	29193-29195	an	_	
168-11	29196-29205	addiction	_	
168-12	29206-29207	(	_	
168-13	29207-29210	ADD	_	
168-14	29210-29211	)	_	
168-15	29212-29217	group	_	
168-16	29218-29220	in	_	
168-17	29221-29229	extended	_	
168-18	29230-29240	abstinence	_	
168-19	29241-29243	on	_	
168-20	29244-29255	behavioural	_	
168-21	29256-29259	and	_	
168-22	29260-29266	neural	_	
168-23	29267-29275	measures	_	
168-24	29276-29278	of	_	
168-25	29279-29280	a	_	
168-26	29281-29289	Monetary	_	
168-27	29290-29299	Incentive	_	
168-28	29300-29305	Delay	_	
168-29	29306-29307	(	_	
168-30	29307-29310	MID	_	
168-31	29310-29311	)	_	
168-32	29312-29316	task	_	
168-33	29316-29317	.	_	

#Text=Behaviourally, the two groups were well matched, enabling us to discount performance as a potential confound on group differences in brain activation and connectivity.
169-1	29318-29331	Behaviourally	_	
169-2	29331-29332	,	_	
169-3	29333-29336	the	_	
169-4	29337-29340	two	_	
169-5	29341-29347	groups	_	
169-6	29348-29352	were	_	
169-7	29353-29357	well	_	
169-8	29358-29365	matched	_	
169-9	29365-29366	,	_	
169-10	29367-29375	enabling	_	
169-11	29376-29378	us	_	
169-12	29379-29381	to	_	
169-13	29382-29390	discount	_	
169-14	29391-29402	performance	_	
169-15	29403-29405	as	_	
169-16	29406-29407	a	_	
169-17	29408-29417	potential	_	
169-18	29418-29426	confound	_	
169-19	29427-29429	on	_	
169-20	29430-29435	group	_	
169-21	29436-29447	differences	_	
169-22	29448-29450	in	_	
169-23	29451-29456	brain	_	
169-24	29457-29467	activation	_	
169-25	29468-29471	and	_	
169-26	29472-29484	connectivity	_	
169-27	29484-29485	.	_	

#Text=These performance effects showed that both groups were equally incentivized to maximize monetary gains, as revealed by significant differences between the gain and neutral conditions.
170-1	29486-29491	These	_	
170-2	29492-29503	performance	_	
170-3	29504-29511	effects	_	
170-4	29512-29518	showed	_	
170-5	29519-29523	that	_	
170-6	29524-29528	both	_	
170-7	29529-29535	groups	_	
170-8	29536-29540	were	_	
170-9	29541-29548	equally	_	
170-10	29549-29561	incentivized	_	
170-11	29562-29564	to	_	
170-12	29565-29573	maximize	_	
170-13	29574-29582	monetary	_	
170-14	29583-29588	gains	_	
170-15	29588-29589	,	_	
170-16	29590-29592	as	_	
170-17	29593-29601	revealed	_	
170-18	29602-29604	by	_	
170-19	29605-29616	significant	_	
170-20	29617-29628	differences	_	
170-21	29629-29636	between	_	
170-22	29637-29640	the	_	
170-23	29641-29645	gain	_	
170-24	29646-29649	and	_	
170-25	29650-29657	neutral	_	
170-26	29658-29668	conditions	_	
170-27	29668-29669	.	_	

#Text=These results, therefore, validate the incentivizing effects of our MID task on instrumental responding for rewards.
171-1	29670-29675	These	_	
171-2	29676-29683	results	_	
171-3	29683-29684	,	_	
171-4	29685-29694	therefore	_	
171-5	29694-29695	,	_	
171-6	29696-29704	validate	_	
171-7	29705-29708	the	_	
171-8	29709-29722	incentivizing	_	
171-9	29723-29730	effects	_	
171-10	29731-29733	of	_	
171-11	29734-29737	our	_	
171-12	29738-29741	MID	_	
171-13	29742-29746	task	_	
171-14	29747-29749	on	_	
171-15	29750-29762	instrumental	_	
171-16	29763-29773	responding	_	
171-17	29774-29777	for	_	
171-18	29778-29785	rewards	_	
171-19	29785-29786	.	_	

#Text=The two groups did, however, show significant differences in brain activation, and to a greater degree, global network connectivity related to the anticipation of monetary reward.
172-1	29787-29790	The	_	
172-2	29791-29794	two	_	
172-3	29795-29801	groups	_	
172-4	29802-29805	did	_	
172-5	29805-29806	,	_	
172-6	29807-29814	however	_	
172-7	29814-29815	,	_	
172-8	29816-29820	show	_	
172-9	29821-29832	significant	_	
172-10	29833-29844	differences	_	
172-11	29845-29847	in	_	
172-12	29848-29853	brain	_	
172-13	29854-29864	activation	_	
172-14	29864-29865	,	_	
172-15	29866-29869	and	_	
172-16	29870-29872	to	_	
172-17	29873-29874	a	_	
172-18	29875-29882	greater	_	
172-19	29883-29889	degree	_	
172-20	29889-29890	,	_	
172-21	29891-29897	global	_	
172-22	29898-29905	network	_	
172-23	29906-29918	connectivity	_	
172-24	29919-29926	related	_	
172-25	29927-29929	to	_	
172-26	29930-29933	the	_	
172-27	29934-29946	anticipation	_	
172-28	29947-29949	of	_	
172-29	29950-29958	monetary	_	
172-30	29959-29965	reward	_	
172-31	29965-29966	.	_	

#Text=These differences, particularly in global connectivity, point to the preservation of widespread neural disturbances in an addiction population, despite being in extended abstinence.
173-1	29967-29972	These	_	
173-2	29973-29984	differences	_	
173-3	29984-29985	,	_	
173-4	29986-29998	particularly	_	
173-5	29999-30001	in	_	
173-6	30002-30008	global	_	
173-7	30009-30021	connectivity	_	
173-8	30021-30022	,	_	
173-9	30023-30028	point	_	
173-10	30029-30031	to	_	
173-11	30032-30035	the	_	
173-12	30036-30048	preservation	_	
173-13	30049-30051	of	_	
173-14	30052-30062	widespread	_	
173-15	30063-30069	neural	_	
173-16	30070-30082	disturbances	_	
173-17	30083-30085	in	_	
173-18	30086-30088	an	_	
173-19	30089-30098	addiction	_	
173-20	30099-30109	population	_	
173-21	30109-30110	,	_	
173-22	30111-30118	despite	_	
173-23	30119-30124	being	_	
173-24	30125-30127	in	_	
173-25	30128-30136	extended	_	
173-26	30137-30147	abstinence	_	
173-27	30147-30148	.	_	

#Text=Disruptions to whole brain activation in the ADD group
#Text=Here we report that the ADD group showed significantly less activation change compared with the CON group, most robustly across temporal and visual cortical regions during the anticipation of monetary reward.
174-1	30149-30160	Disruptions	_	
174-2	30161-30163	to	_	
174-3	30164-30169	whole	_	
174-4	30170-30175	brain	_	
174-5	30176-30186	activation	_	
174-6	30187-30189	in	_	
174-7	30190-30193	the	_	
174-8	30194-30197	ADD	_	
174-9	30198-30203	group	_	
174-10	30204-30208	Here	_	
174-11	30209-30211	we	_	
174-12	30212-30218	report	_	
174-13	30219-30223	that	_	
174-14	30224-30227	the	_	
174-15	30228-30231	ADD	_	
174-16	30232-30237	group	_	
174-17	30238-30244	showed	_	
174-18	30245-30258	significantly	_	
174-19	30259-30263	less	_	
174-20	30264-30274	activation	_	
174-21	30275-30281	change	_	
174-22	30282-30290	compared	_	
174-23	30291-30295	with	_	
174-24	30296-30299	the	_	
174-25	30300-30303	CON	_	
174-26	30304-30309	group	_	
174-27	30309-30310	,	_	
174-28	30311-30315	most	_	
174-29	30316-30324	robustly	_	
174-30	30325-30331	across	_	
174-31	30332-30340	temporal	_	
174-32	30341-30344	and	_	
174-33	30345-30351	visual	_	
174-34	30352-30360	cortical	_	
174-35	30361-30368	regions	_	
174-36	30369-30375	during	_	
174-37	30376-30379	the	_	
174-38	30380-30392	anticipation	_	
174-39	30393-30395	of	_	
174-40	30396-30404	monetary	_	
174-41	30405-30411	reward	_	
174-42	30411-30412	.	_	

#Text=Addiction disorders are commonly associated with disturbances in the reward network, and the present results did also show some evidence for less activation change across reward-associated regions, the most pronounced of which were in the anterior cingulate gyrus (ACG) and amygdala.
175-1	30413-30422	Addiction	_	
175-2	30423-30432	disorders	_	
175-3	30433-30436	are	_	
175-4	30437-30445	commonly	_	
175-5	30446-30456	associated	_	
175-6	30457-30461	with	_	
175-7	30462-30474	disturbances	_	
175-8	30475-30477	in	_	
175-9	30478-30481	the	_	
175-10	30482-30488	reward	_	
175-11	30489-30496	network	_	
175-12	30496-30497	,	_	
175-13	30498-30501	and	_	
175-14	30502-30505	the	_	
175-15	30506-30513	present	_	
175-16	30514-30521	results	_	
175-17	30522-30525	did	_	
175-18	30526-30530	also	_	
175-19	30531-30535	show	_	
175-20	30536-30540	some	_	
175-21	30541-30549	evidence	_	
175-22	30550-30553	for	_	
175-23	30554-30558	less	_	
175-24	30559-30569	activation	_	
175-25	30570-30576	change	_	
175-26	30577-30583	across	_	
175-27	30584-30601	reward-associated	_	
175-28	30602-30609	regions	_	
175-29	30609-30610	,	_	
175-30	30611-30614	the	_	
175-31	30615-30619	most	_	
175-32	30620-30630	pronounced	_	
175-33	30631-30633	of	_	
175-34	30634-30639	which	_	
175-35	30640-30644	were	_	
175-36	30645-30647	in	_	
175-37	30648-30651	the	_	
175-38	30652-30660	anterior	_	
175-39	30661-30670	cingulate	_	
175-40	30671-30676	gyrus	_	
175-41	30677-30678	(	_	
175-42	30678-30681	ACG	_	
175-43	30681-30682	)	_	
175-44	30683-30686	and	_	
175-45	30687-30695	amygdala	_	
175-46	30695-30696	.	_	

#Text=Disturbances in ACG functioning have been commonly reported in addiction populations, which persist into abstinence.
176-1	30697-30709	Disturbances	_	
176-2	30710-30712	in	_	
176-3	30713-30716	ACG	_	
176-4	30717-30728	functioning	_	
176-5	30729-30733	have	_	
176-6	30734-30738	been	_	
176-7	30739-30747	commonly	_	
176-8	30748-30756	reported	_	
176-9	30757-30759	in	_	
176-10	30760-30769	addiction	_	
176-11	30770-30781	populations	_	
176-12	30781-30782	,	_	
176-13	30783-30788	which	_	
176-14	30789-30796	persist	_	
176-15	30797-30801	into	_	
176-16	30802-30812	abstinence	_	
176-17	30812-30813	.	_	

#Text=The differences observed in the current sample were within the dorsal ACG, a region implicated in motivation and cognitive control.
177-1	30814-30817	The	_	
177-2	30818-30829	differences	_	
177-3	30830-30838	observed	_	
177-4	30839-30841	in	_	
177-5	30842-30845	the	_	
177-6	30846-30853	current	_	
177-7	30854-30860	sample	_	
177-8	30861-30865	were	_	
177-9	30866-30872	within	_	
177-10	30873-30876	the	_	
177-11	30877-30883	dorsal	_	
177-12	30884-30887	ACG	_	
177-13	30887-30888	,	_	
177-14	30889-30890	a	_	
177-15	30891-30897	region	_	
177-16	30898-30908	implicated	_	
177-17	30909-30911	in	_	
177-18	30912-30922	motivation	_	
177-19	30923-30926	and	_	
177-20	30927-30936	cognitive	_	
177-21	30937-30944	control	_	
177-22	30944-30945	.	_	

#Text=The amygdala also encodes stimulus value, with disruptions also evident in addiction.
178-1	30946-30949	The	_	
178-2	30950-30958	amygdala	_	
178-3	30959-30963	also	_	
178-4	30964-30971	encodes	_	
178-5	30972-30980	stimulus	_	
178-6	30981-30986	value	_	
178-7	30986-30987	,	_	
178-8	30988-30992	with	_	
178-9	30993-31004	disruptions	_	
178-10	31005-31009	also	_	
178-11	31010-31017	evident	_	
178-12	31018-31020	in	_	
178-13	31021-31030	addiction	_	
178-14	31030-31031	.	_	

#Text=These results point to localised neural disturbances in regions implicated in motivational, executive functioning and reward evaluation, that endure into extended abstinence.
179-1	31032-31037	These	_	
179-2	31038-31045	results	_	
179-3	31046-31051	point	_	
179-4	31052-31054	to	_	
179-5	31055-31064	localised	_	
179-6	31065-31071	neural	_	
179-7	31072-31084	disturbances	_	
179-8	31085-31087	in	_	
179-9	31088-31095	regions	_	
179-10	31096-31106	implicated	_	
179-11	31107-31109	in	_	
179-12	31110-31122	motivational	_	
179-13	31122-31123	,	_	
179-14	31124-31133	executive	_	
179-15	31134-31145	functioning	_	
179-16	31146-31149	and	_	
179-17	31150-31156	reward	_	
179-18	31157-31167	evaluation	_	
179-19	31167-31168	,	_	
179-20	31169-31173	that	_	
179-21	31174-31180	endure	_	
179-22	31181-31185	into	_	
179-23	31186-31194	extended	_	
179-24	31195-31205	abstinence	_	
179-25	31205-31206	.	_	

#Text=This current set of results, however, was in the absence of group differences in striatal activation between the ADD and CON groups.
180-1	31207-31211	This	_	
180-2	31212-31219	current	_	
180-3	31220-31223	set	_	
180-4	31224-31226	of	_	
180-5	31227-31234	results	_	
180-6	31234-31235	,	_	
180-7	31236-31243	however	_	
180-8	31243-31244	,	_	
180-9	31245-31248	was	_	
180-10	31249-31251	in	_	
180-11	31252-31255	the	_	
180-12	31256-31263	absence	_	
180-13	31264-31266	of	_	
180-14	31267-31272	group	_	
180-15	31273-31284	differences	_	
180-16	31285-31287	in	_	
180-17	31288-31296	striatal	_	
180-18	31297-31307	activation	_	
180-19	31308-31315	between	_	
180-20	31316-31319	the	_	
180-21	31320-31323	ADD	_	
180-22	31324-31327	and	_	
180-23	31328-31331	CON	_	
180-24	31332-31338	groups	_	
180-25	31338-31339	.	_	

#Text=This does not appear to concur with previous research findings of altered striatal responses for non-drug rewards in substance dependence, and does not demonstrate evidence of a sustained striatal “reward deficiency syndrome” in this particular sample.
181-1	31340-31344	This	_	
181-2	31345-31349	does	_	
181-3	31350-31353	not	_	
181-4	31354-31360	appear	_	
181-5	31361-31363	to	_	
181-6	31364-31370	concur	_	
181-7	31371-31375	with	_	
181-8	31376-31384	previous	_	
181-9	31385-31393	research	_	
181-10	31394-31402	findings	_	
181-11	31403-31405	of	_	
181-12	31406-31413	altered	_	
181-13	31414-31422	striatal	_	
181-14	31423-31432	responses	_	
181-15	31433-31436	for	_	
181-16	31437-31445	non-drug	_	
181-17	31446-31453	rewards	_	
181-18	31454-31456	in	_	
181-19	31457-31466	substance	_	
181-20	31467-31477	dependence	_	
181-21	31477-31478	,	_	
181-22	31479-31482	and	_	
181-23	31483-31487	does	_	
181-24	31488-31491	not	_	
181-25	31492-31503	demonstrate	_	
181-26	31504-31512	evidence	_	
181-27	31513-31515	of	_	
181-28	31516-31517	a	_	
181-29	31518-31527	sustained	_	
181-30	31528-31536	striatal	_	
181-31	31537-31538	“	_	
181-32	31538-31544	reward	_	
181-33	31545-31555	deficiency	_	
181-34	31556-31564	syndrome	_	
181-35	31564-31565	”	_	
181-36	31566-31568	in	_	
181-37	31569-31573	this	_	
181-38	31574-31584	particular	_	
181-39	31585-31591	sample	_	
181-40	31591-31592	.	_	

#Text=The heterogenous nature of the ADD sample with respect to mono- and multiple- drug dependencies and the variable abstinence length from these substances, may have been a constraining factor, reflecting varying levels of restoration of function in the striatum (and other regions).
182-1	31593-31596	The	_	
182-2	31597-31609	heterogenous	_	
182-3	31610-31616	nature	_	
182-4	31617-31619	of	_	
182-5	31620-31623	the	_	
182-6	31624-31627	ADD	_	
182-7	31628-31634	sample	_	
182-8	31635-31639	with	_	
182-9	31640-31647	respect	_	
182-10	31648-31650	to	_	
182-11	31651-31655	mono	_	
182-12	31655-31656	-	_	
182-13	31657-31660	and	_	
182-14	31661-31669	multiple	_	
182-15	31669-31670	-	_	
182-16	31671-31675	drug	_	
182-17	31676-31688	dependencies	_	
182-18	31689-31692	and	_	
182-19	31693-31696	the	_	
182-20	31697-31705	variable	_	
182-21	31706-31716	abstinence	_	
182-22	31717-31723	length	_	
182-23	31724-31728	from	_	
182-24	31729-31734	these	_	
182-25	31735-31745	substances	_	
182-26	31745-31746	,	_	
182-27	31747-31750	may	_	
182-28	31751-31755	have	_	
182-29	31756-31760	been	_	
182-30	31761-31762	a	_	
182-31	31763-31775	constraining	_	
182-32	31776-31782	factor	_	
182-33	31782-31783	,	_	
182-34	31784-31794	reflecting	_	
182-35	31795-31802	varying	_	
182-36	31803-31809	levels	_	
182-37	31810-31812	of	_	
182-38	31813-31824	restoration	_	
182-39	31825-31827	of	_	
182-40	31828-31836	function	_	
182-41	31837-31839	in	_	
182-42	31840-31843	the	_	
182-43	31844-31852	striatum	_	
182-44	31853-31854	(	_	
182-45	31854-31857	and	_	
182-46	31858-31863	other	_	
182-47	31864-31871	regions	_	
182-48	31871-31872	)	_	
182-49	31872-31873	.	_	

#Text=For example, studies have shown there are deficits in markers of striatal dopamine functioning during early abstinence, with the variable abstinence length in the current sample masking possible disturbances in this region.
183-1	31874-31877	For	_	
183-2	31878-31885	example	_	
183-3	31885-31886	,	_	
183-4	31887-31894	studies	_	
183-5	31895-31899	have	_	
183-6	31900-31905	shown	_	
183-7	31906-31911	there	_	
183-8	31912-31915	are	_	
183-9	31916-31924	deficits	_	
183-10	31925-31927	in	_	
183-11	31928-31935	markers	_	
183-12	31936-31938	of	_	
183-13	31939-31947	striatal	_	
183-14	31948-31956	dopamine	_	
183-15	31957-31968	functioning	_	
183-16	31969-31975	during	_	
183-17	31976-31981	early	_	
183-18	31982-31992	abstinence	_	
183-19	31992-31993	,	_	
183-20	31994-31998	with	_	
183-21	31999-32002	the	_	
183-22	32003-32011	variable	_	
183-23	32012-32022	abstinence	_	
183-24	32023-32029	length	_	
183-25	32030-32032	in	_	
183-26	32033-32036	the	_	
183-27	32037-32044	current	_	
183-28	32045-32051	sample	_	
183-29	32052-32059	masking	_	
183-30	32060-32068	possible	_	
183-31	32069-32081	disturbances	_	
183-32	32082-32084	in	_	
183-33	32085-32089	this	_	
183-34	32090-32096	region	_	
183-35	32096-32097	.	_	

#Text=Another possibility is that a voxel-wise approach was insufficiently sensitive to detect group differences across smaller regions such as the striatum.
184-1	32098-32105	Another	_	
184-2	32106-32117	possibility	_	
184-3	32118-32120	is	_	
184-4	32121-32125	that	_	
184-5	32126-32127	a	_	
184-6	32128-32138	voxel-wise	_	
184-7	32139-32147	approach	_	
184-8	32148-32151	was	_	
184-9	32152-32166	insufficiently	_	
184-10	32167-32176	sensitive	_	
184-11	32177-32179	to	_	
184-12	32180-32186	detect	_	
184-13	32187-32192	group	_	
184-14	32193-32204	differences	_	
184-15	32205-32211	across	_	
184-16	32212-32219	smaller	_	
184-17	32220-32227	regions	_	
184-18	32228-32232	such	_	
184-19	32233-32235	as	_	
184-20	32236-32239	the	_	
184-21	32240-32248	striatum	_	
184-22	32248-32249	.	_	

#Text=The results from the network analyses (discussed below) did reveal striatal regions (e.g., accumbens, caudate) that were part of a sub-network of nodes demonstrating less connectivity in the ADD group.
185-1	32250-32253	The	_	
185-2	32254-32261	results	_	
185-3	32262-32266	from	_	
185-4	32267-32270	the	_	
185-5	32271-32278	network	_	
185-6	32279-32287	analyses	_	
185-7	32288-32289	(	_	
185-8	32289-32298	discussed	_	
185-9	32299-32304	below	_	
185-10	32304-32305	)	_	
185-11	32306-32309	did	_	
185-12	32310-32316	reveal	_	
185-13	32317-32325	striatal	_	
185-14	32326-32333	regions	_	
185-15	32334-32335	(	_	
185-16	32335-32338	e.g	_	
185-17	32338-32339	.	_	
185-18	32339-32340	,	_	
185-19	32341-32350	accumbens	_	
185-20	32350-32351	,	_	
185-21	32352-32359	caudate	_	
185-22	32359-32360	)	_	
185-23	32361-32365	that	_	
185-24	32366-32370	were	_	
185-25	32371-32375	part	_	
185-26	32376-32378	of	_	
185-27	32379-32380	a	_	
185-28	32381-32392	sub-network	_	
185-29	32393-32395	of	_	
185-30	32396-32401	nodes	_	
185-31	32402-32415	demonstrating	_	
185-32	32416-32420	less	_	
185-33	32421-32433	connectivity	_	
185-34	32434-32436	in	_	
185-35	32437-32440	the	_	
185-36	32441-32444	ADD	_	
185-37	32445-32450	group	_	
185-38	32450-32451	.	_	

#Text=This may further endorse the sensitivity of exploring measures of functional network connectivity over voxel-wise approaches for detecting more extensive disruptions in neural processing.
186-1	32452-32456	This	_	
186-2	32457-32460	may	_	
186-3	32461-32468	further	_	
186-4	32469-32476	endorse	_	
186-5	32477-32480	the	_	
186-6	32481-32492	sensitivity	_	
186-7	32493-32495	of	_	
186-8	32496-32505	exploring	_	
186-9	32506-32514	measures	_	
186-10	32515-32517	of	_	
186-11	32518-32528	functional	_	
186-12	32529-32536	network	_	
186-13	32537-32549	connectivity	_	
186-14	32550-32554	over	_	
186-15	32555-32565	voxel-wise	_	
186-16	32566-32576	approaches	_	
186-17	32577-32580	for	_	
186-18	32581-32590	detecting	_	
186-19	32591-32595	more	_	
186-20	32596-32605	extensive	_	
186-21	32606-32617	disruptions	_	
186-22	32618-32620	in	_	
186-23	32621-32627	neural	_	
186-24	32628-32638	processing	_	
186-25	32638-32639	.	_	

#Text=Finally, it is possible that the ADD and CON groups simply did not differ in the striatum, which has recently been shown in other studies of stimulant users (e.g.).
187-1	32640-32647	Finally	_	
187-2	32647-32648	,	_	
187-3	32649-32651	it	_	
187-4	32652-32654	is	_	
187-5	32655-32663	possible	_	
187-6	32664-32668	that	_	
187-7	32669-32672	the	_	
187-8	32673-32676	ADD	_	
187-9	32677-32680	and	_	
187-10	32681-32684	CON	_	
187-11	32685-32691	groups	_	
187-12	32692-32698	simply	_	
187-13	32699-32702	did	_	
187-14	32703-32706	not	_	
187-15	32707-32713	differ	_	
187-16	32714-32716	in	_	
187-17	32717-32720	the	_	
187-18	32721-32729	striatum	_	
187-19	32729-32730	,	_	
187-20	32731-32736	which	_	
187-21	32737-32740	has	_	
187-22	32741-32749	recently	_	
187-23	32750-32754	been	_	
187-24	32755-32760	shown	_	
187-25	32761-32763	in	_	
187-26	32764-32769	other	_	
187-27	32770-32777	studies	_	
187-28	32778-32780	of	_	
187-29	32781-32790	stimulant	_	
187-30	32791-32796	users	_	
187-31	32797-32798	(	_	
187-32	32798-32801	e.g	_	
187-33	32801-32802	.	_	
187-34	32802-32803	)	_	
187-35	32803-32804	.	_	

#Text=Disruptions in global network connectivity in the ADD group
#Text=The ADD group had an increased mean global characteristic path length compared to the CON group.
188-1	32805-32816	Disruptions	_	
188-2	32817-32819	in	_	
188-3	32820-32826	global	_	
188-4	32827-32834	network	_	
188-5	32835-32847	connectivity	_	
188-6	32848-32850	in	_	
188-7	32851-32854	the	_	
188-8	32855-32858	ADD	_	
188-9	32859-32864	group	_	
188-10	32865-32868	The	_	
188-11	32869-32872	ADD	_	
188-12	32873-32878	group	_	
188-13	32879-32882	had	_	
188-14	32883-32885	an	_	
188-15	32886-32895	increased	_	
188-16	32896-32900	mean	_	
188-17	32901-32907	global	_	
188-18	32908-32922	characteristic	_	
188-19	32923-32927	path	_	
188-20	32928-32934	length	_	
188-21	32935-32943	compared	_	
188-22	32944-32946	to	_	
188-23	32947-32950	the	_	
188-24	32951-32954	CON	_	
188-25	32955-32960	group	_	
188-26	32960-32961	.	_	

#Text=As described above, path length is a topological measure indicating the average shortest path length between all node pairs in a network, whereby fewer processing steps across the network has the advantage of propagating more rapid and accurate communication.
189-1	32962-32964	As	_	
189-2	32965-32974	described	_	
189-3	32975-32980	above	_	
189-4	32980-32981	,	_	
189-5	32982-32986	path	_	
189-6	32987-32993	length	_	
189-7	32994-32996	is	_	
189-8	32997-32998	a	_	
189-9	32999-33010	topological	_	
189-10	33011-33018	measure	_	
189-11	33019-33029	indicating	_	
189-12	33030-33033	the	_	
189-13	33034-33041	average	_	
189-14	33042-33050	shortest	_	
189-15	33051-33055	path	_	
189-16	33056-33062	length	_	
189-17	33063-33070	between	_	
189-18	33071-33074	all	_	
189-19	33075-33079	node	_	
189-20	33080-33085	pairs	_	
189-21	33086-33088	in	_	
189-22	33089-33090	a	_	
189-23	33091-33098	network	_	
189-24	33098-33099	,	_	
189-25	33100-33107	whereby	_	
189-26	33108-33113	fewer	_	
189-27	33114-33124	processing	_	
189-28	33125-33130	steps	_	
189-29	33131-33137	across	_	
189-30	33138-33141	the	_	
189-31	33142-33149	network	_	
189-32	33150-33153	has	_	
189-33	33154-33157	the	_	
189-34	33158-33167	advantage	_	
189-35	33168-33170	of	_	
189-36	33171-33182	propagating	_	
189-37	33183-33187	more	_	
189-38	33188-33193	rapid	_	
189-39	33194-33197	and	_	
189-40	33198-33206	accurate	_	
189-41	33207-33220	communication	_	
189-42	33220-33221	.	_	

#Text=We observed this metric to be elevated in the ADD group, representing a possible reduction in processing efficiency.
190-1	33222-33224	We	_	
190-2	33225-33233	observed	_	
190-3	33234-33238	this	_	
190-4	33239-33245	metric	_	
190-5	33246-33248	to	_	
190-6	33249-33251	be	_	
190-7	33252-33260	elevated	_	
190-8	33261-33263	in	_	
190-9	33264-33267	the	_	
190-10	33268-33271	ADD	_	
190-11	33272-33277	group	_	
190-12	33277-33278	,	_	
190-13	33279-33291	representing	_	
190-14	33292-33293	a	_	
190-15	33294-33302	possible	_	
190-16	33303-33312	reduction	_	
190-17	33313-33315	in	_	
190-18	33316-33326	processing	_	
190-19	33327-33337	efficiency	_	
190-20	33337-33338	.	_	

#Text=This may be due to a loss of long range connections between remote brain regions, which are critical for minimising path lengths and maintaining network efficiency.
191-1	33339-33343	This	_	
191-2	33344-33347	may	_	
191-3	33348-33350	be	_	
191-4	33351-33354	due	_	
191-5	33355-33357	to	_	
191-6	33358-33359	a	_	
191-7	33360-33364	loss	_	
191-8	33365-33367	of	_	
191-9	33368-33372	long	_	
191-10	33373-33378	range	_	
191-11	33379-33390	connections	_	
191-12	33391-33398	between	_	
191-13	33399-33405	remote	_	
191-14	33406-33411	brain	_	
191-15	33412-33419	regions	_	
191-16	33419-33420	,	_	
191-17	33421-33426	which	_	
191-18	33427-33430	are	_	
191-19	33431-33439	critical	_	
191-20	33440-33443	for	_	
191-21	33444-33454	minimising	_	
191-22	33455-33459	path	_	
191-23	33460-33467	lengths	_	
191-24	33468-33471	and	_	
191-25	33472-33483	maintaining	_	
191-26	33484-33491	network	_	
191-27	33492-33502	efficiency	_	
191-28	33502-33503	.	_	

#Text=This disruption in processing efficiency concurs with that reported in other addiction populations during rest, but not during reward processing.
192-1	33504-33508	This	_	
192-2	33509-33519	disruption	_	
192-3	33520-33522	in	_	
192-4	33523-33533	processing	_	
192-5	33534-33544	efficiency	_	
192-6	33545-33552	concurs	_	
192-7	33553-33557	with	_	
192-8	33558-33562	that	_	
192-9	33563-33571	reported	_	
192-10	33572-33574	in	_	
192-11	33575-33580	other	_	
192-12	33581-33590	addiction	_	
192-13	33591-33602	populations	_	
192-14	33603-33609	during	_	
192-15	33610-33614	rest	_	
192-16	33614-33615	,	_	
192-17	33616-33619	but	_	
192-18	33620-33623	not	_	
192-19	33624-33630	during	_	
192-20	33631-33637	reward	_	
192-21	33638-33648	processing	_	
192-22	33648-33649	.	_	

#Text=We further report that the ADD group demonstrated a lower clustering coefficient across the network.
193-1	33650-33652	We	_	
193-2	33653-33660	further	_	
193-3	33661-33667	report	_	
193-4	33668-33672	that	_	
193-5	33673-33676	the	_	
193-6	33677-33680	ADD	_	
193-7	33681-33686	group	_	
193-8	33687-33699	demonstrated	_	
193-9	33700-33701	a	_	
193-10	33702-33707	lower	_	
193-11	33708-33718	clustering	_	
193-12	33719-33730	coefficient	_	
193-13	33731-33737	across	_	
193-14	33738-33741	the	_	
193-15	33742-33749	network	_	
193-16	33749-33750	.	_	

#Text=Clustering quantifies the number of connections existing between a node’s nearest neighbours, which has been proposed as an index of local specialised processing and economic pressure for minimal wiring cost.
194-1	33751-33761	Clustering	_	
194-2	33762-33772	quantifies	_	
194-3	33773-33776	the	_	
194-4	33777-33783	number	_	
194-5	33784-33786	of	_	
194-6	33787-33798	connections	_	
194-7	33799-33807	existing	_	
194-8	33808-33815	between	_	
194-9	33816-33817	a	_	
194-10	33818-33822	node	_	
194-11	33822-33823	’	_	
194-12	33823-33824	s	_	
194-13	33825-33832	nearest	_	
194-14	33833-33843	neighbours	_	
194-15	33843-33844	,	_	
194-16	33845-33850	which	_	
194-17	33851-33854	has	_	
194-18	33855-33859	been	_	
194-19	33860-33868	proposed	_	
194-20	33869-33871	as	_	
194-21	33872-33874	an	_	
194-22	33875-33880	index	_	
194-23	33881-33883	of	_	
194-24	33884-33889	local	_	
194-25	33890-33901	specialised	_	
194-26	33902-33912	processing	_	
194-27	33913-33916	and	_	
194-28	33917-33925	economic	_	
194-29	33926-33934	pressure	_	
194-30	33935-33938	for	_	
194-31	33939-33946	minimal	_	
194-32	33947-33953	wiring	_	
194-33	33954-33958	cost	_	
194-34	33958-33959	.	_	

#Text=The reduction in clustering we report here contrasts with the increased clustering found in an addiction population during resting state, and which was reversed by acute naltrexone.
195-1	33960-33963	The	_	
195-2	33964-33973	reduction	_	
195-3	33974-33976	in	_	
195-4	33977-33987	clustering	_	
195-5	33988-33990	we	_	
195-6	33991-33997	report	_	
195-7	33998-34002	here	_	
195-8	34003-34012	contrasts	_	
195-9	34013-34017	with	_	
195-10	34018-34021	the	_	
195-11	34022-34031	increased	_	
195-12	34032-34042	clustering	_	
195-13	34043-34048	found	_	
195-14	34049-34051	in	_	
195-15	34052-34054	an	_	
195-16	34055-34064	addiction	_	
195-17	34065-34075	population	_	
195-18	34076-34082	during	_	
195-19	34083-34090	resting	_	
195-20	34091-34096	state	_	
195-21	34096-34097	,	_	
195-22	34098-34101	and	_	
195-23	34102-34107	which	_	
195-24	34108-34111	was	_	
195-25	34112-34120	reversed	_	
195-26	34121-34123	by	_	
195-27	34124-34129	acute	_	
195-28	34130-34140	naltrexone	_	
195-29	34140-34141	.	_	

#Text=Alterations in clustering observed during reward anticipation may suggest less interconnectedness in local networks for specialised or segregated information processing, which could be more economically costly for brain functioning.
196-1	34142-34153	Alterations	_	
196-2	34154-34156	in	_	
196-3	34157-34167	clustering	_	
196-4	34168-34176	observed	_	
196-5	34177-34183	during	_	
196-6	34184-34190	reward	_	
196-7	34191-34203	anticipation	_	
196-8	34204-34207	may	_	
196-9	34208-34215	suggest	_	
196-10	34216-34220	less	_	
196-11	34221-34239	interconnectedness	_	
196-12	34240-34242	in	_	
196-13	34243-34248	local	_	
196-14	34249-34257	networks	_	
196-15	34258-34261	for	_	
196-16	34262-34273	specialised	_	
196-17	34274-34276	or	_	
196-18	34277-34287	segregated	_	
196-19	34288-34299	information	_	
196-20	34300-34310	processing	_	
196-21	34310-34311	,	_	
196-22	34312-34317	which	_	
196-23	34318-34323	could	_	
196-24	34324-34326	be	_	
196-25	34327-34331	more	_	
196-26	34332-34344	economically	_	
196-27	34345-34351	costly	_	
196-28	34352-34355	for	_	
196-29	34356-34361	brain	_	
196-30	34362-34373	functioning	_	
196-31	34373-34374	.	_	

#Text=Significantly, these global functional alterations could be due to changes in anatomical network architecture, as functional connectivity is generally tightly aligned with anatomical connectivity.
197-1	34375-34388	Significantly	_	
197-2	34388-34389	,	_	
197-3	34390-34395	these	_	
197-4	34396-34402	global	_	
197-5	34403-34413	functional	_	
197-6	34414-34425	alterations	_	
197-7	34426-34431	could	_	
197-8	34432-34434	be	_	
197-9	34435-34438	due	_	
197-10	34439-34441	to	_	
197-11	34442-34449	changes	_	
197-12	34450-34452	in	_	
197-13	34453-34463	anatomical	_	
197-14	34464-34471	network	_	
197-15	34472-34484	architecture	_	
197-16	34484-34485	,	_	
197-17	34486-34488	as	_	
197-18	34489-34499	functional	_	
197-19	34500-34512	connectivity	_	
197-20	34513-34515	is	_	
197-21	34516-34525	generally	_	
197-22	34526-34533	tightly	_	
197-23	34534-34541	aligned	_	
197-24	34542-34546	with	_	
197-25	34547-34557	anatomical	_	
197-26	34558-34570	connectivity	_	
197-27	34570-34571	.	_	

#Text=Decreased reward-related connectivity in the ADD group
#Text=Taking a network based statistics (NBS) analysis approach, we showed that the ADD group exhibited reduced connectivity across a sub-network of nodes during the anticipation of reward.
198-1	34572-34581	Decreased	_	
198-2	34582-34596	reward-related	_	
198-3	34597-34609	connectivity	_	
198-4	34610-34612	in	_	
198-5	34613-34616	the	_	
198-6	34617-34620	ADD	_	
198-7	34621-34626	group	_	
198-8	34627-34633	Taking	_	
198-9	34634-34635	a	_	
198-10	34636-34643	network	_	
198-11	34644-34649	based	_	
198-12	34650-34660	statistics	_	
198-13	34661-34662	(	_	
198-14	34662-34665	NBS	_	
198-15	34665-34666	)	_	
198-16	34667-34675	analysis	_	
198-17	34676-34684	approach	_	
198-18	34684-34685	,	_	
198-19	34686-34688	we	_	
198-20	34689-34695	showed	_	
198-21	34696-34700	that	_	
198-22	34701-34704	the	_	
198-23	34705-34708	ADD	_	
198-24	34709-34714	group	_	
198-25	34715-34724	exhibited	_	
198-26	34725-34732	reduced	_	
198-27	34733-34745	connectivity	_	
198-28	34746-34752	across	_	
198-29	34753-34754	a	_	
198-30	34755-34766	sub-network	_	
198-31	34767-34769	of	_	
198-32	34770-34775	nodes	_	
198-33	34776-34782	during	_	
198-34	34783-34786	the	_	
198-35	34787-34799	anticipation	_	
198-36	34800-34802	of	_	
198-37	34803-34809	reward	_	
198-38	34809-34810	.	_	

#Text=This reduction in connectivity comprised a total of 153 connections, the majority of which were confined to the right hemisphere.
199-1	34811-34815	This	_	
199-2	34816-34825	reduction	_	
199-3	34826-34828	in	_	
199-4	34829-34841	connectivity	_	
199-5	34842-34851	comprised	_	
199-6	34852-34853	a	_	
199-7	34854-34859	total	_	
199-8	34860-34862	of	_	
199-9	34863-34866	153	_	
199-10	34867-34878	connections	_	
199-11	34878-34879	,	_	
199-12	34880-34883	the	_	
199-13	34884-34892	majority	_	
199-14	34893-34895	of	_	
199-15	34896-34901	which	_	
199-16	34902-34906	were	_	
199-17	34907-34915	confined	_	
199-18	34916-34918	to	_	
199-19	34919-34922	the	_	
199-20	34923-34928	right	_	
199-21	34929-34939	hemisphere	_	
199-22	34939-34940	.	_	

#Text=The anatomical distribution of these between-group connectivity differences involved frontal (insula, inferior frontal gyrus, orbitofrontal cortex), striatal (accumbens, caudate), limbic-associated (ACG, amygdala, hippocampus) and visual (lateral occipital cortex, lingual gyrus, intracalcarine cortex) regions.
200-1	34941-34944	The	_	
200-2	34945-34955	anatomical	_	
200-3	34956-34968	distribution	_	
200-4	34969-34971	of	_	
200-5	34972-34977	these	_	
200-6	34978-34991	between-group	_	
200-7	34992-35004	connectivity	_	
200-8	35005-35016	differences	_	
200-9	35017-35025	involved	_	
200-10	35026-35033	frontal	_	
200-11	35034-35035	(	_	
200-12	35035-35041	insula	_	
200-13	35041-35042	,	_	
200-14	35043-35051	inferior	_	
200-15	35052-35059	frontal	_	
200-16	35060-35065	gyrus	_	
200-17	35065-35066	,	_	
200-18	35067-35080	orbitofrontal	_	
200-19	35081-35087	cortex	_	
200-20	35087-35088	)	_	
200-21	35088-35089	,	_	
200-22	35090-35098	striatal	_	
200-23	35099-35100	(	_	
200-24	35100-35109	accumbens	_	
200-25	35109-35110	,	_	
200-26	35111-35118	caudate	_	
200-27	35118-35119	)	_	
200-28	35119-35120	,	_	
200-29	35121-35138	limbic-associated	_	
200-30	35139-35140	(	_	
200-31	35140-35143	ACG	_	
200-32	35143-35144	,	_	
200-33	35145-35153	amygdala	_	
200-34	35153-35154	,	_	
200-35	35155-35166	hippocampus	_	
200-36	35166-35167	)	_	
200-37	35168-35171	and	_	
200-38	35172-35178	visual	_	
200-39	35179-35180	(	_	
200-40	35180-35187	lateral	_	
200-41	35188-35197	occipital	_	
200-42	35198-35204	cortex	_	
200-43	35204-35205	,	_	
200-44	35206-35213	lingual	_	
200-45	35214-35219	gyrus	_	
200-46	35219-35220	,	_	
200-47	35221-35235	intracalcarine	_	
200-48	35236-35242	cortex	_	
200-49	35242-35243	)	_	
200-50	35244-35251	regions	_	
200-51	35251-35252	.	_	

#Text=Similar analysis approaches have also revealed differences across sub-networks in addiction, however, during resting state.
201-1	35253-35260	Similar	_	
201-2	35261-35269	analysis	_	
201-3	35270-35280	approaches	_	
201-4	35281-35285	have	_	
201-5	35286-35290	also	_	
201-6	35291-35299	revealed	_	
201-7	35300-35311	differences	_	
201-8	35312-35318	across	_	
201-9	35319-35331	sub-networks	_	
201-10	35332-35334	in	_	
201-11	35335-35344	addiction	_	
201-12	35344-35345	,	_	
201-13	35346-35353	however	_	
201-14	35353-35354	,	_	
201-15	35355-35361	during	_	
201-16	35362-35369	resting	_	
201-17	35370-35375	state	_	
201-18	35375-35376	.	_	

#Text=The connectivity differences reported in this ADD sample indicate alterations between cognitive, striatal and limbic-associated regions during reward anticipation that persist into extended abstinence.
202-1	35377-35380	The	_	
202-2	35381-35393	connectivity	_	
202-3	35394-35405	differences	_	
202-4	35406-35414	reported	_	
202-5	35415-35417	in	_	
202-6	35418-35422	this	_	
202-7	35423-35426	ADD	_	
202-8	35427-35433	sample	_	
202-9	35434-35442	indicate	_	
202-10	35443-35454	alterations	_	
202-11	35455-35462	between	_	
202-12	35463-35472	cognitive	_	
202-13	35472-35473	,	_	
202-14	35474-35482	striatal	_	
202-15	35483-35486	and	_	
202-16	35487-35504	limbic-associated	_	
202-17	35505-35512	regions	_	
202-18	35513-35519	during	_	
202-19	35520-35526	reward	_	
202-20	35527-35539	anticipation	_	
202-21	35540-35544	that	_	
202-22	35545-35552	persist	_	
202-23	35553-35557	into	_	
202-24	35558-35566	extended	_	
202-25	35567-35577	abstinence	_	
202-26	35577-35578	.	_	

#Text=Furthermore, the emergence of a more extensive network of regions in this connectivity analysis highlights a more sensitive approach for detecting widespread disruptions across neural networks in addiction, that may fail to emerge through conventional voxel-wise analysis approaches.
203-1	35579-35590	Furthermore	_	
203-2	35590-35591	,	_	
203-3	35592-35595	the	_	
203-4	35596-35605	emergence	_	
203-5	35606-35608	of	_	
203-6	35609-35610	a	_	
203-7	35611-35615	more	_	
203-8	35616-35625	extensive	_	
203-9	35626-35633	network	_	
203-10	35634-35636	of	_	
203-11	35637-35644	regions	_	
203-12	35645-35647	in	_	
203-13	35648-35652	this	_	
203-14	35653-35665	connectivity	_	
203-15	35666-35674	analysis	_	
203-16	35675-35685	highlights	_	
203-17	35686-35687	a	_	
203-18	35688-35692	more	_	
203-19	35693-35702	sensitive	_	
203-20	35703-35711	approach	_	
203-21	35712-35715	for	_	
203-22	35716-35725	detecting	_	
203-23	35726-35736	widespread	_	
203-24	35737-35748	disruptions	_	
203-25	35749-35755	across	_	
203-26	35756-35762	neural	_	
203-27	35763-35771	networks	_	
203-28	35772-35774	in	_	
203-29	35775-35784	addiction	_	
203-30	35784-35785	,	_	
203-31	35786-35790	that	_	
203-32	35791-35794	may	_	
203-33	35795-35799	fail	_	
203-34	35800-35802	to	_	
203-35	35803-35809	emerge	_	
203-36	35810-35817	through	_	
203-37	35818-35830	conventional	_	
203-38	35831-35841	voxel-wise	_	
203-39	35842-35850	analysis	_	
203-40	35851-35861	approaches	_	
203-41	35861-35862	.	_	

#Text=The presence of these connectivity differences across a distributed sub-network of nodes, concomitant with differences on global topological measures, is also noteworthy.
204-1	35863-35866	The	_	
204-2	35867-35875	presence	_	
204-3	35876-35878	of	_	
204-4	35879-35884	these	_	
204-5	35885-35897	connectivity	_	
204-6	35898-35909	differences	_	
204-7	35910-35916	across	_	
204-8	35917-35918	a	_	
204-9	35919-35930	distributed	_	
204-10	35931-35942	sub-network	_	
204-11	35943-35945	of	_	
204-12	35946-35951	nodes	_	
204-13	35951-35952	,	_	
204-14	35953-35964	concomitant	_	
204-15	35965-35969	with	_	
204-16	35970-35981	differences	_	
204-17	35982-35984	on	_	
204-18	35985-35991	global	_	
204-19	35992-36003	topological	_	
204-20	36004-36012	measures	_	
204-21	36012-36013	,	_	
204-22	36014-36016	is	_	
204-23	36017-36021	also	_	
204-24	36022-36032	noteworthy	_	
204-25	36032-36033	.	_	

#Text=Previous studies using combined graph- and network-based approaches have failed to report differences using both types of measures.
205-1	36034-36042	Previous	_	
205-2	36043-36050	studies	_	
205-3	36051-36056	using	_	
205-4	36057-36065	combined	_	
205-5	36066-36071	graph	_	
205-6	36071-36072	-	_	
205-7	36073-36076	and	_	
205-8	36077-36090	network-based	_	
205-9	36091-36101	approaches	_	
205-10	36102-36106	have	_	
205-11	36107-36113	failed	_	
205-12	36114-36116	to	_	
205-13	36117-36123	report	_	
205-14	36124-36135	differences	_	
205-15	36136-36141	using	_	
205-16	36142-36146	both	_	
205-17	36147-36152	types	_	
205-18	36153-36155	of	_	
205-19	36156-36164	measures	_	
205-20	36164-36165	.	_	

#Text=While topological and network-based measures of connectivity may be distinct, there does appear to be some convergence across both analyses that suggests the preservation of functional disruptions in a latent and more widespread network in this addiction group.
206-1	36166-36171	While	_	
206-2	36172-36183	topological	_	
206-3	36184-36187	and	_	
206-4	36188-36201	network-based	_	
206-5	36202-36210	measures	_	
206-6	36211-36213	of	_	
206-7	36214-36226	connectivity	_	
206-8	36227-36230	may	_	
206-9	36231-36233	be	_	
206-10	36234-36242	distinct	_	
206-11	36242-36243	,	_	
206-12	36244-36249	there	_	
206-13	36250-36254	does	_	
206-14	36255-36261	appear	_	
206-15	36262-36264	to	_	
206-16	36265-36267	be	_	
206-17	36268-36272	some	_	
206-18	36273-36284	convergence	_	
206-19	36285-36291	across	_	
206-20	36292-36296	both	_	
206-21	36297-36305	analyses	_	
206-22	36306-36310	that	_	
206-23	36311-36319	suggests	_	
206-24	36320-36323	the	_	
206-25	36324-36336	preservation	_	
206-26	36337-36339	of	_	
206-27	36340-36350	functional	_	
206-28	36351-36362	disruptions	_	
206-29	36363-36365	in	_	
206-30	36366-36367	a	_	
206-31	36368-36374	latent	_	
206-32	36375-36378	and	_	
206-33	36379-36383	more	_	
206-34	36384-36394	widespread	_	
206-35	36395-36402	network	_	
206-36	36403-36405	in	_	
206-37	36406-36410	this	_	
206-38	36411-36420	addiction	_	
206-39	36421-36426	group	_	
206-40	36426-36427	.	_	

#Text=Conclusion
#Text=The spatial distribution of functional disturbances reported in addiction populations during functional MRI studies is commonplace, and is likely driven by extensive disruptions in connectivity across the whole brain network.
207-1	36428-36438	Conclusion	_	
207-2	36439-36442	The	_	
207-3	36443-36450	spatial	_	
207-4	36451-36463	distribution	_	
207-5	36464-36466	of	_	
207-6	36467-36477	functional	_	
207-7	36478-36490	disturbances	_	
207-8	36491-36499	reported	_	
207-9	36500-36502	in	_	
207-10	36503-36512	addiction	_	
207-11	36513-36524	populations	_	
207-12	36525-36531	during	_	
207-13	36532-36542	functional	_	
207-14	36543-36546	MRI	_	
207-15	36547-36554	studies	_	
207-16	36555-36557	is	_	
207-17	36558-36569	commonplace	_	
207-18	36569-36570	,	_	
207-19	36571-36574	and	_	
207-20	36575-36577	is	_	
207-21	36578-36584	likely	_	
207-22	36585-36591	driven	_	
207-23	36592-36594	by	_	
207-24	36595-36604	extensive	_	
207-25	36605-36616	disruptions	_	
207-26	36617-36619	in	_	
207-27	36620-36632	connectivity	_	
207-28	36633-36639	across	_	
207-29	36640-36643	the	_	
207-30	36644-36649	whole	_	
207-31	36650-36655	brain	_	
207-32	36656-36663	network	_	
207-33	36663-36664	.	_	

#Text=The current study, taking a novel analytical approach, has revealed reward-related functional alterations across a global network in an addiction disorder population who are in extended abstinence.
208-1	36665-36668	The	_	
208-2	36669-36676	current	_	
208-3	36677-36682	study	_	
208-4	36682-36683	,	_	
208-5	36684-36690	taking	_	
208-6	36691-36692	a	_	
208-7	36693-36698	novel	_	
208-8	36699-36709	analytical	_	
208-9	36710-36718	approach	_	
208-10	36718-36719	,	_	
208-11	36720-36723	has	_	
208-12	36724-36732	revealed	_	
208-13	36733-36747	reward-related	_	
208-14	36748-36758	functional	_	
208-15	36759-36770	alterations	_	
208-16	36771-36777	across	_	
208-17	36778-36779	a	_	
208-18	36780-36786	global	_	
208-19	36787-36794	network	_	
208-20	36795-36797	in	_	
208-21	36798-36800	an	_	
208-22	36801-36810	addiction	_	
208-23	36811-36819	disorder	_	
208-24	36820-36830	population	_	
208-25	36831-36834	who	_	
208-26	36835-36838	are	_	
208-27	36839-36841	in	_	
208-28	36842-36850	extended	_	
208-29	36851-36861	abstinence	_	
208-30	36861-36862	.	_	

#Text=These differences in connectivity feature in the presence of more localised activation disruptions that emerge from a conventional voxel-wise analytic approach.
209-1	36863-36868	These	_	
209-2	36869-36880	differences	_	
209-3	36881-36883	in	_	
209-4	36884-36896	connectivity	_	
209-5	36897-36904	feature	_	
209-6	36905-36907	in	_	
209-7	36908-36911	the	_	
209-8	36912-36920	presence	_	
209-9	36921-36923	of	_	
209-10	36924-36928	more	_	
209-11	36929-36938	localised	_	
209-12	36939-36949	activation	_	
209-13	36950-36961	disruptions	_	
209-14	36962-36966	that	_	
209-15	36967-36973	emerge	_	
209-16	36974-36978	from	_	
209-17	36979-36980	a	_	
209-18	36981-36993	conventional	_	
209-19	36994-37004	voxel-wise	_	
209-20	37005-37013	analytic	_	
209-21	37014-37022	approach	_	
209-22	37022-37023	.	_	

#Text=We propose that examining measures of global network functioning may be more sensitive for highlighting latent and more widespread disruptions to neural functioning during critical psychological processes in addiction and other psychiatric disorders.
210-1	37024-37026	We	_	
210-2	37027-37034	propose	_	
210-3	37035-37039	that	_	
210-4	37040-37049	examining	_	
210-5	37050-37058	measures	_	
210-6	37059-37061	of	_	
210-7	37062-37068	global	_	
210-8	37069-37076	network	_	
210-9	37077-37088	functioning	_	
210-10	37089-37092	may	_	
210-11	37093-37095	be	_	
210-12	37096-37100	more	_	
210-13	37101-37110	sensitive	_	
210-14	37111-37114	for	_	
210-15	37115-37127	highlighting	_	
210-16	37128-37134	latent	_	
210-17	37135-37138	and	_	
210-18	37139-37143	more	_	
210-19	37144-37154	widespread	_	
210-20	37155-37166	disruptions	_	
210-21	37167-37169	to	_	
210-22	37170-37176	neural	_	
210-23	37177-37188	functioning	_	
210-24	37189-37195	during	_	
210-25	37196-37204	critical	_	
210-26	37205-37218	psychological	_	
210-27	37219-37228	processes	_	
210-28	37229-37231	in	_	
210-29	37232-37241	addiction	_	
210-30	37242-37245	and	_	
210-31	37246-37251	other	_	
210-32	37252-37263	psychiatric	_	
210-33	37264-37273	disorders	_	
210-34	37273-37274	.	_	

#Text=Alterations in functioning across global networks could act as markers for relapse risk during abstinence, that may be potential targets for medication development in addiction disorders.
211-1	37275-37286	Alterations	_	
211-2	37287-37289	in	_	
211-3	37290-37301	functioning	_	
211-4	37302-37308	across	_	
211-5	37309-37315	global	_	
211-6	37316-37324	networks	_	
211-7	37325-37330	could	_	
211-8	37331-37334	act	_	
211-9	37335-37337	as	_	
211-10	37338-37345	markers	_	
211-11	37346-37349	for	_	
211-12	37350-37357	relapse	_	
211-13	37358-37362	risk	_	
211-14	37363-37369	during	_	
211-15	37370-37380	abstinence	_	
211-16	37380-37381	,	_	
211-17	37382-37386	that	_	
211-18	37387-37390	may	_	
211-19	37391-37393	be	_	
211-20	37394-37403	potential	_	
211-21	37404-37411	targets	_	
211-22	37412-37415	for	_	
211-23	37416-37426	medication	_	
211-24	37427-37438	development	_	
211-25	37439-37441	in	_	
211-26	37442-37451	addiction	_	
211-27	37452-37461	disorders	_	
211-28	37461-37462	.	_	

#Text=Funding
#Text=The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article presents independent research funded by the MRC as part of their addiction initiative (grant number G1000018).
212-1	37463-37470	Funding	_	
212-2	37471-37474	The	_	
212-3	37475-37482	authors	_	
212-4	37483-37492	disclosed	_	
212-5	37493-37500	receipt	_	
212-6	37501-37503	of	_	
212-7	37504-37507	the	_	
212-8	37508-37517	following	_	
212-9	37518-37527	financial	_	
212-10	37528-37535	support	_	
212-11	37536-37539	for	_	
212-12	37540-37543	the	_	
212-13	37544-37552	research	_	
212-14	37552-37553	,	_	
212-15	37554-37564	authorship	_	
212-16	37564-37565	,	_	
212-17	37566-37569	and	_	
212-18	37569-37570	/	_	
212-19	37570-37572	or	_	
212-20	37573-37584	publication	_	
212-21	37585-37587	of	_	
212-22	37588-37592	this	_	
212-23	37593-37600	article	_	
212-24	37600-37601	:	_	
212-25	37602-37606	This	_	
212-26	37607-37614	article	_	
212-27	37615-37623	presents	_	
212-28	37624-37635	independent	_	
212-29	37636-37644	research	_	
212-30	37645-37651	funded	_	
212-31	37652-37654	by	_	
212-32	37655-37658	the	_	
212-33	37659-37662	MRC	_	
212-34	37663-37665	as	_	
212-35	37666-37670	part	_	
212-36	37671-37673	of	_	
212-37	37674-37679	their	_	
212-38	37680-37689	addiction	_	
212-39	37690-37700	initiative	_	
212-40	37701-37702	(	_	
212-41	37702-37707	grant	_	
212-42	37708-37714	number	_	
212-43	37715-37723	G1000018	_	
212-44	37723-37724	)	_	
212-45	37724-37725	.	_	

#Text=GSK kindly funded the functional and structural MRI scans that took place at the London site for this study.
213-1	37726-37729	GSK	_	
213-2	37730-37736	kindly	_	
213-3	37737-37743	funded	_	
213-4	37744-37747	the	_	
213-5	37748-37758	functional	_	
213-6	37759-37762	and	_	
213-7	37763-37773	structural	_	
213-8	37774-37777	MRI	_	
213-9	37778-37783	scans	_	
213-10	37784-37788	that	_	
213-11	37789-37793	took	_	
213-12	37794-37799	place	_	
213-13	37800-37802	at	_	
213-14	37803-37806	the	_	
213-15	37807-37813	London	_	
213-16	37814-37818	site	_	
213-17	37819-37822	for	_	
213-18	37823-37827	this	_	
213-19	37828-37833	study	_	
213-20	37833-37834	.	_	

#Text=Declaration of competing interests
#Text=The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:
#Text=David J Nutt is an advisor to British National Formulary, MRC, General Medical Council, Department of Health, is President of the European Brain Council, past President of the British Neuroscience Association and European College of Neuropsychopharmacology, chair of the Independent Scientific Committee on Drugs (UK), is a member of the International Centre for Science in Drug Policy, advisor to Swedish government on drug, alcohol and tobacco research, editor of the Journal of Psychopharmacology, sits on advisory Boards at Lundbeck, MSD, Nalpharm, Orexigen, Shire, has received speaking honoraria (in addition to above) from BMS/Otsuka, GSK, Lilly, Janssen, Servier, is a member of the Lundbeck International Neuroscience Foundation, has received grants or clinical trial payments from P1vital, MRC, NHS, Lundbeck, has share options with P1vital, has been expert witness in a number of legal cases relating to psychotropic drugs, and has edited/written 27 books, some purchased by pharmaceutical companies.
214-1	37835-37846	Declaration	_	
214-2	37847-37849	of	_	
214-3	37850-37859	competing	_	
214-4	37860-37869	interests	_	
214-5	37870-37873	The	_	
214-6	37874-37881	authors	_	
214-7	37882-37890	declared	_	
214-8	37891-37894	the	_	
214-9	37895-37904	following	_	
214-10	37905-37914	potential	_	
214-11	37915-37924	conflicts	_	
214-12	37925-37927	of	_	
214-13	37928-37936	interest	_	
214-14	37937-37941	with	_	
214-15	37942-37949	respect	_	
214-16	37950-37952	to	_	
214-17	37953-37956	the	_	
214-18	37957-37965	research	_	
214-19	37965-37966	,	_	
214-20	37967-37977	authorship	_	
214-21	37977-37978	,	_	
214-22	37979-37982	and	_	
214-23	37982-37983	/	_	
214-24	37983-37985	or	_	
214-25	37986-37997	publication	_	
214-26	37998-38000	of	_	
214-27	38001-38005	this	_	
214-28	38006-38013	article	_	
214-29	38013-38014	:	_	
214-30	38015-38020	David	_	
214-31	38021-38022	J	_	
214-32	38023-38027	Nutt	_	
214-33	38028-38030	is	_	
214-34	38031-38033	an	_	
214-35	38034-38041	advisor	_	
214-36	38042-38044	to	_	
214-37	38045-38052	British	_	
214-38	38053-38061	National	_	
214-39	38062-38071	Formulary	_	
214-40	38071-38072	,	_	
214-41	38073-38076	MRC	_	
214-42	38076-38077	,	_	
214-43	38078-38085	General	_	
214-44	38086-38093	Medical	_	
214-45	38094-38101	Council	_	
214-46	38101-38102	,	_	
214-47	38103-38113	Department	_	
214-48	38114-38116	of	_	
214-49	38117-38123	Health	_	
214-50	38123-38124	,	_	
214-51	38125-38127	is	_	
214-52	38128-38137	President	_	
214-53	38138-38140	of	_	
214-54	38141-38144	the	_	
214-55	38145-38153	European	_	
214-56	38154-38159	Brain	_	
214-57	38160-38167	Council	_	
214-58	38167-38168	,	_	
214-59	38169-38173	past	_	
214-60	38174-38183	President	_	
214-61	38184-38186	of	_	
214-62	38187-38190	the	_	
214-63	38191-38198	British	_	
214-64	38199-38211	Neuroscience	_	
214-65	38212-38223	Association	_	
214-66	38224-38227	and	_	
214-67	38228-38236	European	_	
214-68	38237-38244	College	_	
214-69	38245-38247	of	_	
214-70	38248-38271	Neuropsychopharmacology	_	
214-71	38271-38272	,	_	
214-72	38273-38278	chair	_	
214-73	38279-38281	of	_	
214-74	38282-38285	the	_	
214-75	38286-38297	Independent	_	
214-76	38298-38308	Scientific	_	
214-77	38309-38318	Committee	_	
214-78	38319-38321	on	_	
214-79	38322-38327	Drugs	_	
214-80	38328-38329	(	_	
214-81	38329-38331	UK	_	
214-82	38331-38332	)	_	
214-83	38332-38333	,	_	
214-84	38334-38336	is	_	
214-85	38337-38338	a	_	
214-86	38339-38345	member	_	
214-87	38346-38348	of	_	
214-88	38349-38352	the	_	
214-89	38353-38366	International	_	
214-90	38367-38373	Centre	_	
214-91	38374-38377	for	_	
214-92	38378-38385	Science	_	
214-93	38386-38388	in	_	
214-94	38389-38393	Drug	_	
214-95	38394-38400	Policy	_	
214-96	38400-38401	,	_	
214-97	38402-38409	advisor	_	
214-98	38410-38412	to	_	
214-99	38413-38420	Swedish	_	
214-100	38421-38431	government	_	
214-101	38432-38434	on	_	
214-102	38435-38439	drug	_	
214-103	38439-38440	,	_	
214-104	38441-38448	alcohol	_	
214-105	38449-38452	and	_	
214-106	38453-38460	tobacco	_	
214-107	38461-38469	research	_	
214-108	38469-38470	,	_	
214-109	38471-38477	editor	_	
214-110	38478-38480	of	_	
214-111	38481-38484	the	_	
214-112	38485-38492	Journal	_	
214-113	38493-38495	of	_	
214-114	38496-38514	Psychopharmacology	_	
214-115	38514-38515	,	_	
214-116	38516-38520	sits	_	
214-117	38521-38523	on	_	
214-118	38524-38532	advisory	_	
214-119	38533-38539	Boards	_	
214-120	38540-38542	at	_	
214-121	38543-38551	Lundbeck	_	
214-122	38551-38552	,	_	
214-123	38553-38556	MSD	_	
214-124	38556-38557	,	_	
214-125	38558-38566	Nalpharm	_	
214-126	38566-38567	,	_	
214-127	38568-38576	Orexigen	_	
214-128	38576-38577	,	_	
214-129	38578-38583	Shire	_	
214-130	38583-38584	,	_	
214-131	38585-38588	has	_	
214-132	38589-38597	received	_	
214-133	38598-38606	speaking	_	
214-134	38607-38616	honoraria	_	
214-135	38617-38618	(	_	
214-136	38618-38620	in	_	
214-137	38621-38629	addition	_	
214-138	38630-38632	to	_	
214-139	38633-38638	above	_	
214-140	38638-38639	)	_	
214-141	38640-38644	from	_	
214-142	38645-38648	BMS	_	
214-143	38648-38649	/	_	
214-144	38649-38655	Otsuka	_	
214-145	38655-38656	,	_	
214-146	38657-38660	GSK	_	
214-147	38660-38661	,	_	
214-148	38662-38667	Lilly	_	
214-149	38667-38668	,	_	
214-150	38669-38676	Janssen	_	
214-151	38676-38677	,	_	
214-152	38678-38685	Servier	_	
214-153	38685-38686	,	_	
214-154	38687-38689	is	_	
214-155	38690-38691	a	_	
214-156	38692-38698	member	_	
214-157	38699-38701	of	_	
214-158	38702-38705	the	_	
214-159	38706-38714	Lundbeck	_	
214-160	38715-38728	International	_	
214-161	38729-38741	Neuroscience	_	
214-162	38742-38752	Foundation	_	
214-163	38752-38753	,	_	
214-164	38754-38757	has	_	
214-165	38758-38766	received	_	
214-166	38767-38773	grants	_	
214-167	38774-38776	or	_	
214-168	38777-38785	clinical	_	
214-169	38786-38791	trial	_	
214-170	38792-38800	payments	_	
214-171	38801-38805	from	_	
214-172	38806-38813	P1vital	_	
214-173	38813-38814	,	_	
214-174	38815-38818	MRC	_	
214-175	38818-38819	,	_	
214-176	38820-38823	NHS	_	
214-177	38823-38824	,	_	
214-178	38825-38833	Lundbeck	_	
214-179	38833-38834	,	_	
214-180	38835-38838	has	_	
214-181	38839-38844	share	_	
214-182	38845-38852	options	_	
214-183	38853-38857	with	_	
214-184	38858-38865	P1vital	_	
214-185	38865-38866	,	_	
214-186	38867-38870	has	_	
214-187	38871-38875	been	_	
214-188	38876-38882	expert	_	
214-189	38883-38890	witness	_	
214-190	38891-38893	in	_	
214-191	38894-38895	a	_	
214-192	38896-38902	number	_	
214-193	38903-38905	of	_	
214-194	38906-38911	legal	_	
214-195	38912-38917	cases	_	
214-196	38918-38926	relating	_	
214-197	38927-38929	to	_	
214-198	38930-38942	psychotropic	_	
214-199	38943-38948	drugs	_	
214-200	38948-38949	,	_	
214-201	38950-38953	and	_	
214-202	38954-38957	has	_	
214-203	38958-38964	edited	_	
214-204	38964-38965	/	_	
214-205	38965-38972	written	_	
214-206	38973-38975	27	_	
214-207	38976-38981	books	_	
214-208	38981-38982	,	_	
214-209	38983-38987	some	_	
214-210	38988-38997	purchased	_	
214-211	38998-39000	by	_	
214-212	39001-39015	pharmaceutical	_	
214-213	39016-39025	companies	_	
214-214	39025-39026	.	_	

#Text=Trevor W Robbins has research grants with Eli Lilly and Lundbeck, has received royalties from Cambridge Cognition, has received editorial honoraria from Springer Verlag, Elsevier, Society for Neuroscience; has performed educational lectures for Merck, Sharpe and Dohme and does consultancy work for Cambridge Cognition, Eli Lilly, Lundbeck, Teva and Shire Pharmaceuticals.
215-1	39027-39033	Trevor	_	
215-2	39034-39035	W	_	
215-3	39036-39043	Robbins	_	
215-4	39044-39047	has	_	
215-5	39048-39056	research	_	
215-6	39057-39063	grants	_	
215-7	39064-39068	with	_	
215-8	39069-39072	Eli	_	
215-9	39073-39078	Lilly	_	
215-10	39079-39082	and	_	
215-11	39083-39091	Lundbeck	_	
215-12	39091-39092	,	_	
215-13	39093-39096	has	_	
215-14	39097-39105	received	_	
215-15	39106-39115	royalties	_	
215-16	39116-39120	from	_	
215-17	39121-39130	Cambridge	_	
215-18	39131-39140	Cognition	_	
215-19	39140-39141	,	_	
215-20	39142-39145	has	_	
215-21	39146-39154	received	_	
215-22	39155-39164	editorial	_	
215-23	39165-39174	honoraria	_	
215-24	39175-39179	from	_	
215-25	39180-39188	Springer	_	
215-26	39189-39195	Verlag	_	
215-27	39195-39196	,	_	
215-28	39197-39205	Elsevier	_	
215-29	39205-39206	,	_	
215-30	39207-39214	Society	_	
215-31	39215-39218	for	_	
215-32	39219-39231	Neuroscience	_	
215-33	39231-39232	;	_	
215-34	39233-39236	has	_	
215-35	39237-39246	performed	_	
215-36	39247-39258	educational	_	
215-37	39259-39267	lectures	_	
215-38	39268-39271	for	_	
215-39	39272-39277	Merck	_	
215-40	39277-39278	,	_	
215-41	39279-39285	Sharpe	_	
215-42	39286-39289	and	_	
215-43	39290-39295	Dohme	_	
215-44	39296-39299	and	_	
215-45	39300-39304	does	_	
215-46	39305-39316	consultancy	_	
215-47	39317-39321	work	_	
215-48	39322-39325	for	_	
215-49	39326-39335	Cambridge	_	
215-50	39336-39345	Cognition	_	
215-51	39345-39346	,	_	
215-52	39347-39350	Eli	_	
215-53	39351-39356	Lilly	_	
215-54	39356-39357	,	_	
215-55	39358-39366	Lundbeck	_	
215-56	39366-39367	,	_	
215-57	39368-39372	Teva	_	
215-58	39373-39376	and	_	
215-59	39377-39382	Shire	_	
215-60	39383-39398	Pharmaceuticals	_	
215-61	39398-39399	.	_	

#Text=Barbara J Sahakian consults for Cambridge Cognition, Greenfield BioVentures, and Casssava Sciences.
216-1	39400-39407	Barbara	_	
216-2	39408-39409	J	_	
216-3	39410-39418	Sahakian	_	
216-4	39419-39427	consults	_	
216-5	39428-39431	for	_	
216-6	39432-39441	Cambridge	_	
216-7	39442-39451	Cognition	_	
216-8	39451-39452	,	_	
216-9	39453-39463	Greenfield	_	
216-10	39464-39475	BioVentures	_	
216-11	39475-39476	,	_	
216-12	39477-39480	and	_	
216-13	39481-39489	Casssava	_	
216-14	39490-39498	Sciences	_	
216-15	39498-39499	.	_	

#Text=William Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier.
217-1	39500-39507	William	_	
217-2	39508-39514	Deakin	_	
217-3	39515-39524	currently	_	
217-4	39525-39532	advises	_	
217-5	39533-39535	or	_	
217-6	39536-39543	carries	_	
217-7	39544-39547	out	_	
217-8	39548-39556	research	_	
217-9	39557-39563	funded	_	
217-10	39564-39566	by	_	
217-11	39567-39575	Autifony	_	
217-12	39575-39576	,	_	
217-13	39577-39585	Sunovion	_	
217-14	39585-39586	,	_	
217-15	39587-39595	Lundbeck	_	
217-16	39595-39596	,	_	
217-17	39597-39608	AstraZeneca	_	
217-18	39609-39612	and	_	
217-19	39613-39620	Servier	_	
217-20	39620-39621	.	_	

#Text=All payment is to the University of Manchester.
218-1	39622-39625	All	_	
218-2	39626-39633	payment	_	
218-3	39634-39636	is	_	
218-4	39637-39639	to	_	
218-5	39640-39643	the	_	
218-6	39644-39654	University	_	
218-7	39655-39657	of	_	
218-8	39658-39668	Manchester	_	
218-9	39668-39669	.	_	

#Text=Edward T Bullmore was employed half-time by the University of Cambridge and half-time by GSK during some of this work and is a shareholder in GSK.
219-1	39670-39676	Edward	_	
219-2	39677-39678	T	_	
219-3	39679-39687	Bullmore	_	
219-4	39688-39691	was	_	
219-5	39692-39700	employed	_	
219-6	39701-39710	half-time	_	
219-7	39711-39713	by	_	
219-8	39714-39717	the	_	
219-9	39718-39728	University	_	
219-10	39729-39731	of	_	
219-11	39732-39741	Cambridge	_	
219-12	39742-39745	and	_	
219-13	39746-39755	half-time	_	
219-14	39756-39758	by	_	
219-15	39759-39762	GSK	_	
219-16	39763-39769	during	_	
219-17	39770-39774	some	_	
219-18	39775-39777	of	_	
219-19	39778-39782	this	_	
219-20	39783-39787	work	_	
219-21	39788-39791	and	_	
219-22	39792-39794	is	_	
219-23	39795-39796	a	_	
219-24	39797-39808	shareholder	_	
219-25	39809-39811	in	_	
219-26	39812-39815	GSK	_	
219-27	39815-39816	.	_	

#Text=Liam J Nestor was employed by GSK during some of this work.
220-1	39817-39821	Liam	_	
220-2	39822-39823	J	_	
220-3	39824-39830	Nestor	_	
220-4	39831-39834	was	_	
220-5	39835-39843	employed	_	
220-6	39844-39846	by	_	
220-7	39847-39850	GSK	_	
220-8	39851-39857	during	_	
220-9	39858-39862	some	_	
220-10	39863-39865	of	_	
220-11	39866-39870	this	_	
220-12	39871-39875	work	_	
220-13	39875-39876	.	_	

#Text=Eugenii Rabiner worked for GSK until 2011 and is a shareholder in GSK.
221-1	39877-39884	Eugenii	_	
221-2	39885-39892	Rabiner	_	
221-3	39893-39899	worked	_	
221-4	39900-39903	for	_	
221-5	39904-39907	GSK	_	
221-6	39908-39913	until	_	
221-7	39914-39918	2011	_	
221-8	39919-39922	and	_	
221-9	39923-39925	is	_	
221-10	39926-39927	a	_	
221-11	39928-39939	shareholder	_	
221-12	39940-39942	in	_	
221-13	39943-39946	GSK	_	
221-14	39946-39947	.	_	

#Text=He is a consultant to GSK, TEVA, Lightlake Therapeutics, AbbVie, and Roche.
222-1	39948-39950	He	_	
222-2	39951-39953	is	_	
222-3	39954-39955	a	_	
222-4	39956-39966	consultant	_	
222-5	39967-39969	to	_	
222-6	39970-39973	GSK	_	
222-7	39973-39974	,	_	
222-8	39975-39979	TEVA	_	
222-9	39979-39980	,	_	
222-10	39981-39990	Lightlake	_	
222-11	39991-40003	Therapeutics	_	
222-12	40003-40004	,	_	
222-13	40005-40011	AbbVie	_	
222-14	40011-40012	,	_	
222-15	40013-40016	and	_	
222-16	40017-40022	Roche	_	
222-17	40022-40023	.	_	

#Text=CRediT authorship contribution statement
#Text=Liam J.
223-1	40024-40030	CRediT	_	
223-2	40031-40041	authorship	_	
223-3	40042-40054	contribution	_	
223-4	40055-40064	statement	_	
223-5	40065-40069	Liam	_	
223-6	40070-40071	J	_	
223-7	40071-40072	.	_	

#Text=Nestor: Conceptualization, Methodology, Software, Validation, Formal analysis, Data curation, Writing - original draft, Visualization.
224-1	40073-40079	Nestor	_	
224-2	40079-40080	:	_	
224-3	40081-40098	Conceptualization	_	
224-4	40098-40099	,	_	
224-5	40100-40111	Methodology	_	
224-6	40111-40112	,	_	
224-7	40113-40121	Software	_	
224-8	40121-40122	,	_	
224-9	40123-40133	Validation	_	
224-10	40133-40134	,	_	
224-11	40135-40141	Formal	_	
224-12	40142-40150	analysis	_	
224-13	40150-40151	,	_	
224-14	40152-40156	Data	_	
224-15	40157-40165	curation	_	
224-16	40165-40166	,	_	
224-17	40167-40174	Writing	_	
224-18	40175-40176	-	_	
224-19	40177-40185	original	_	
224-20	40186-40191	draft	_	
224-21	40191-40192	,	_	
224-22	40193-40206	Visualization	_	
224-23	40206-40207	.	_	

#Text=John Suckling: Conceptualization, Resources, Writing - original draft, Supervision, Project administration.
225-1	40208-40212	John	_	
225-2	40213-40221	Suckling	_	
225-3	40221-40222	:	_	
225-4	40223-40240	Conceptualization	_	
225-5	40240-40241	,	_	
225-6	40242-40251	Resources	_	
225-7	40251-40252	,	_	
225-8	40253-40260	Writing	_	
225-9	40261-40262	-	_	
225-10	40263-40271	original	_	
225-11	40272-40277	draft	_	
225-12	40277-40278	,	_	
225-13	40279-40290	Supervision	_	
225-14	40290-40291	,	_	
225-15	40292-40299	Project	_	
225-16	40300-40314	administration	_	
225-17	40314-40315	.	_	

#Text=Karen D.
226-1	40316-40321	Karen	_	
226-2	40322-40323	D	_	
226-3	40323-40324	.	_	

#Text=Ersche: Investigation, Supervision, Funding acquisition, Project administration, Writing - original draft.
227-1	40325-40331	Ersche	_	
227-2	40331-40332	:	_	
227-3	40333-40346	Investigation	_	
227-4	40346-40347	,	_	
227-5	40348-40359	Supervision	_	
227-6	40359-40360	,	_	
227-7	40361-40368	Funding	_	
227-8	40369-40380	acquisition	_	
227-9	40380-40381	,	_	
227-10	40382-40389	Project	_	
227-11	40390-40404	administration	_	
227-12	40404-40405	,	_	
227-13	40406-40413	Writing	_	
227-14	40414-40415	-	_	
227-15	40416-40424	original	_	
227-16	40425-40430	draft	_	
227-17	40430-40431	.	_	

#Text=Anna Murphy: Investigation, Data curation, Project administration.
228-1	40432-40436	Anna	_	
228-2	40437-40443	Murphy	_	
228-3	40443-40444	:	_	
228-4	40445-40458	Investigation	_	
228-5	40458-40459	,	_	
228-6	40460-40464	Data	_	
228-7	40465-40473	curation	_	
228-8	40473-40474	,	_	
228-9	40475-40482	Project	_	
228-10	40483-40497	administration	_	
228-11	40497-40498	.	_	

#Text=John McGonigle: Investigation, Data curation, Project administration.
229-1	40499-40503	John	_	
229-2	40504-40513	McGonigle	_	
229-3	40513-40514	:	_	
229-4	40515-40528	Investigation	_	
229-5	40528-40529	,	_	
229-6	40530-40534	Data	_	
229-7	40535-40543	curation	_	
229-8	40543-40544	,	_	
229-9	40545-40552	Project	_	
229-10	40553-40567	administration	_	
229-11	40567-40568	.	_	

#Text=Csaba Orban: Investigation, Data curation, Project administration.
230-1	40569-40574	Csaba	_	
230-2	40575-40580	Orban	_	
230-3	40580-40581	:	_	
230-4	40582-40595	Investigation	_	
230-5	40595-40596	,	_	
230-6	40597-40601	Data	_	
230-7	40602-40610	curation	_	
230-8	40610-40611	,	_	
230-9	40612-40619	Project	_	
230-10	40620-40634	administration	_	
230-11	40634-40635	.	_	

#Text=Louise M.
231-1	40636-40642	Louise	_	
231-2	40643-40644	M	_	
231-3	40644-40645	.	_	

#Text=Paterson: Investigation, Data curation, Project administration, Writing - original draft.
232-1	40646-40654	Paterson	_	
232-2	40654-40655	:	_	
232-3	40656-40669	Investigation	_	
232-4	40669-40670	,	_	
232-5	40671-40675	Data	_	
232-6	40676-40684	curation	_	
232-7	40684-40685	,	_	
232-8	40686-40693	Project	_	
232-9	40694-40708	administration	_	
232-10	40708-40709	,	_	
232-11	40710-40717	Writing	_	
232-12	40718-40719	-	_	
232-13	40720-40728	original	_	
232-14	40729-40734	draft	_	
232-15	40734-40735	.	_	

#Text=Laurence Reed: Funding acquisition.
233-1	40736-40744	Laurence	_	
233-2	40745-40749	Reed	_	
233-3	40749-40750	:	_	
233-4	40751-40758	Funding	_	
233-5	40759-40770	acquisition	_	
233-6	40770-40771	.	_	

#Text=Eleanor Taylor: Investigation, Data curation, Project administration.
234-1	40772-40779	Eleanor	_	
234-2	40780-40786	Taylor	_	
234-3	40786-40787	:	_	
234-4	40788-40801	Investigation	_	
234-5	40801-40802	,	_	
234-6	40803-40807	Data	_	
234-7	40808-40816	curation	_	
234-8	40816-40817	,	_	
234-9	40818-40825	Project	_	
234-10	40826-40840	administration	_	
234-11	40840-40841	.	_	

#Text=Remy Flechais: Investigation, Data curation, Project administration.
235-1	40842-40846	Remy	_	
235-2	40847-40855	Flechais	_	
235-3	40855-40856	:	_	
235-4	40857-40870	Investigation	_	
235-5	40870-40871	,	_	
235-6	40872-40876	Data	_	
235-7	40877-40885	curation	_	
235-8	40885-40886	,	_	
235-9	40887-40894	Project	_	
235-10	40895-40909	administration	_	
235-11	40909-40910	.	_	

#Text=Dana Smith: Investigation, Data curation, Project administration.
236-1	40911-40915	Dana	_	
236-2	40916-40921	Smith	_	
236-3	40921-40922	:	_	
236-4	40923-40936	Investigation	_	
236-5	40936-40937	,	_	
236-6	40938-40942	Data	_	
236-7	40943-40951	curation	_	
236-8	40951-40952	,	_	
236-9	40953-40960	Project	_	
236-10	40961-40975	administration	_	
236-11	40975-40976	.	_	

#Text=Edward T.
237-1	40977-40983	Edward	_	
237-2	40984-40985	T	_	
237-3	40985-40986	.	_	

#Text=Bullmore: Funding acquisition.
238-1	40987-40995	Bullmore	_	
238-2	40995-40996	:	_	
238-3	40997-41004	Funding	_	
238-4	41005-41016	acquisition	_	
238-5	41016-41017	.	_	

#Text=Rebecca Elliott: Funding acquisition.
239-1	41018-41025	Rebecca	_	
239-2	41026-41033	Elliott	_	
239-3	41033-41034	:	_	
239-4	41035-41042	Funding	_	
239-5	41043-41054	acquisition	_	
239-6	41054-41055	.	_	

#Text=Bill Deakin: Funding acquisition.
240-1	41056-41060	Bill	_	
240-2	41061-41067	Deakin	_	
240-3	41067-41068	:	_	
240-4	41069-41076	Funding	_	
240-5	41077-41088	acquisition	_	
240-6	41088-41089	.	_	

#Text=Ilan Rabiner: Funding acquisition.
241-1	41090-41094	Ilan	_	
241-2	41095-41102	Rabiner	_	
241-3	41102-41103	:	_	
241-4	41104-41111	Funding	_	
241-5	41112-41123	acquisition	_	
241-6	41123-41124	.	_	

#Text=Anne-Lingford Hughes: Writing - original draft, Funding acquisition.
242-1	41125-41138	Anne-Lingford	_	
242-2	41139-41145	Hughes	_	
242-3	41145-41146	:	_	
242-4	41147-41154	Writing	_	
242-5	41155-41156	-	_	
242-6	41157-41165	original	_	
242-7	41166-41171	draft	_	
242-8	41171-41172	,	_	
242-9	41173-41180	Funding	_	
242-10	41181-41192	acquisition	_	
242-11	41192-41193	.	_	

#Text=Barbara J.
243-1	41194-41201	Barbara	_	
243-2	41202-41203	J	_	
243-3	41203-41204	.	_	

#Text=Sahakian: Writing - original draft, Funding acquisition.
244-1	41205-41213	Sahakian	_	
244-2	41213-41214	:	_	
244-3	41215-41222	Writing	_	
244-4	41223-41224	-	_	
244-5	41225-41233	original	_	
244-6	41234-41239	draft	_	
244-7	41239-41240	,	_	
244-8	41241-41248	Funding	_	
244-9	41249-41260	acquisition	_	
244-10	41260-41261	.	_	

#Text=Trevor W.
245-1	41262-41268	Trevor	_	
245-2	41269-41270	W	_	
245-3	41270-41271	.	_	

#Text=Robbins: Writing - original draft, Supervision, Funding acquisition.
246-1	41272-41279	Robbins	_	
246-2	41279-41280	:	_	
246-3	41281-41288	Writing	_	
246-4	41289-41290	-	_	
246-5	41291-41299	original	_	
246-6	41300-41305	draft	_	
246-7	41305-41306	,	_	
246-8	41307-41318	Supervision	_	
246-9	41318-41319	,	_	
246-10	41320-41327	Funding	_	
246-11	41328-41339	acquisition	_	
246-12	41339-41340	.	_	

#Text=David J.
247-1	41341-41346	David	_	
247-2	41347-41348	J	_	
247-3	41348-41349	.	_	

#Text=Nutt: Writing - original draft, Supervision, Funding acquisition. : .
248-1	41350-41354	Nutt	_	
248-2	41354-41355	:	_	
248-3	41356-41363	Writing	_	
248-4	41364-41365	-	_	
248-5	41366-41374	original	_	
248-6	41375-41380	draft	_	
248-7	41380-41381	,	_	
248-8	41382-41393	Supervision	_	
248-9	41393-41394	,	_	
248-10	41395-41402	Funding	_	
248-11	41403-41414	acquisition	_	
248-12	41414-41415	.	_	
248-13	41416-41417	:	_	
248-14	41418-41419	.	_	

#Text=References
#Text=Efficiency and cost of economical brain functional networks
#Text=Disrupted resting-state brain network properties in obesity: Decreased global and putaminal cortico-striatal network efficiency
#Text=Anticipatory reward processing in addicted populations: A focus on the monetary incentive delay task
#Text=Hierarchical organization of human cortical networks in health and schizophrenia
#Text=Cocaine seeking habits depend upon doparnine-dependent serial connectivity linking the ventral with the dorsal striatum
#Text=Reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors
#Text=Rapid recovery of vesicular dopamine levels in methamphetamine users in early abstinence
#Text=Prefrontal cortical dysfunction in abstinent cocaine abusers
#Text=Nicotine dependence is characterized by disordered reward processing in a network driving motivation
#Text=Complex brain networks: graph theoretical analysis of structural and functional systems (vol 10, pg 186, 2009)
#Text=The economy of brain network organization
#Text=Brain graphs: Graphical models of the human brain connectome
#Text=Abstinence duration modulates striatal functioning during monetary reward processing in cocaine patients
#Text=Altered functional brain connectivity in a non-clinical sample of young adults with attention-deficit/hyperactivity disorder
#Text=Functional neuroimaging of reward processing and decision-making: a review of aberrant motivational and affective processing in addiction and mood disorders
#Text=Evidence for segregated and integrative connectivity patterns in the human Basal Ganglia
#Text=Abnormal brain activity in prefrontal brain regions in abstinent marijuana users
#Text=General and specific functional connectivity disturbances in first-episode schizophrenia during cognitive control performance
#Text=Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex
#Text=Individualized relapse prediction: Personality measures and striatal and insular activity during reward-processing robustly predict relapse
#Text=Abnormal brain activity during a reward and loss task in opiate-dependent patients receiving methadone maintenance therapy
#Text=The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Disrupted resting brain graph measures in individuals at high risk for alcoholism
#Text=Imaging brain response to reward in addictive disorders
#Text=Predicting human resting-state functional connectivity from structural connectivity
#Text=Decreased functional brain connectivity in adolescents with internet addiction
#Text=Value encoding in single neurons in the human amygdala during decision making
#Text=Disrupted topological organization in whole-brain functional networks of heroin-dependent individuals: A Resting-State fMRI Study
#Text=Effects of familial risk and stimulant drug use on the anticipation of monetary reward: An fMRI study
#Text=Nonoptimal component placement, but short processing paths, due to long-distance projections in neural systems
#Text=Anticipation of increasing monetary reward selectively recruits nucleus accumbens
#Text=Plasticity of reward neurocircuitry and the 'dark side' of drug addiction
#Text=Neurobiological mechanisms in the transition from drug use to drug dependence
#Text=Motivation and cognitive control in the human prefrontal cortex
#Text=GraphVar: A user-friendly toolbox for comprehensive graph analyses of functional brain connectivity
#Text=Efficient behavior of small-world networks
#Text=Economic small-world behavior in weighted networks
#Text=Compulsive drug use and its neural substrates
#Text=Altered brain functional networks in heavy smokers
#Text=Disruption of reward processing in addiction: An image-based meta-analysis of functional magnetic resonance imaging studies
#Text=Frequency dependant topological alterations of intrinsic functional connectome in major depressive disorder
#Text=Anticipation-related brain connectivity in bipolar and unipolar depression: A graph theory approach
#Text=Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum
#Text=The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction.
249-1	41420-41430	References	_	
249-2	41431-41441	Efficiency	_	
249-3	41442-41445	and	_	
249-4	41446-41450	cost	_	
249-5	41451-41453	of	_	
249-6	41454-41464	economical	_	
249-7	41465-41470	brain	_	
249-8	41471-41481	functional	_	
249-9	41482-41490	networks	_	
249-10	41491-41500	Disrupted	_	
249-11	41501-41514	resting-state	_	
249-12	41515-41520	brain	_	
249-13	41521-41528	network	_	
249-14	41529-41539	properties	_	
249-15	41540-41542	in	_	
249-16	41543-41550	obesity	_	
249-17	41550-41551	:	_	
249-18	41552-41561	Decreased	_	
249-19	41562-41568	global	_	
249-20	41569-41572	and	_	
249-21	41573-41582	putaminal	_	
249-22	41583-41599	cortico-striatal	_	
249-23	41600-41607	network	_	
249-24	41608-41618	efficiency	_	
249-25	41619-41631	Anticipatory	_	
249-26	41632-41638	reward	_	
249-27	41639-41649	processing	_	
249-28	41650-41652	in	_	
249-29	41653-41661	addicted	_	
249-30	41662-41673	populations	_	
249-31	41673-41674	:	_	
249-32	41675-41676	A	_	
249-33	41677-41682	focus	_	
249-34	41683-41685	on	_	
249-35	41686-41689	the	_	
249-36	41690-41698	monetary	_	
249-37	41699-41708	incentive	_	
249-38	41709-41714	delay	_	
249-39	41715-41719	task	_	
249-40	41720-41732	Hierarchical	_	
249-41	41733-41745	organization	_	
249-42	41746-41748	of	_	
249-43	41749-41754	human	_	
249-44	41755-41763	cortical	_	
249-45	41764-41772	networks	_	
249-46	41773-41775	in	_	
249-47	41776-41782	health	_	
249-48	41783-41786	and	_	
249-49	41787-41800	schizophrenia	_	
249-50	41801-41808	Cocaine	_	
249-51	41809-41816	seeking	_	
249-52	41817-41823	habits	_	
249-53	41824-41830	depend	_	
249-54	41831-41835	upon	_	
249-55	41836-41855	doparnine-dependent	_	
249-56	41856-41862	serial	_	
249-57	41863-41875	connectivity	_	
249-58	41876-41883	linking	_	
249-59	41884-41887	the	_	
249-60	41888-41895	ventral	_	
249-61	41896-41900	with	_	
249-62	41901-41904	the	_	
249-63	41905-41911	dorsal	_	
249-64	41912-41920	striatum	_	
249-65	41921-41927	Reward	_	
249-66	41928-41938	deficiency	_	
249-67	41939-41947	syndrome	_	
249-68	41947-41948	:	_	
249-69	41949-41950	A	_	
249-70	41951-41961	biogenetic	_	
249-71	41962-41967	model	_	
249-72	41968-41971	for	_	
249-73	41972-41975	the	_	
249-74	41976-41985	diagnosis	_	
249-75	41986-41989	and	_	
249-76	41990-41999	treatment	_	
249-77	42000-42002	of	_	
249-78	42003-42012	impulsive	_	
249-79	42012-42013	,	_	
249-80	42014-42023	addictive	_	
249-81	42023-42024	,	_	
249-82	42025-42028	and	_	
249-83	42029-42039	compulsive	_	
249-84	42040-42049	behaviors	_	
249-85	42050-42055	Rapid	_	
249-86	42056-42064	recovery	_	
249-87	42065-42067	of	_	
249-88	42068-42077	vesicular	_	
249-89	42078-42086	dopamine	_	
249-90	42087-42093	levels	_	
249-91	42094-42096	in	_	
249-92	42097-42112	methamphetamine	_	
249-93	42113-42118	users	_	
249-94	42119-42121	in	_	
249-95	42122-42127	early	_	
249-96	42128-42138	abstinence	_	
249-97	42139-42149	Prefrontal	_	
249-98	42150-42158	cortical	_	
249-99	42159-42170	dysfunction	_	
249-100	42171-42173	in	_	
249-101	42174-42183	abstinent	_	
249-102	42184-42191	cocaine	_	
249-103	42192-42199	abusers	_	
249-104	42200-42208	Nicotine	_	
249-105	42209-42219	dependence	_	
249-106	42220-42222	is	_	
249-107	42223-42236	characterized	_	
249-108	42237-42239	by	_	
249-109	42240-42250	disordered	_	
249-110	42251-42257	reward	_	
249-111	42258-42268	processing	_	
249-112	42269-42271	in	_	
249-113	42272-42273	a	_	
249-114	42274-42281	network	_	
249-115	42282-42289	driving	_	
249-116	42290-42300	motivation	_	
249-117	42301-42308	Complex	_	
249-118	42309-42314	brain	_	
249-119	42315-42323	networks	_	
249-120	42323-42324	:	_	
249-121	42325-42330	graph	_	
249-122	42331-42342	theoretical	_	
249-123	42343-42351	analysis	_	
249-124	42352-42354	of	_	
249-125	42355-42365	structural	_	
249-126	42366-42369	and	_	
249-127	42370-42380	functional	_	
249-128	42381-42388	systems	_	
249-129	42389-42390	(	_	
249-130	42390-42393	vol	_	
249-131	42394-42396	10	_	
249-132	42396-42397	,	_	
249-133	42398-42400	pg	_	
249-134	42401-42404	186	_	
249-135	42404-42405	,	_	
249-136	42406-42410	2009	_	
249-137	42410-42411	)	_	
249-138	42412-42415	The	_	
249-139	42416-42423	economy	_	
249-140	42424-42426	of	_	
249-141	42427-42432	brain	_	
249-142	42433-42440	network	_	
249-143	42441-42453	organization	_	
249-144	42454-42459	Brain	_	
249-145	42460-42466	graphs	_	
249-146	42466-42467	:	_	
249-147	42468-42477	Graphical	_	
249-148	42478-42484	models	_	
249-149	42485-42487	of	_	
249-150	42488-42491	the	_	
249-151	42492-42497	human	_	
249-152	42498-42503	brain	_	
249-153	42504-42514	connectome	_	
249-154	42515-42525	Abstinence	_	
249-155	42526-42534	duration	_	
249-156	42535-42544	modulates	_	
249-157	42545-42553	striatal	_	
249-158	42554-42565	functioning	_	
249-159	42566-42572	during	_	
249-160	42573-42581	monetary	_	
249-161	42582-42588	reward	_	
249-162	42589-42599	processing	_	
249-163	42600-42602	in	_	
249-164	42603-42610	cocaine	_	
249-165	42611-42619	patients	_	
249-166	42620-42627	Altered	_	
249-167	42628-42638	functional	_	
249-168	42639-42644	brain	_	
249-169	42645-42657	connectivity	_	
249-170	42658-42660	in	_	
249-171	42661-42662	a	_	
249-172	42663-42675	non-clinical	_	
249-173	42676-42682	sample	_	
249-174	42683-42685	of	_	
249-175	42686-42691	young	_	
249-176	42692-42698	adults	_	
249-177	42699-42703	with	_	
249-178	42704-42721	attention-deficit	_	
249-179	42721-42722	/	_	
249-180	42722-42735	hyperactivity	_	
249-181	42736-42744	disorder	_	
249-182	42745-42755	Functional	_	
249-183	42756-42768	neuroimaging	_	
249-184	42769-42771	of	_	
249-185	42772-42778	reward	_	
249-186	42779-42789	processing	_	
249-187	42790-42793	and	_	
249-188	42794-42809	decision-making	_	
249-189	42809-42810	:	_	
249-190	42811-42812	a	_	
249-191	42813-42819	review	_	
249-192	42820-42822	of	_	
249-193	42823-42831	aberrant	_	
249-194	42832-42844	motivational	_	
249-195	42845-42848	and	_	
249-196	42849-42858	affective	_	
249-197	42859-42869	processing	_	
249-198	42870-42872	in	_	
249-199	42873-42882	addiction	_	
249-200	42883-42886	and	_	
249-201	42887-42891	mood	_	
249-202	42892-42901	disorders	_	
249-203	42902-42910	Evidence	_	
249-204	42911-42914	for	_	
249-205	42915-42925	segregated	_	
249-206	42926-42929	and	_	
249-207	42930-42941	integrative	_	
249-208	42942-42954	connectivity	_	
249-209	42955-42963	patterns	_	
249-210	42964-42966	in	_	
249-211	42967-42970	the	_	
249-212	42971-42976	human	_	
249-213	42977-42982	Basal	_	
249-214	42983-42990	Ganglia	_	
249-215	42991-42999	Abnormal	_	
249-216	43000-43005	brain	_	
249-217	43006-43014	activity	_	
249-218	43015-43017	in	_	
249-219	43018-43028	prefrontal	_	
249-220	43029-43034	brain	_	
249-221	43035-43042	regions	_	
249-222	43043-43045	in	_	
249-223	43046-43055	abstinent	_	
249-224	43056-43065	marijuana	_	
249-225	43066-43071	users	_	
249-226	43072-43079	General	_	
249-227	43080-43083	and	_	
249-228	43084-43092	specific	_	
249-229	43093-43103	functional	_	
249-230	43104-43116	connectivity	_	
249-231	43117-43129	disturbances	_	
249-232	43130-43132	in	_	
249-233	43133-43146	first-episode	_	
249-234	43147-43160	schizophrenia	_	
249-235	43161-43167	during	_	
249-236	43168-43177	cognitive	_	
249-237	43178-43185	control	_	
249-238	43186-43197	performance	_	
249-239	43198-43202	Drug	_	
249-240	43203-43212	addiction	_	
249-241	43213-43216	and	_	
249-242	43217-43220	its	_	
249-243	43221-43231	underlying	_	
249-244	43232-43247	neurobiological	_	
249-245	43248-43253	basis	_	
249-246	43253-43254	:	_	
249-247	43255-43267	Neuroimaging	_	
249-248	43268-43276	evidence	_	
249-249	43277-43280	for	_	
249-250	43281-43284	the	_	
249-251	43285-43296	involvement	_	
249-252	43297-43299	of	_	
249-253	43300-43303	the	_	
249-254	43304-43311	frontal	_	
249-255	43312-43318	cortex	_	
249-256	43319-43333	Individualized	_	
249-257	43334-43341	relapse	_	
249-258	43342-43352	prediction	_	
249-259	43352-43353	:	_	
249-260	43354-43365	Personality	_	
249-261	43366-43374	measures	_	
249-262	43375-43378	and	_	
249-263	43379-43387	striatal	_	
249-264	43388-43391	and	_	
249-265	43392-43399	insular	_	
249-266	43400-43408	activity	_	
249-267	43409-43415	during	_	
249-268	43416-43433	reward-processing	_	
249-269	43434-43442	robustly	_	
249-270	43443-43450	predict	_	
249-271	43451-43458	relapse	_	
249-272	43459-43467	Abnormal	_	
249-273	43468-43473	brain	_	
249-274	43474-43482	activity	_	
249-275	43483-43489	during	_	
249-276	43490-43491	a	_	
249-277	43492-43498	reward	_	
249-278	43499-43502	and	_	
249-279	43503-43507	loss	_	
249-280	43508-43512	task	_	
249-281	43513-43515	in	_	
249-282	43516-43532	opiate-dependent	_	
249-283	43533-43541	patients	_	
249-284	43542-43551	receiving	_	
249-285	43552-43561	methadone	_	
249-286	43562-43573	maintenance	_	
249-287	43574-43581	therapy	_	
249-288	43582-43585	The	_	
249-289	43586-43593	Alcohol	_	
249-290	43593-43594	,	_	
249-291	43595-43602	Smoking	_	
249-292	43603-43606	and	_	
249-293	43607-43616	Substance	_	
249-294	43617-43628	Involvement	_	
249-295	43629-43638	Screening	_	
249-296	43639-43643	Test	_	
249-297	43644-43645	(	_	
249-298	43645-43651	ASSIST	_	
249-299	43651-43652	)	_	
249-300	43652-43653	:	_	
249-301	43654-43665	Development	_	
249-302	43665-43666	,	_	
249-303	43667-43678	reliability	_	
249-304	43679-43682	and	_	
249-305	43683-43694	feasibility	_	
249-306	43695-43698	The	_	
249-307	43699-43705	reward	_	
249-308	43706-43713	circuit	_	
249-309	43713-43714	:	_	
249-310	43715-43722	linking	_	
249-311	43723-43730	primate	_	
249-312	43731-43738	anatomy	_	
249-313	43739-43742	and	_	
249-314	43743-43748	human	_	
249-315	43749-43756	imaging	_	
249-316	43757-43766	Disrupted	_	
249-317	43767-43774	resting	_	
249-318	43775-43780	brain	_	
249-319	43781-43786	graph	_	
249-320	43787-43795	measures	_	
249-321	43796-43798	in	_	
249-322	43799-43810	individuals	_	
249-323	43811-43813	at	_	
249-324	43814-43818	high	_	
249-325	43819-43823	risk	_	
249-326	43824-43827	for	_	
249-327	43828-43838	alcoholism	_	
249-328	43839-43846	Imaging	_	
249-329	43847-43852	brain	_	
249-330	43853-43861	response	_	
249-331	43862-43864	to	_	
249-332	43865-43871	reward	_	
249-333	43872-43874	in	_	
249-334	43875-43884	addictive	_	
249-335	43885-43894	disorders	_	
249-336	43895-43905	Predicting	_	
249-337	43906-43911	human	_	
249-338	43912-43925	resting-state	_	
249-339	43926-43936	functional	_	
249-340	43937-43949	connectivity	_	
249-341	43950-43954	from	_	
249-342	43955-43965	structural	_	
249-343	43966-43978	connectivity	_	
249-344	43979-43988	Decreased	_	
249-345	43989-43999	functional	_	
249-346	44000-44005	brain	_	
249-347	44006-44018	connectivity	_	
249-348	44019-44021	in	_	
249-349	44022-44033	adolescents	_	
249-350	44034-44038	with	_	
249-351	44039-44047	internet	_	
249-352	44048-44057	addiction	_	
249-353	44058-44063	Value	_	
249-354	44064-44072	encoding	_	
249-355	44073-44075	in	_	
249-356	44076-44082	single	_	
249-357	44083-44090	neurons	_	
249-358	44091-44093	in	_	
249-359	44094-44097	the	_	
249-360	44098-44103	human	_	
249-361	44104-44112	amygdala	_	
249-362	44113-44119	during	_	
249-363	44120-44128	decision	_	
249-364	44129-44135	making	_	
249-365	44136-44145	Disrupted	_	
249-366	44146-44157	topological	_	
249-367	44158-44170	organization	_	
249-368	44171-44173	in	_	
249-369	44174-44185	whole-brain	_	
249-370	44186-44196	functional	_	
249-371	44197-44205	networks	_	
249-372	44206-44208	of	_	
249-373	44209-44225	heroin-dependent	_	
249-374	44226-44237	individuals	_	
249-375	44237-44238	:	_	
249-376	44239-44240	A	_	
249-377	44241-44254	Resting-State	_	
249-378	44255-44259	fMRI	_	
249-379	44260-44265	Study	_	
249-380	44266-44273	Effects	_	
249-381	44274-44276	of	_	
249-382	44277-44285	familial	_	
249-383	44286-44290	risk	_	
249-384	44291-44294	and	_	
249-385	44295-44304	stimulant	_	
249-386	44305-44309	drug	_	
249-387	44310-44313	use	_	
249-388	44314-44316	on	_	
249-389	44317-44320	the	_	
249-390	44321-44333	anticipation	_	
249-391	44334-44336	of	_	
249-392	44337-44345	monetary	_	
249-393	44346-44352	reward	_	
249-394	44352-44353	:	_	
249-395	44354-44356	An	_	
249-396	44357-44361	fMRI	_	
249-397	44362-44367	study	_	
249-398	44368-44378	Nonoptimal	_	
249-399	44379-44388	component	_	
249-400	44389-44398	placement	_	
249-401	44398-44399	,	_	
249-402	44400-44403	but	_	
249-403	44404-44409	short	_	
249-404	44410-44420	processing	_	
249-405	44421-44426	paths	_	
249-406	44426-44427	,	_	
249-407	44428-44431	due	_	
249-408	44432-44434	to	_	
249-409	44435-44448	long-distance	_	
249-410	44449-44460	projections	_	
249-411	44461-44463	in	_	
249-412	44464-44470	neural	_	
249-413	44471-44478	systems	_	
249-414	44479-44491	Anticipation	_	
249-415	44492-44494	of	_	
249-416	44495-44505	increasing	_	
249-417	44506-44514	monetary	_	
249-418	44515-44521	reward	_	
249-419	44522-44533	selectively	_	
249-420	44534-44542	recruits	_	
249-421	44543-44550	nucleus	_	
249-422	44551-44560	accumbens	_	
249-423	44561-44571	Plasticity	_	
249-424	44572-44574	of	_	
249-425	44575-44581	reward	_	
249-426	44582-44596	neurocircuitry	_	
249-427	44597-44600	and	_	
249-428	44601-44604	the	_	
249-429	44605-44606	'	_	
249-430	44606-44610	dark	_	
249-431	44611-44615	side	_	
249-432	44615-44616	'	_	
249-433	44617-44619	of	_	
249-434	44620-44624	drug	_	
249-435	44625-44634	addiction	_	
249-436	44635-44650	Neurobiological	_	
249-437	44651-44661	mechanisms	_	
249-438	44662-44664	in	_	
249-439	44665-44668	the	_	
249-440	44669-44679	transition	_	
249-441	44680-44684	from	_	
249-442	44685-44689	drug	_	
249-443	44690-44693	use	_	
249-444	44694-44696	to	_	
249-445	44697-44701	drug	_	
249-446	44702-44712	dependence	_	
249-447	44713-44723	Motivation	_	
249-448	44724-44727	and	_	
249-449	44728-44737	cognitive	_	
249-450	44738-44745	control	_	
249-451	44746-44748	in	_	
249-452	44749-44752	the	_	
249-453	44753-44758	human	_	
249-454	44759-44769	prefrontal	_	
249-455	44770-44776	cortex	_	
249-456	44777-44785	GraphVar	_	
249-457	44785-44786	:	_	
249-458	44787-44788	A	_	
249-459	44789-44802	user-friendly	_	
249-460	44803-44810	toolbox	_	
249-461	44811-44814	for	_	
249-462	44815-44828	comprehensive	_	
249-463	44829-44834	graph	_	
249-464	44835-44843	analyses	_	
249-465	44844-44846	of	_	
249-466	44847-44857	functional	_	
249-467	44858-44863	brain	_	
249-468	44864-44876	connectivity	_	
249-469	44877-44886	Efficient	_	
249-470	44887-44895	behavior	_	
249-471	44896-44898	of	_	
249-472	44899-44910	small-world	_	
249-473	44911-44919	networks	_	
249-474	44920-44928	Economic	_	
249-475	44929-44940	small-world	_	
249-476	44941-44949	behavior	_	
249-477	44950-44952	in	_	
249-478	44953-44961	weighted	_	
249-479	44962-44970	networks	_	
249-480	44971-44981	Compulsive	_	
249-481	44982-44986	drug	_	
249-482	44987-44990	use	_	
249-483	44991-44994	and	_	
249-484	44995-44998	its	_	
249-485	44999-45005	neural	_	
249-486	45006-45016	substrates	_	
249-487	45017-45024	Altered	_	
249-488	45025-45030	brain	_	
249-489	45031-45041	functional	_	
249-490	45042-45050	networks	_	
249-491	45051-45053	in	_	
249-492	45054-45059	heavy	_	
249-493	45060-45067	smokers	_	
249-494	45068-45078	Disruption	_	
249-495	45079-45081	of	_	
249-496	45082-45088	reward	_	
249-497	45089-45099	processing	_	
249-498	45100-45102	in	_	
249-499	45103-45112	addiction	_	
249-500	45112-45113	:	_	
249-501	45114-45116	An	_	
249-502	45117-45128	image-based	_	
249-503	45129-45142	meta-analysis	_	
249-504	45143-45145	of	_	
249-505	45146-45156	functional	_	
249-506	45157-45165	magnetic	_	
249-507	45166-45175	resonance	_	
249-508	45176-45183	imaging	_	
249-509	45184-45191	studies	_	
249-510	45192-45201	Frequency	_	
249-511	45202-45211	dependant	_	
249-512	45212-45223	topological	_	
249-513	45224-45235	alterations	_	
249-514	45236-45238	of	_	
249-515	45239-45248	intrinsic	_	
249-516	45249-45259	functional	_	
249-517	45260-45270	connectome	_	
249-518	45271-45273	in	_	
249-519	45274-45279	major	_	
249-520	45280-45290	depressive	_	
249-521	45291-45299	disorder	_	
249-522	45300-45320	Anticipation-related	_	
249-523	45321-45326	brain	_	
249-524	45327-45339	connectivity	_	
249-525	45340-45342	in	_	
249-526	45343-45350	bipolar	_	
249-527	45351-45354	and	_	
249-528	45355-45363	unipolar	_	
249-529	45364-45374	depression	_	
249-530	45374-45375	:	_	
249-531	45376-45377	A	_	
249-532	45378-45383	graph	_	
249-533	45384-45390	theory	_	
249-534	45391-45399	approach	_	
249-535	45400-45407	Alcohol	_	
249-536	45408-45418	dependence	_	
249-537	45419-45421	is	_	
249-538	45422-45432	associated	_	
249-539	45433-45437	with	_	
249-540	45438-45445	blunted	_	
249-541	45446-45454	dopamine	_	
249-542	45455-45467	transmission	_	
249-543	45468-45470	in	_	
249-544	45471-45474	the	_	
249-545	45475-45482	ventral	_	
249-546	45483-45491	striatum	_	
249-547	45492-45495	The	_	
249-548	45496-45501	ICCAM	_	
249-549	45502-45510	platform	_	
249-550	45511-45516	study	_	
249-551	45516-45517	:	_	
249-552	45518-45520	An	_	
249-553	45521-45533	experimental	_	
249-554	45534-45542	medicine	_	
249-555	45543-45551	platform	_	
249-556	45552-45555	for	_	
249-557	45556-45566	evaluating	_	
249-558	45567-45570	new	_	
249-559	45571-45576	drugs	_	
249-560	45577-45580	for	_	
249-561	45581-45588	relapse	_	
249-562	45589-45599	prevention	_	
249-563	45600-45602	in	_	
249-564	45603-45612	addiction	_	
249-565	45612-45613	.	_	

#Text=Part B: fMRI description
#Text=Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals
#Text=Acute D3 antagonist GSK598809 selectively enhances neural response during monetary reward anticipation in drug and alcohol dependence
#Text=Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects
#Text=Cannabis-dependent adolescents show differences in global reward-associated network topology: A functional connectomics approach
#Text=Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task
#Text=Abstract reward and punishment representations in the human orbitofrontal cortex
#Text=The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction.
250-1	45614-45618	Part	_	
250-2	45619-45620	B	_	
250-3	45620-45621	:	_	
250-4	45622-45626	fMRI	_	
250-5	45627-45638	description	_	
250-6	45639-45649	Naltrexone	_	
250-7	45650-45661	ameliorates	_	
250-8	45662-45672	functional	_	
250-9	45673-45680	network	_	
250-10	45681-45694	abnormalities	_	
250-11	45695-45697	in	_	
250-12	45698-45715	alcohol-dependent	_	
250-13	45716-45727	individuals	_	
250-14	45728-45733	Acute	_	
250-15	45734-45736	D3	_	
250-16	45737-45747	antagonist	_	
250-17	45748-45757	GSK598809	_	
250-18	45758-45769	selectively	_	
250-19	45770-45778	enhances	_	
250-20	45779-45785	neural	_	
250-21	45786-45794	response	_	
250-22	45795-45801	during	_	
250-23	45802-45810	monetary	_	
250-24	45811-45817	reward	_	
250-25	45818-45830	anticipation	_	
250-26	45831-45833	in	_	
250-27	45834-45838	drug	_	
250-28	45839-45842	and	_	
250-29	45843-45850	alcohol	_	
250-30	45851-45861	dependence	_	
250-31	45862-45872	Prefrontal	_	
250-32	45873-45887	hypoactivation	_	
250-33	45888-45894	during	_	
250-34	45895-45904	cognitive	_	
250-35	45905-45912	control	_	
250-36	45913-45915	in	_	
250-37	45916-45921	early	_	
250-38	45922-45931	abstinent	_	
250-39	45932-45957	methamphetamine-dependent	_	
250-40	45958-45966	subjects	_	
250-41	45967-45985	Cannabis-dependent	_	
250-42	45986-45997	adolescents	_	
250-43	45998-46002	show	_	
250-44	46003-46014	differences	_	
250-45	46015-46017	in	_	
250-46	46018-46024	global	_	
250-47	46025-46042	reward-associated	_	
250-48	46043-46050	network	_	
250-49	46051-46059	topology	_	
250-50	46059-46060	:	_	
250-51	46061-46062	A	_	
250-52	46063-46073	functional	_	
250-53	46074-46086	connectomics	_	
250-54	46087-46095	approach	_	
250-55	46096-46101	Acute	_	
250-56	46102-46112	naltrexone	_	
250-57	46113-46117	does	_	
250-58	46118-46121	not	_	
250-59	46122-46131	remediate	_	
250-60	46132-46147	fronto-striatal	_	
250-61	46148-46160	disturbances	_	
250-62	46161-46163	in	_	
250-63	46164-46173	alcoholic	_	
250-64	46174-46177	and	_	
250-65	46178-46187	alcoholic	_	
250-66	46188-46211	polysubstance-dependent	_	
250-67	46212-46223	populations	_	
250-68	46224-46230	during	_	
250-69	46231-46232	a	_	
250-70	46233-46241	monetary	_	
250-71	46242-46251	incentive	_	
250-72	46252-46257	delay	_	
250-73	46258-46262	task	_	
250-74	46263-46271	Abstract	_	
250-75	46272-46278	reward	_	
250-76	46279-46282	and	_	
250-77	46283-46293	punishment	_	
250-78	46294-46309	representations	_	
250-79	46310-46312	in	_	
250-80	46313-46316	the	_	
250-81	46317-46322	human	_	
250-82	46323-46336	orbitofrontal	_	
250-83	46337-46343	cortex	_	
250-84	46344-46347	The	_	
250-85	46348-46356	Imperial	_	
250-86	46357-46364	College	_	
250-87	46365-46374	Cambridge	_	
250-88	46375-46385	Manchester	_	
250-89	46386-46387	(	_	
250-90	46387-46392	ICCAM	_	
250-91	46392-46393	)	_	
250-92	46394-46402	platform	_	
250-93	46403-46408	study	_	
250-94	46408-46409	:	_	
250-95	46410-46412	An	_	
250-96	46413-46425	experimental	_	
250-97	46426-46434	medicine	_	
250-98	46435-46443	platform	_	
250-99	46444-46447	for	_	
250-100	46448-46458	evaluating	_	
250-101	46459-46462	new	_	
250-102	46463-46468	drugs	_	
250-103	46469-46472	for	_	
250-104	46473-46480	relapse	_	
250-105	46481-46491	prevention	_	
250-106	46492-46494	in	_	
250-107	46495-46504	addiction	_	
250-108	46504-46505	.	_	

#Text=Part A: Study description
#Text=Will, anterior cingulate cortex, and addiction
#Text=Lower ventral striatal activation during reward anticipation in adolescent smokers
#Text=Functional network changes and cognitive control in schizophrenia
#Text=Complex network measures of brain connectivity: Uses and interpretations
#Text=Blunted rostral anterior cingulate response during a simplified decoding task of negative emotional facial expressions in alcoholic patients
#Text=Drug addiction, relapse, and the amygdala
#Text=Sheehan, D.
251-1	46506-46510	Part	_	
251-2	46511-46512	A	_	
251-3	46512-46513	:	_	
251-4	46514-46519	Study	_	
251-5	46520-46531	description	_	
251-6	46532-46536	Will	_	
251-7	46536-46537	,	_	
251-8	46538-46546	anterior	_	
251-9	46547-46556	cingulate	_	
251-10	46557-46563	cortex	_	
251-11	46563-46564	,	_	
251-12	46565-46568	and	_	
251-13	46569-46578	addiction	_	
251-14	46579-46584	Lower	_	
251-15	46585-46592	ventral	_	
251-16	46593-46601	striatal	_	
251-17	46602-46612	activation	_	
251-18	46613-46619	during	_	
251-19	46620-46626	reward	_	
251-20	46627-46639	anticipation	_	
251-21	46640-46642	in	_	
251-22	46643-46653	adolescent	_	
251-23	46654-46661	smokers	_	
251-24	46662-46672	Functional	_	
251-25	46673-46680	network	_	
251-26	46681-46688	changes	_	
251-27	46689-46692	and	_	
251-28	46693-46702	cognitive	_	
251-29	46703-46710	control	_	
251-30	46711-46713	in	_	
251-31	46714-46727	schizophrenia	_	
251-32	46728-46735	Complex	_	
251-33	46736-46743	network	_	
251-34	46744-46752	measures	_	
251-35	46753-46755	of	_	
251-36	46756-46761	brain	_	
251-37	46762-46774	connectivity	_	
251-38	46774-46775	:	_	
251-39	46776-46780	Uses	_	
251-40	46781-46784	and	_	
251-41	46785-46800	interpretations	_	
251-42	46801-46808	Blunted	_	
251-43	46809-46816	rostral	_	
251-44	46817-46825	anterior	_	
251-45	46826-46835	cingulate	_	
251-46	46836-46844	response	_	
251-47	46845-46851	during	_	
251-48	46852-46853	a	_	
251-49	46854-46864	simplified	_	
251-50	46865-46873	decoding	_	
251-51	46874-46878	task	_	
251-52	46879-46881	of	_	
251-53	46882-46890	negative	_	
251-54	46891-46900	emotional	_	
251-55	46901-46907	facial	_	
251-56	46908-46919	expressions	_	
251-57	46920-46922	in	_	
251-58	46923-46932	alcoholic	_	
251-59	46933-46941	patients	_	
251-60	46942-46946	Drug	_	
251-61	46947-46956	addiction	_	
251-62	46956-46957	,	_	
251-63	46958-46965	relapse	_	
251-64	46965-46966	,	_	
251-65	46967-46970	and	_	
251-66	46971-46974	the	_	
251-67	46975-46983	amygdala	_	
251-68	46984-46991	Sheehan	_	
251-69	46991-46992	,	_	
251-70	46993-46994	D	_	
251-71	46994-46995	.	_	

#Text=V., Lecrubier, Y., Sheehan, K.
252-1	46996-46997	V	_	
252-2	46997-46998	.	_	
252-3	46998-46999	,	_	
252-4	47000-47009	Lecrubier	_	
252-5	47009-47010	,	_	
252-6	47011-47012	Y	_	
252-7	47012-47013	.	_	
252-8	47013-47014	,	_	
252-9	47015-47022	Sheehan	_	
252-10	47022-47023	,	_	
252-11	47024-47025	K	_	
252-12	47025-47026	.	_	

#Text=H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., & Dunbar, G.
253-1	47027-47028	H	_	
253-2	47028-47029	.	_	
253-3	47029-47030	,	_	
253-4	47031-47037	Amorim	_	
253-5	47037-47038	,	_	
253-6	47039-47040	P	_	
253-7	47040-47041	.	_	
253-8	47041-47042	,	_	
253-9	47043-47049	Janavs	_	
253-10	47049-47050	,	_	
253-11	47051-47052	J	_	
253-12	47052-47053	.	_	
253-13	47053-47054	,	_	
253-14	47055-47062	Weiller	_	
253-15	47062-47063	,	_	
253-16	47064-47065	E	_	
253-17	47065-47066	.	_	
253-18	47066-47067	,	_	
253-19	47068-47076	Hergueta	_	
253-20	47076-47077	,	_	
253-21	47078-47079	T	_	
253-22	47079-47080	.	_	
253-23	47080-47081	,	_	
253-24	47082-47087	Baker	_	
253-25	47087-47088	,	_	
253-26	47089-47090	R	_	
253-27	47090-47091	.	_	
253-28	47091-47092	,	_	
253-29	47093-47094	&	_	
253-30	47095-47101	Dunbar	_	
253-31	47101-47102	,	_	
253-32	47103-47104	G	_	
253-33	47104-47105	.	_	

#Text=C. (1998).
254-1	47106-47107	C	_	
254-2	47107-47108	.	_	
254-3	47109-47110	(	_	
254-4	47110-47114	1998	_	
254-5	47114-47115	)	_	
254-6	47115-47116	.	_	

#Text=The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
255-1	47117-47120	The	_	
255-2	47121-47139	Mini-International	_	
255-3	47140-47156	Neuropsychiatric	_	
255-4	47157-47166	Interview	_	
255-5	47167-47168	(	_	
255-6	47168-47175	M.I.N.I	_	
255-7	47175-47176	.	_	
255-8	47176-47177	)	_	
255-9	47177-47178	:	_	
255-10	47179-47182	the	_	
255-11	47183-47194	development	_	
255-12	47195-47198	and	_	
255-13	47199-47209	validation	_	
255-14	47210-47212	of	_	
255-15	47213-47214	a	_	
255-16	47215-47225	structured	_	
255-17	47226-47236	diagnostic	_	
255-18	47237-47248	psychiatric	_	
255-19	47249-47258	interview	_	
255-20	47259-47262	for	_	
255-21	47263-47269	DSM-IV	_	
255-22	47270-47273	and	_	
255-23	47274-47277	ICD	_	
255-24	47277-47278	-	_	
255-25	47278-47280	10	_	
255-26	47280-47281	.	_	

#Text=J Clin Psychiatry, 59 Suppl 20, 22-33;quiz 34-57.
256-1	47282-47283	J	_	
256-2	47284-47288	Clin	_	
256-3	47289-47299	Psychiatry	_	
256-4	47299-47300	,	_	
256-5	47301-47303	59	_	
256-6	47304-47309	Suppl	_	
256-7	47310-47312	20	_	
256-8	47312-47313	,	_	
256-9	47314-47316	22	_	
256-10	47316-47317	-	_	
256-11	47317-47319	33	_	
256-12	47319-47320	;	_	
256-13	47320-47324	quiz	_	
256-14	47325-47327	34	_	
256-15	47327-47328	-	_	
256-16	47328-47330	57	_	
256-17	47330-47331	.	_	

#Text=Loss of brain graph network efficiency in alcohol dependence
#Text=Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference
#Text=The non-random brain: Efficiency, economy, and complex dynamics
#Text=Organization, development and function of complex brain networks
#Text=Striatum and insula dysfunction during reinforcement learning differentiates abstinent and relapsed methamphetamine-dependent individuals
#Text=Abnormalities of functional brain networks in pathological gambling: a graph-theoretical approach
#Text=Functionally linked resting-state networks reflect the underlying structural connectivity architecture of the human brain
#Text=Comparing brain networks of different size and connectivity density using graph theory
#Text=Independent functional connectivity networks underpin food and monetary reward sensitivity in excess weight
#Text=Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies
#Text=Decreased dopamine activity predicts relapse in methamphetamine abusers
#Text=A hyper-connected but less efficient small-world network in the substance-dependent brain
#Text=Disrupted brain functional network in internet addiction disorder: A resting-state functional magnetic resonance imaging study
#Text=Permutation inference for the general linear model
#Text=Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics
#Text=Changes of functional brain networks in major depressive disorder: A graph theoretical analysis of resting-state fMRI
#Text=Altered small-world brain functional networks and duration of heroin use in male abstinent heroin-dependent individuals
#Text=Network-based statistic: Identifying differences in brain networks
#Text=Supplementary data
#Text=The following are the Supplementary data to this article:
#Text=Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2020.102297.
257-1	47332-47336	Loss	_	
257-2	47337-47339	of	_	
257-3	47340-47345	brain	_	
257-4	47346-47351	graph	_	
257-5	47352-47359	network	_	
257-6	47360-47370	efficiency	_	
257-7	47371-47373	in	_	
257-8	47374-47381	alcohol	_	
257-9	47382-47392	dependence	_	
257-10	47393-47407	Threshold-free	_	
257-11	47408-47415	cluster	_	
257-12	47416-47427	enhancement	_	
257-13	47427-47428	:	_	
257-14	47429-47439	addressing	_	
257-15	47440-47448	problems	_	
257-16	47449-47451	of	_	
257-17	47452-47461	smoothing	_	
257-18	47461-47462	,	_	
257-19	47463-47472	threshold	_	
257-20	47473-47483	dependence	_	
257-21	47484-47487	and	_	
257-22	47488-47500	localisation	_	
257-23	47501-47503	in	_	
257-24	47504-47511	cluster	_	
257-25	47512-47521	inference	_	
257-26	47522-47525	The	_	
257-27	47526-47536	non-random	_	
257-28	47537-47542	brain	_	
257-29	47542-47543	:	_	
257-30	47544-47554	Efficiency	_	
257-31	47554-47555	,	_	
257-32	47556-47563	economy	_	
257-33	47563-47564	,	_	
257-34	47565-47568	and	_	
257-35	47569-47576	complex	_	
257-36	47577-47585	dynamics	_	
257-37	47586-47598	Organization	_	
257-38	47598-47599	,	_	
257-39	47600-47611	development	_	
257-40	47612-47615	and	_	
257-41	47616-47624	function	_	
257-42	47625-47627	of	_	
257-43	47628-47635	complex	_	
257-44	47636-47641	brain	_	
257-45	47642-47650	networks	_	
257-46	47651-47659	Striatum	_	
257-47	47660-47663	and	_	
257-48	47664-47670	insula	_	
257-49	47671-47682	dysfunction	_	
257-50	47683-47689	during	_	
257-51	47690-47703	reinforcement	_	
257-52	47704-47712	learning	_	
257-53	47713-47727	differentiates	_	
257-54	47728-47737	abstinent	_	
257-55	47738-47741	and	_	
257-56	47742-47750	relapsed	_	
257-57	47751-47776	methamphetamine-dependent	_	
257-58	47777-47788	individuals	_	
257-59	47789-47802	Abnormalities	_	
257-60	47803-47805	of	_	
257-61	47806-47816	functional	_	
257-62	47817-47822	brain	_	
257-63	47823-47831	networks	_	
257-64	47832-47834	in	_	
257-65	47835-47847	pathological	_	
257-66	47848-47856	gambling	_	
257-67	47856-47857	:	_	
257-68	47858-47859	a	_	
257-69	47860-47877	graph-theoretical	_	
257-70	47878-47886	approach	_	
257-71	47887-47899	Functionally	_	
257-72	47900-47906	linked	_	
257-73	47907-47920	resting-state	_	
257-74	47921-47929	networks	_	
257-75	47930-47937	reflect	_	
257-76	47938-47941	the	_	
257-77	47942-47952	underlying	_	
257-78	47953-47963	structural	_	
257-79	47964-47976	connectivity	_	
257-80	47977-47989	architecture	_	
257-81	47990-47992	of	_	
257-82	47993-47996	the	_	
257-83	47997-48002	human	_	
257-84	48003-48008	brain	_	
257-85	48009-48018	Comparing	_	
257-86	48019-48024	brain	_	
257-87	48025-48033	networks	_	
257-88	48034-48036	of	_	
257-89	48037-48046	different	_	
257-90	48047-48051	size	_	
257-91	48052-48055	and	_	
257-92	48056-48068	connectivity	_	
257-93	48069-48076	density	_	
257-94	48077-48082	using	_	
257-95	48083-48088	graph	_	
257-96	48089-48095	theory	_	
257-97	48096-48107	Independent	_	
257-98	48108-48118	functional	_	
257-99	48119-48131	connectivity	_	
257-100	48132-48140	networks	_	
257-101	48141-48149	underpin	_	
257-102	48150-48154	food	_	
257-103	48155-48158	and	_	
257-104	48159-48167	monetary	_	
257-105	48168-48174	reward	_	
257-106	48175-48186	sensitivity	_	
257-107	48187-48189	in	_	
257-108	48190-48196	excess	_	
257-109	48197-48203	weight	_	
257-110	48204-48208	Role	_	
257-111	48209-48211	of	_	
257-112	48212-48220	dopamine	_	
257-113	48220-48221	,	_	
257-114	48222-48225	the	_	
257-115	48226-48233	frontal	_	
257-116	48234-48240	cortex	_	
257-117	48241-48244	and	_	
257-118	48245-48251	memory	_	
257-119	48252-48260	circuits	_	
257-120	48261-48263	in	_	
257-121	48264-48268	drug	_	
257-122	48269-48278	addiction	_	
257-123	48278-48279	:	_	
257-124	48280-48287	Insight	_	
257-125	48288-48292	from	_	
257-126	48293-48300	imaging	_	
257-127	48301-48308	studies	_	
257-128	48309-48318	Decreased	_	
257-129	48319-48327	dopamine	_	
257-130	48328-48336	activity	_	
257-131	48337-48345	predicts	_	
257-132	48346-48353	relapse	_	
257-133	48354-48356	in	_	
257-134	48357-48372	methamphetamine	_	
257-135	48373-48380	abusers	_	
257-136	48381-48382	A	_	
257-137	48383-48398	hyper-connected	_	
257-138	48399-48402	but	_	
257-139	48403-48407	less	_	
257-140	48408-48417	efficient	_	
257-141	48418-48429	small-world	_	
257-142	48430-48437	network	_	
257-143	48438-48440	in	_	
257-144	48441-48444	the	_	
257-145	48445-48464	substance-dependent	_	
257-146	48465-48470	brain	_	
257-147	48471-48480	Disrupted	_	
257-148	48481-48486	brain	_	
257-149	48487-48497	functional	_	
257-150	48498-48505	network	_	
257-151	48506-48508	in	_	
257-152	48509-48517	internet	_	
257-153	48518-48527	addiction	_	
257-154	48528-48536	disorder	_	
257-155	48536-48537	:	_	
257-156	48538-48539	A	_	
257-157	48540-48553	resting-state	_	
257-158	48554-48564	functional	_	
257-159	48565-48573	magnetic	_	
257-160	48574-48583	resonance	_	
257-161	48584-48591	imaging	_	
257-162	48592-48597	study	_	
257-163	48598-48609	Permutation	_	
257-164	48610-48619	inference	_	
257-165	48620-48623	for	_	
257-166	48624-48627	the	_	
257-167	48628-48635	general	_	
257-168	48636-48642	linear	_	
257-169	48643-48648	model	_	
257-170	48649-48660	Dysfunction	_	
257-171	48661-48663	of	_	
257-172	48664-48670	reward	_	
257-173	48671-48681	processing	_	
257-174	48682-48692	correlates	_	
257-175	48693-48697	with	_	
257-176	48698-48705	alcohol	_	
257-177	48706-48713	craving	_	
257-178	48714-48716	in	_	
257-179	48717-48727	detoxified	_	
257-180	48728-48738	alcoholics	_	
257-181	48739-48746	Changes	_	
257-182	48747-48749	of	_	
257-183	48750-48760	functional	_	
257-184	48761-48766	brain	_	
257-185	48767-48775	networks	_	
257-186	48776-48778	in	_	
257-187	48779-48784	major	_	
257-188	48785-48795	depressive	_	
257-189	48796-48804	disorder	_	
257-190	48804-48805	:	_	
257-191	48806-48807	A	_	
257-192	48808-48813	graph	_	
257-193	48814-48825	theoretical	_	
257-194	48826-48834	analysis	_	
257-195	48835-48837	of	_	
257-196	48838-48851	resting-state	_	
257-197	48852-48856	fMRI	_	
257-198	48857-48864	Altered	_	
257-199	48865-48876	small-world	_	
257-200	48877-48882	brain	_	
257-201	48883-48893	functional	_	
257-202	48894-48902	networks	_	
257-203	48903-48906	and	_	
257-204	48907-48915	duration	_	
257-205	48916-48918	of	_	
257-206	48919-48925	heroin	_	
257-207	48926-48929	use	_	
257-208	48930-48932	in	_	
257-209	48933-48937	male	_	
257-210	48938-48947	abstinent	_	
257-211	48948-48964	heroin-dependent	_	
257-212	48965-48976	individuals	_	
257-213	48977-48990	Network-based	_	
257-214	48991-49000	statistic	_	
257-215	49000-49001	:	_	
257-216	49002-49013	Identifying	_	
257-217	49014-49025	differences	_	
257-218	49026-49028	in	_	
257-219	49029-49034	brain	_	
257-220	49035-49043	networks	_	
257-221	49044-49057	Supplementary	_	
257-222	49058-49062	data	_	
257-223	49063-49066	The	_	
257-224	49067-49076	following	_	
257-225	49077-49080	are	_	
257-226	49081-49084	the	_	
257-227	49085-49098	Supplementary	_	
257-228	49099-49103	data	_	
257-229	49104-49106	to	_	
257-230	49107-49111	this	_	
257-231	49112-49119	article	_	
257-232	49119-49120	:	_	
257-233	49121-49134	Supplementary	_	
257-234	49135-49139	data	_	
257-235	49140-49142	to	_	
257-236	49143-49147	this	_	
257-237	49148-49155	article	_	
257-238	49156-49159	can	_	
257-239	49160-49162	be	_	
257-240	49163-49168	found	_	
257-241	49169-49175	online	_	
257-242	49176-49178	at	_	
257-243	49179-49184	https	_	
257-244	49184-49185	:	_	
257-245	49185-49186	/	_	
257-246	49186-49187	/	_	
257-247	49187-49194	doi.org	_	
257-248	49194-49195	/	_	
257-249	49195-49202	10.1016	_	
257-250	49202-49203	/	_	
257-251	49203-49209	j.nicl	_	
257-252	49209-49221	.2020.102297	_	
257-253	49221-49222	.	_	
